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Unraveling the role of heme oxygenase-1/ carbon monoxide in pulmonary and 
cardiovascular disease 
By  
Anuli Caroline Anyanwu  
 
Chair: David J. Pinsky and Co-Chair: Marc B. Hershenson 
Heme oxygenase (HO) is an enzyme found in many cell types, and is expressed in 
multiple isoforms, each of which is responsible for the breakdown of heme into biliverdin 
and iron. In the process of catabolizing heme, CO gas is liberated as a byproduct. HO-1 is 
also known in the literature as heat shock protein 32 because of its molecular weight and 
its inducibility by cellular stress. Though it is well established that HO-1 possesses anti-
inflammatory properties, which had initially been presumed to occur through antioxidant 
actions of biliverdin. Recent reports suggests that CO itself triggers potent cellular 
protective mechanisms, via its ability to suppress key regulatory transcription factors 
responsible for induction of many gene targets which lead to inflammation and 
coagulation. This led to the hypothesis that HO-1 is a critical regulator of inflammation 
through the catabolism of carbon monoxide. Studies of macrophage and neutrophil flux 
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into perinatal hyperoxia-induced lung tissue and of thrombosed vascular tissue reveal a 
novel role for HO-1/CO in the regulation of leukocyte activation. In the setting of 
hyperoxia-induced lung injury in the neonatal lung, inhalation of low dose CO mitigates 
the effect of neonatal hyperoxia on alveolar development and the developing lung by an 
anti-inflammatory mechanism. In the setting of deep venous thrombosis, HO-1/CO 
mediated-reduction of key inflammatory mediators manifests a profound suppression of 
leukocyte trafficking into the vascular milieu, and a concordant decrease in platelet 
aggregation. Further exploration of the role of HO-1/CO in other disease models reveal 
CO has emerged as a potently protective, homeostatic molecule that prevents the 
development of vascular and alveolar disorders when administered prophylactically. 
Accumulating evidence suggests that CO exerts key physiological functions in 
pulmonary and cardiovascular biology and more recently, has been demonstrated to have 
anti-apoptotic, anti-inflammatory and anti-proliferative effects. In total, this thesis will 
elucidate the signaling pathway involved in the anti-inflammatory effects of HO-1/CO as 
important not only for our basic understanding of mechanisms of action of HO-1/CO, but 
also for the consideration of novel therapeutic for acute and chronic inflammation with 





PUTTING IT ALL TOGETHER: HEME OXYGENASE-1/CARBON MONOXIDE 
SIGNALING PATHWAYS, HYPEROXIA-INDUCED BRONCHOPULMONARY 
DYSPLASIA AND DEEP VENOUS THROMBOSIS 
 
INTRODUCTION 
HO-1/CO Structure and Function 
Heme degradation catalyzed by heme oxygenase 
Heme is a prosthetic group that consists of an iron atom that is contained in the 
center of a porphyrin ring. There are several major types of heme in cells, including heme 
A, heme B, heme C, and heme O. The heme in heme oxygenase (HO) is a b-type heme 
with the iron coordinated to the four nitrogen atoms of the porphyrin and has a chemical 
formula of C34H32FeN4O4. In the presence of NADPH - cytochrome P450 reductase 
(CPR), heme oxygenase (HO, EC 1:14:99:3) catalyzes the degradation of heme into iron, 
CO and biliverdin, which is quickly reduced to bilirubin by biliverdin reductase (Figure 
1).1,2 The degradation of one molecule of heme to biliverdin requires seven electrons to 
be transferred and three molecules of oxygen to be consumed (Equation 1). 
Subsequently, biliverdin reductase (BVR) catalyzes the two-electron reduction of 
biliverdin to bilirubin using NADPH as an electron donor (Equation 2). A distinct color 




HO is present in organisms ranging from bacteria to eukaryotes, and is the only 
known enzyme that can degrade heme. In mammals, the electrons are provided by 
NADPH–cytochrome P450 reductase.3 In HO, heme acts as not only a cofactor but also 
as a substrate that catalyzes its own destruction (Figure 2). The HO-bound heme is first 
oxidized to α-meso-hydroxyheme through a peroxy intermediate. The deprotonated state 
of α-meso-hydroxyheme has free radical character, which can react with oxygen to 
produce α-verdoheme and eliminate the α carbon atom from the porphyrin ring as CO. 
The α-verdoheme is subsequently converted to biliverdin and free iron in a reaction that 
requires NADPH–cytochrome P450 reductase and O2. Recent studies indicated that 
product release involves sequential reduction of the ferric to the ferrous biliverdin 
complex, release of the ferrous iron, and finally dissociation of the biliverdin from the 
protein.4 
Physiological functions of heme oxygenase 
Heme and iron homeostasis 
Iron is an essential element for all living organisms. It acts as a cofactor for many 
heme-containing proteins such as CPR and HO, forms iron-sulfur clusters in many non- 
heme-containing proteins such as ferredoxins and CODH, and provides oxygen transport 
and storage for hemoglobin and myoglobin, respectively. However, excess iron can be 
toxic,5 since it can produce large amounts of highly reactive hydroxyl radical (·OH) by 
the Fenton reaction in cells.6 An efficient way to maintain iron balance in cells is through 
regulation of its uptake. Dietary iron mainly exists as iron salts and heme iron. Uptake of 
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inorganic iron is mainly mediated by the iron transporters located in the brush border 
membrane, including DMT1 (divalent metal transporter-1)7 and Dcytb (duodenal 
cytochrome b).8 In comparison to inorganic iron uptake, heme uptake is very different 
and its transport mechanism has not been fully elucidated. A very recent report indicated 
that the HRG (histidine-rich glycoprotein) family proteins are potential heme transporters 
in Caenorhabditis elegans. 9 However, the heme transport pathway in mammals remains 
mysterious. After heme is transported into cells, the iron is released by heme degradation 
in a reaction that is catalyzed by HO. In addition to playing a role as an iron reservoir, 
heme has other critical physiological functions in cells. Heme is a common prosthetic 
group that is structurally associated with many electron transfer and redox enzymes and 
regulates genes involved in oxygen utilization in lower eukaryotes and prokaryotes. 
10,11,12 Although heme plays crucial roles in various physiological processes, free heme 
can be toxic at concentrations greater than 1 µM,13 causing oxidative stress induced by 
reactive oxygen species (ROS), hemolytic effects, and abnormal inflammation.14 Because 
of the contradictory biological functions for heme and iron, their metabolism in mammals 
needs to be tightly and delicately regulated. 
HO is the only known enzyme that can degrade heme in cells, playing a critical 
role in heme and iron homeostasis. Although the precise molecular mechanisms by which 
HO confers tissue protection are not clearly defined, it is believed that HO-dependent 
protection is mediated by the reaction products of heme degradation, including biliverdin, 
CO, and iron (Figure 3). Each product could contribute alone or in concert to the 
restoration of cellular homeostasis under inducing conditions. One potential mechanism 
of the HO-mediated cytoprotective effect is that HO may provide a possible antioxidative 
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function by accelerating the removal of heme to limit oxidative stress sustained through 
heme-dependent mechanisms. It has recently been reported that free iron, at physiological 
levels, has crucial effects on cytoprotection.15,16 Furthermore, iron can also promote the 
ferritin-mediated cytoprotective process against mitochondrial dysfunction and oxidative 
stress.17 In contrast, evidence showed that iron released from the HO reaction may 
potentially act as a catalyst of deleterious pro-oxidant reactions, such as the metal-
catalyzed Haber-Weiss cycle, or iron-dependent lipid peroxidation.18 In addition, HO-
derived iron may also stimulate ferritin synthesis, sequestering reactive iron.19  
CO signaling in cells 
Historically, CO has been regarded as a lethal gas and is toxic at high levels (>500 
ppm). The first identified molecular target of CO was the heme iron center of 
hemoproteins, such as hemoglobin. Carbon monoxide is a colorless, tasteless and 
odorless gas that, when inhaled, enters the bloodstream and replaces the oxygen on 
hemoglobin to form carboxyhemoglobin. High CO concentrations cause hypoxemia by 
competitive binding to the oxygen-binding sites of hemoglobin to form 
carboxyhemoglobin (CO-Hb), with an affinity that is > 200-fold higher than that of 
oxygen13. In humans, prolonged or elevated CO exposure can cause a number of acute 
clinical effects, including nausea, dizziness, and loss of consciousness.13 Symptoms of 
CO poisoning begin to appear at 20% CO-Hb, while death occurs between 50 and 
80% CO-Hb.13 However, when CO is applied at low concentrations (typically within the 
15 to 20% CO-Hb) range, it can influence a number of signaling pathways in cells to 
confer various cytoprotective effects, including anti-inflammation, anti-apoptosis, and 
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anti- proliferation (Figure 1.3).20,21 The CO signaling pathway is still not clearly 
elucidated. At a physiological level, CO can trigger the production of cyclic-guanosine-
monophosphate (cGMP) to stimulate neuronal signaling processes and regulate vascular 
functions, including vessel tone, smooth muscle proliferation and platelet 
aggregation.22,23 Furthermore, recent studies indicate that the activation of MAPK 
pathways, particularly the p38 MAPK signaling pathway, can be modulated by CO 
treatment.24 MAPK pathways have been demonstrated to be critical for cellular response 
to inflammatory, apoptotic and proliferative stress.24,25,26,27 The activation of p38 MAPK 
by CO has been reported to be dependent or independent of soluble guanylate cyclase 
(sGC), depending on the cell type. In addition, modulation of cellular ROS production, 
inhibition of cellular O2 production, membrane NADPH-oxidase, and Toll-like receptor 
(TLR) trafficking and activation have also been implicated in CO dependent 
signaling.28,29,30 Thus, CO can confer tissue protection in various models of acute lung 
injury, vascular injury, pulmonary hypertension, liver injury, organ I/R injury, organ 
transplantation, and numerous other condition.23,31 Observations of CO-mediated tissue 
protection have also been described in transplantation of heart, lung, kidney, liver, and 
intestinal allografts or xenografts, whereby application of CO to the recipient or to the 
graft reduced inflammation and apoptosis associated with I/R injury, thus reducing the 
probability of graft, rejection.32,33 In fact, CO-based inhalation therapies have been 
applied in the clinic. A recently reported clinical trial demonstrates that reduction of 
sputum eosinophils and improvement of methacholine responsiveness through inhalation 




In cells, HO-catalyzed heme degradation is the major source of CO, especially in 
neurons and in the carotid body.35 HO-derived CO is usually produced locally within 
tissues, serving as an endogenous physiological mediator. In the early 1990s, HO-derived 
CO was discovered as a neurotransmitter in olfactory neurotransmission.36 Since then 
increasing evidence has been presented that HO-derived CO, instead of being a waste 
product of heme oxidation, actually plays critical roles in various physiological 
phenomena, including circadian modulation of heme biosynthesis, regulation of T cell 
function, modulation of caveolin-1 status in growth control,37 activation of guanylate 
cyclase,38 and mediation of O2 sensing and the hypoxic response.39 It is now believed 
that CO acts as a signaling molecule like another diatomic molecule, nitric oxide (NO), 
possessing anti-apoptotic, anti-inflammatory, and anti-proliferative properties.26,37,40,41 
Although the toxicity of CO has been studied extensively, it is now being explore for its 
physiological effects and potential therapeutic benefits.42 Since the realization that the 
poisonous gas nitric oxide (NO) has a significant biological role in physiology and 
pathophysiology, CO, which is structurally similar gas, has gained a lot of attention as a 
molecule with many analogous chemical and biological properties. Like NO, CO is 
produced endogenously during cellular metabolism, primarily from the degradation of 
heme by the HO enzyme.43 CO differs from NO in that CO is a highly stable diatomic 
gas, which lacks unpaired electron of NO and hence is unreactive with superoxide or 
other radicals produced during cellular or vascular injury. Endogenous CO formation has 
been measured in several biological systems, and normal human adults have been shown 
to exhale ~12mL of CO per day.44 However, the major exogenous source for CO is 
generated from the incomplete burning of carbon from solid, liquid, and gaseous fuels. 
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Biliverdin and bilirubin homeostasis 
Bilirubin, the final product of heme metabolism, is rapidly derived from biliverdin 
by biliverdin reductase (BVR) in mammals. Bilirubin can revert to biliverdin via 
oxidation, although the mechanism is unclear. The function of the BVR pathway in cells 
is not clearly understood because bilirubin is toxic and insoluble, while biliverdin is more 
water soluble. Bilirubin must be glucuronidated before its excretion in bile, which is 
primarily catalyzed by UDP-glucuronyl transferase (UDPGT) in liver.45 Compared to 
bilirubin, biliverdin is more easily excreted. Bilirubin was first reported to mainly exist in 
the plasma and can cause brain damage.46 However, it has been recently reported that 
biliverdin and bilirubin can act as chain-breaking antioxidants in vitro, which may 
provide cytoprotection (Figure 1.3).47 
The cytotoxicity associated with deletion of HO appears to reflect a loss of 
bilirubin. Mice with targeted deletion of either HO-1 or HO-2 have reduced bilirubin 
levels and are more susceptible to neurotoxic damage, seizures, stroke damage, and 
traumatic brain injury.48,49 The antioxidant actions of bilirubin are dramatically amplified 
by BVR in a biliverdin–bilirubin cycle. Depletion of BVR by RNA interference markedly 
diminishes the cytoprotective effects of exogenous bilirubin and leads to increased 
cellular levels of oxygen free radicals and cell death.50,51 A recent study suggested that 
water-soluble glutathione (GSH) primarily protects water soluble proteins, whereas 
lipophilic bilirubin protects against lipid peroxidation of cell membranes.51 Mice with 
deletion of HO-2, which generates biliverdin, display more oxidation of lipid than that of 
protein, while the reverse holds for GSH depletion. Pharmacologic application of 
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biliverdin and bilirubin can protect cultured cells against injury by oxidative or 
nitrosative stress.52 One possible mechanism is that bilirubin can surpass α-tocopherol as 
the most potent protector against lipid peroxidation and acts as an antioxidant that is 
involved in resistance to oxidative stress.47,53,54 
Differences between HO-1 and HO-2 
There are two forms of HO (HO-1 and HO-2), which share similar physical and 
kinetic properties, but are differentially regulated and exhibit dissimilar physiological 
roles and tissue distributions.55,43 Another isoform, HO-3, was recently reported in rat;56 
however, no activity was detected for this isoform and it is considered to be a 
pseudogene. Phylogenetic analysis of heme oxygenase indicates that HO-1 and HO-2 
have a very high degree of evolutionary conservation among mammals.57 Bacterial heme 
oxygenases have a closer evolutionary relationship with those in plants. However, the 
bacterial, plant and mammalian HOs have high structural similarity in their catalytic 
domains. A bacterial HO-2 crystal structure has been reported recently, which shows a 
high similarity at the core domain region with human HO-1 and HO-2 structures.58 Plants 
contain several HOs, including one named HO-2, but these lack the C-terminal 
membrane spanning region seen in mammalian HOs 59 and are more closely related to the 
bacterial and insect HO-1 than to the mammalian HOs.57 In higher plants, ferredoxin is 
utilized instead of NADPH-cytochrome P450 reductase as the reducing partner in the HO 
reaction.7 Many plants do not produce bilirubin since they lack biliverdin reductase.9 
HO-1, considered to be the inducible HO, is also known as heat-shock protein 32 
and is found in most tissues, with particularly high levels in spleen and liver.60,61 
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Expression of HO-1 is regulated by heat shock and various oxidative stress conditions 
such as ischemia, hypoxia, hyperoxia, and alterations in glutathione levels.43,62 On the 
other hand, HO-2 appears to be constitutively expressed, but exhibits a narrow tissue 
distribution, with high levels in the brain and in testes.56,63,64 HO-2 has been implicated in 
oxygen sensing by the carotid body,39,57 mediating oxidative stress in neurons,65 and 
regulating cerebral blood flow and vascular tone in certain tissues.66 
HO-1/CO and Bronchoplumonary Dysplasia (BPD) 
Premature birth and Bronchoplumonary Dysplasia (BPD) 
The incidence of human premature delivery, i.e. birth at gestational age of less 
than 37 weeks, is approximately 13% in the United States.67 Due to lung immaturity, 
preterm infants are at risk of developing respiratory distress syndrome (RDS or hyaline-
membrane disease). An estimated 30% of infants with a birth weight between 500g and 
1,500g will develop RDS. RDS is a risk factor for the development of bronchoplumonary 
dysplasia (BPD). BPD is a significant global health problem with 65 to 75% patients 
having high risk for morbidity and mortality during the first years of life and respiratory 
problems throughout childhood and young adulthood.68 Infants with BPD are more likely 
to need prolonged hospitalization and readmission in the first years of life than preterm 
infants without BPD69. Some infants with BPD continue to show lung function 
abnormalities into childhood and even early adulthood.69, 70, 71 The patho-physiology of 
BPD is multifactorial and not completely clear. However, the main pathological 
hallmarks of BPD is marked inflammation and an arrest of alveolar development, 
characterized by large and simplified distal airspaces.72, 73 (Figure 4) In addition, lungs of 
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ventilated premature infants with early stage BPD show increased levels of alveolar 
endothelial and epithelial cell death.74, 75, 76 Even though, the number of endothelial cells 
has not been quantified in human BPD, decreased endothelial cells and microvascular 
dysmorphogenesis are characteristics of experimental BPD in perinatal mice.77  
Lung development 
During the saccular stage of lung development, the segments distal to the terminal 
bronchioles dilate and expand resulting in the formation of alveolar saccules and ducts, 
with associated reduction of interstitial tissue. Peripheral epithelial cells continue to 
differentiate into type I and type II pneumocyte epithelial cells, and the capillaries 
become more closely associated with type I epithelial cells. Elastin is deposited in areas 
where the future alveolar septa will form to create alveoli from the terminal alveolar 
saccules.78, 79 During the alveolar stage, the saccules subdivide into smaller alveoli and a 
single capillary is formed to enable efficient gas exchange after birth.78 In human lung, 
alveoli begin to form during the weeks preceding birth but the large majority of alveoli 
are formed postnatally.78 Since the mouse is born during the saccular stage, its 
alveolarization takes place postnatally beginning around postnatal day 3 (PN-3) (Table 
1). Murine alveolar development begins on postnatal day 3, and saccular division is 
completed by the 14th postnatal day. This sequence and relative timing of alveolarization 
resembles human lung development. Murine models have several advantages compared 
to rats or primates, including ease of maintenance, amenable to genetic alteration or 




Inflammation and BPD 
Mechanical ventilation and oxygen supplemention of preterm infants can cause an 
inflammatory response, interrupting the alveolar and vascular development of the lung 79, 
80, 81, and may possibly accelerate the development of injury and BPD in the already 
inflamed lung. This loss of compartmentalization results in increased fluid influx to the 
alveoli from the capillaries, causing pulmonary edema. The injured or ruptured cells 
attract neutrophil leukocytes and activate alveolar macrophages, causing inflammation in 
the lung.82 In the lung, resident alveolar macrophages are important in the clearance of 
foreign material by phagocytosis.83 When activated, alveolar macrophages secrete 
cytokines and chemokines that attract neutrophils and monocytes from the circulation.84 
Neutophils are often the first inflammatory cells to infiltrate the site of inflammatory 
response.85 Neutrophils are critical for subsequent increase in lung 
monocytes/macrophages,86 regulate their activation through an autocrine loop, 
perpetuating the inflammatory signal in lung injury. Neutrophil influx into the airways 
was observed immediately after initiation of ventilation and was associated with a 
decrease in the number of circulating neutrophils. This phenomenon was shown to 
correlate with the extent of pulmonary edema formation and an increased risk of 
developing BPD.  
The development of BPD is associated with increased levels of pro-inflammtory 
and chemotatic factors IL-1β, IL-6, IL-8, tumor necrosis factor α, CC chemokines and 
transforming growth factor (TGF)-β1 in the lung of preterm infants.87, 88, 89 However, the 
increase levels and enhanced mRNA expression of pro-inflammatory cytokines present in 
pulmonary tissue of premature infants may reflect an inability to regulate inflammation 
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through sufficient expression of anti-inflammatory cytokines (IL-10, IL-4, IL-12 and IL-
13 or IL-1) receptor antagonist.88, 90, 91 An imbalance between expression of pro-
inflammatory and anti-inflammatory cytokines can be considered an important feature of 
lung injury. Prior to neutrophil migration, cellular attachment to endothelial cells is 
mediated through complex interaction of adhesion molecules. Infants developing BPD 
have increased levels of endothelial cell intracellular adhesion molecules (ICAM)-1 and 
selectin, which enable circulating inflammatory cells to transmigrate into the tissue.92 
Previous studies suggest these adhesion receptors are upregulated and accumulate into 
the alveolar septae during hyperoxic insult.93 In newborn animals, hyperoxia has been 
shown to be a strong and independent inducer of various proinflammatory cytokines in 
airway cells and pulmonary tissue.94, 95 
When organisms are faced with hyperoxic stress, they have evolved sophisticated 
and redundant mechanisms to ensure survival. Accumulating data exist in the literature 
supporting the paradigm that the stress-inducible heme-oxygenase-1, or its catalytic 
product, carbon monoxide, can confer potent cytoprotective effects in various models of 
tissue and cellular injury. 24, 32, 96, 97One possible mechanism which HO-1/CO mediates 
cytoprotective effect is via anti-inflammatory properties.97 CO has been shown to 
downregulate some these pro-inflammatory molecules, namely TNFα and IL1β in mouse 
models.98 CO suppresses the pro-inflammatory response (TNFα) and promotes the anti-
inflammatory (IL-10) response of macrophage, a cell that probably controls the balance 
of inflammation in many conditions through activation of p38 mitogen-activated protein 




HO-1/CO and Hyperoxia-induced lung injury 
Heme oxygenase is an enzyme found in many cell types, and is expressed in 
multiple isoforms, each of which is responsible for the breakdown of heme into biliverdin 
and iron. In the process of catabolizing heme, CO gas is liberated as a byproduct. HO-1, 
initially described as heat shock protein 32, has been found to have an important role in 
hyperoxia injury. HO-1 is an enzyme that degrades heme to bilirubin, is markedly 
induced by hyperoxia in multiple cell types including the lungs, and had been found to 
have profound cyoprotective effects. Overexpression of HO-1 in human epithelial cells 
conferred resistance to hyperoxia.99 This effect was strengthened in vivo when exogenous 
HO-1 by gene transfer attenuated hyperoxic lung injury in rats.100 Findings from human 
HO-1 deficiency indicate that the activity of this enzyme is essential for modulating the 
inflammatory response, apoptosis and cellular proliferation.49 
One of the most interesting facets of HO-1 biology is that the reaction products of 
HO-1 catalysis also have intrinsic antioxidant, anti-inflammatory, and antiapoptotic 
properties that can collaboratively impose significant cytoprotective effects. My proposal 
focuses on the anti-inflammatory properties of HO-1.101, 102 Unpublished data collected 
from our laboratory, suggests that CO itself triggers potent cellular protective 
mechanisms, acting as a signaling moiety in inflammation and coagulation, whether it is 
exogenously administered or produced by HO-1. This data is further supported by other 
reports that CO provides potent cytoprotection in model of ventilated-associated lung 
injury,20 ischemia/reperfusion,103 hyperoxia-induced lung injury100 and many other 
clinically relevant research models. Despite the recognized cytoprotective effects of HO-
1 and CO, the molecular pathways mediating the protective effects in neonatal hyperoxia-
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induced lung injury are still not well defined and will thus be determined through the 
aims outlined in this proposal. 
 
Significance 
Bronchopulmonary dysplasia is a major crippling disease characterized by 
impairment of lung vascular and alveolar development. BPD is one of the most 
devastating complications of prematurity. Clinical studies have identified numerous risk 
factors for the development of BPD in premature infants, including hyperoxia, ventilator-
induced pulmonary injury, and prenatal and antenatal infection. Despite attempts to avoid 
excessive oxygen supplementation, restrict fluids, prevent infection, and use “gentle” 
ventilation techniques, the incidence of BPD has not changed significantly. Carbon 
monoxide has emerged as a potently protective, homeostatic molecule that prevents the 
development of vascular and alveolar disorders when administered prophylactically.96, 103 
Accumulating evidence suggests that CO exerts key physiological functions in neuronal 
and cardiovascular biology and more recently, has been demonstrated to have anti-
apoptotic, anti-inflammatory and anti-proliferative effects.104 Studies here will elucidate 
the signaling pathway involved in the anti-inflammatory effects of CO as important not 
only for our basic understanding of the mechanisms of action of CO, but also for the 




HO-1/CO and Deep Venous Thrombosis 
Venous Thrombogenesis   
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality 
worldwide. Thrombus, which develops in great veins of the legs and pelvis, represent an 
enormous public health burden, particularly when it embolizes to the lungs in a third of 
all cases. VTE, is a disease that manifested either by the development of deep venous 
thrombosis (DVT) or pulmonary embolism (PE). Studies have estimated, that 
approximately 2 million Americans will suffer from DVT annually, and more than 
600,000 patients will develop PE.105 Although anticoagulant therapy represents the 
mainstay of thromboprophylaxis and treatment, refractory VTE is not at all uncommon 
and the long term consequences, such as chronic venous insufficiency, remains a major 
burden to the health of an individual and to society at large. VTE is a multifactorial 
disease that can be influences by genetic factors, acquired factors and environmental 
factors.  In spite of the enormous disease burden, surprisingly little is known about the 
pathophysiology of DVT. This is contrary to arterial thrombosis, in which the general 
outline of its mechanism is well defined, even at a molecular level.106 
One of the most important advances in our understanding of venous thrombosis was 
proposed in the late 1870s by Rudolph Virchow. He deduced the major pathogenic determinants 
for DVT and PE. The triad of vessel wall injury, venous stasis, and blood hypercoagulability have 
historically been considered the major factors responsible for the development of venous 
thrombosis 107 (Figure 5). Veins are particularly susceptible loci as blood flow is generally 
lower than on the arterial side of the circulation, there exist venous valve cusps on whose surfaces 
thrombi are known to form,108 and local hypoxemia prevails as oxygen has been extracted from 
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blood in transit through the capillary plexus. The hemostatic system is faced with the complex 
task of maintaining the blood in a fluid state so that it can circulate, while simultaneously being 
able to convert the blood into an insoluble gel at sites of vascular injury. The hemostatic system is 
made up of two distinct but interlocking systems: platelets and the coagulation proteins. In 
normal blood flow or absence of vascular injury or inflammation, platelets do not adhere to the 
endothelium primarily because unstimulated endothelium has no receptors for unactivated 
platelets and the endothelium produces substances such as nitric oxide, proinflammatory 
mediators and prostacyclin that maintain the platelets in the unactivated state and impairs their 
adhesion.  During vessel wall injury (such as hypoxia or loss of endothelium layer), platelets are 
exposed to subendothelial ligands for which they have specific receptors. Our work109,110,111 as 
well as that of others, has shown that hypoxia alone is sufficient to trigger thrombosis at the blood 
wall interface, by mechanisms which include de novo expression of tissue factor and plasminogen 
activator inhibitor-1 (PAI-1) in local mononuclear phagocytes, as well as triggered release of von 
Willebrand Factor (vWF) and P-selectin from endothelium.  
How platelets invite leukocytes to dance 
For many years it has been known that platelets play an important role in thrombosis and 
hemostasis. Recently, it has become evident that platelets also have relevant functions in 
inflammation. It has been shown that thrombosis and inflammation share two intrinsically linked 
molecular and cellular mechanisms in the endothelium. The primary molecules responsible for 
initiation of platelet and leukocyte adhesion are von Willebrand factor (vWF) and P-selectin, 
respectively. These two molecules are stored in the same storage granules called Weibel-palade 
bodies (WPBs).112,113,114,115 Endothelial cells fuse to endothelial surface and release there WPB 
content in response to vascular injury, releasing vWF, which triggeres platelet rolling and 
externalizing P-selectin, which in turn activates leukocytes trafficking.112 
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Endothelial exocytosis is one of the earliest responses to vascular damage and 
plays a pivotal role in thrombosis and inflammation. vWF is essential for WPBs 
formation,116 and therefore mice with vWF deficiency cannot store P-selectin in 
endothelium leading to its partial degradation. This makes the mice less responsive to 
inflammatory stimuli.117 P-selectin, an adhesion receptor that triggers leukocyte rolling 
along vessel wall, is externalized to the plasma membrane during vascular injury. P-
selectin glycoprotein ligand-1(PSGL-1), the main ligand of P-selectin, expressed on 
leukocytes interacts with P-selectin and mediates leukocyte rolling along blood vessels. 
Mice lacking P-selectin have decreased leukocyte recruitment to sites of vascular 
injury.118 Recent evidence even implicates both vWF and P-selectin freshly secreted from 
activated endothelium, mediate platelet interaction with the endothelial surface. Shear 
rates in the vessel wall determined which vascular modulator is activated. In stimulated 
veins under low shear rates, a large number of resting platelets translocate on vWF that is 
transiently bound to the endothelial.119 However, higher venus shear rates, activated and 
non activated platelets are able to roll on endothelial cells (similar to leukocyte 
transmigration) a process mediated by P-selectin and E-selectin.120,121 (Figure 6) Platelet 
glycoprotein (GP) GPIbα is another ligand of P-selectin and may therefore also support 
platelet rolling on activated endothelium.122 The precise mechanism by which P-selectin 
promotes platelets rolling still remains unclear, however, they may include direct 
interactions between platelets and endothelial cells or involve the formation of 
microparticles.123,121,122 Exocytosis of both vWF and P-selectin promotes thrombosis by 
distinct and complementary mechanisms. By externalizing P-selectin, exocytosis of 
WPBs is thus both procoagulant and proinflammatory.  
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Bidirectional relationship between thrombosis and inflammation  
Inflammation can beget local thrombosis and thrombosis can amplify 
inflammation. Inflammation leads to an imbalance between procoagulant and 
anticoagulant properties of the endothelium that can lead to a local stimulation of the 
coagulant cascade. In order to preserve the smooth flow of blood under quiescent 
conditions, endothelium has evolved a powerful arsenal of anticoagulant forces, which 
can be arrayed against the forces of thrombosis, to keep them at bay. TNF- α (a 
pleiotropic cytokine), the first proinflammatory cytokine released at the site of infection, 
is a potent inducer of immune defense mechanism and a mediator of leukocyte 
recruitment.124 The endothelium expresses thrombomodulin and promotes procoagulant 
state by inhibiting synthesis of the anticoagulant protein C125 and eliciting tissue factor 
(TF) production on the endothelium and monocytes, thereby stimulating thrombin and 
fibrin formation.126  
Increased expression of glycoprotein adhesion receptors on vascular endothelium, 
by hypoxia-triggered transcriptional cascades beginning with early growth response 
gene-1127 leads to induction of ICAM-1, and consequent recruitment of activated 
leukocytes particularly mononuclear phagocytes which contribute to the local 
procoagulant milieu. Recent evidence even implicates the local formation of tissue factor-
bearing microparticles128 in the processes leading to venous thrombogenesis. Circulating 
TF, in the form of microparticles released by activated leukocytes, accumulate in areas of 
stasis, such as the vein valve pockets.129 Leukocyte microparticles that express PSGL-1 
bind to P-selectin both on platelets and activated endothelial cells130,131, and this source of 
TF could sustain the production of thrombin on the forming thrombus, promoting its 
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propagation.132 Although there is a consensus that tissue factor plays a prominent role in 
driving early coagulant cascades leading to venous thrombosis,132,133 conventional notions 
of just where this tissue factor resides and how it is expressed are changing. Classically, 
tissue factor is known to reside and be enriched in the subendothelial stroma. Following 
vascular injury, when subendothelial material is placed in direct contact with blood, this 
can rapidly act with Factor VIIa to trigger thrombosis. We now know however that 
macrophages recruited to sites of hypoxemia or vascular injury are rich sources of tissue 
factor,109 and substantially can contribute to the initiation or propagation of thrombus. 
The relative contribution of leukocyte microparticles to venous thrombogenesis is not 
clear, however, several studies have shown that the vessel wall is the most important 
source of TF that promotes thrombogenesis,134 and therefore activation of the 
endothelium may be pivotal in the inflammatory processes that lead to thrombosis.  
As all or nearly all biological triggers have countervailing measures to dampen 
cascade reactions, so too the cascade of events initiating with the activation of red blood 
cells (RBCs) must be terminated rather than run unchecked in an inflammatory / 
coagulant maelstrom. The contribution of RBCs to venous thrombosis remains poorly 
understood, despite their abundance in the early venous thrombus and their contribution 
to platelet rich arterial thrombi.135 The cytoplasm of RBCs is rich in iron, which when 
released into circulation is highly inflammatory because of its oxidative effects on the 
endothelium. Natural antioxidant, such as heme oxygenase -1 (HO-1)-derived carbon 
monoxide (CO) and superoxide dismutase, produced by cells within the vessel wall and 
thrombus, may limit these proinflammatory effects produced during thrombogenesis. 
This putative mechanism by which RBCs may influence the development of venous 
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thrombi is supported by the finding that propagation of venous thrombosis is enhanced in 
HO-1-/- mice136 and genetic variants (long GT-repeat alleles) in the HO-1 gene appear to 
confer increased risk of recurrent venous thromboembolism in humans.137 One of the 
primary focuses of this thesis is to explore the role of HO-1/CO in luekosequestration 
during thrombogensis.  
Crosstalk between HO-1/CO, thrombosis and inflammation: 
HO-1 has been implicated in maintaining cellular homeostasis and providing 
cellular defense by virtue of the anti-apoptotic, anti-inflammatory and anti-oxidative 
properties mediated by HO-reaction products.138 Previous studies have indicated that 
products of HO-1 activity possess antithrombotic properties, and impairment of HO-1 
activity may contribute to thrombus formation.137,136 Elucidating the intrinsic mechanism 
involved in thrombus formation is critical to understanding the pathophysiology of DVT. 
Stewart et al demonstrated leukocyte migration into the vein wall with an intact layer of 
endothelial cells during DVT139, linking inflammation and thrombosis. Recent studies 
also highlight the role of HO-1 expression and/or CO in modulation of vascular 
endothelial cell damage, which is a key factor in thrombus formation following hypoxia 
or oxidant injury,140,141 irradiation-induced apoptosis,142 and interleukin-18-dependent 
inflammation.143  
HO-1 expression or endogenously generated CO inhibits production of 
proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1, and monocyte 
chemoattractant protein-1, most likely through inhibition of NF-κB activation.144,145 
These same mechanisms also limit the expression of adhesion molecules such as E- and 
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P-selectin, and the expression of tissue factor von Willebrand factor and plasminogen 
activator inhibitor-1, which can facilitate intravascular thrombus formation.146 Part of this 
thesis tests the hypothesis that heme oxygenase-1 and carbon monoxide play a critical 
role to mitigate venous thrombogenesis by squelching inflammatory reactions and key 
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FIGURE I.1:  HEME-DEGRADATION CATALYZED BY HEME OXYGENASE. 
Heme oxygenase (HO-1, HO-2) catalyzes the NADPH-cytochrome P450 reductase 
(CPR)-dependent degradation of heme into iron, CO and biliverdin, which is quickly 
reduced to bilirubin. Seven electrons are transferred and three molecules of O2 are 
consumed when one molecule of heme is oxidized to generate one molecule of biliverdin, 
one molecule of CO, one molecule of Fe (II), and three molecules of H2O. Two electrons 
are required for the reduction of one molecule of biliverdin. 


















FIGURE I.2: HEME DEGRADATION PATHWAY 
Heme is degraded to biliverdin through several key intermediates, including a peroxy 
intermediate, α-meso-hydroxyheme, α- verdoheme, and a ferric biliverdin complex. 
Heme Peroxy Intermediate α-meso-hydroxyheme












FIGURE I.3 TISSUE PROTECTION CONFERRED BY HO END PRODUCTS 
All three end-products of heme degradation, including Fe, CO, and bilverdin/bilirubin, 
can contribute to the cytoprotective process. Iron released by HO activity stimulates a 
cytoprotective pathway involving the synthesis of ferritin. CO has been implicated in 
anti-inflammatory, anti-apoptotic, and anti-proliferative pathways. Biliverdin and 

























FIGURE I.4: THEORY ON THE PATHOGENESIS OF BPD. 
There are two major events in the pathogenesis of BPD the prenatal and postnatal events. 
Prenatal event, which occurs when there is an increased expression of cytokines exposure 
in the fetus and postnatal event, which can occur due to improper resuscitation, oxygen 
toxicity, mechanical ventilation and pulmonary and/or systemic infection. Ultimately 
both events lead to the sequential lung Injury, pulmonary inflammatory response, 
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FIGURE I.5: VIRCHOW TRIAD 
This schematic diagram describes the three categories of factors that are though to contribute to 


















FIGURE I.6: LEUKOCYTE EXTRAVASATION 
The diagram depicts the movement of leukocytes out of the circulatory system, towards the site of 
tissue damage or infection. This process forms part of the innate immune response, involving the 
recruitment of non-specific leukocytes. Monocytes also use this process in the absence of 











TABLE I.1: TIMING OF THE DEVELOPMENTAL STAGES IN HUMAN AND 
MOUSE.  
 
In human lung, alveoli begin to form during the weeks preceding birth but the large 
majority of alveoli are formed PN. Since the mouse is born during the saccular stage, its 
alveolarization takes place postnatally beginning around day 4, but in humans the alveoli 







Stage Human (weeks)Term 40 weeks
Mouse (days) 




Saccular 24-38 17-PN 4
Alveolar 36-(1-2 years) PN 4 -28
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SUPPRESSION OF CCL2-DEPENDENT INFLAMMATORY CELL 
TRAFFICKING AND ALVEOLAR SIMPLIFICATION BY THE HEME 




Bronchopulmonary dysplasia (BPD), a lung disease of prematurely-born infants, 
is characterized in part by arrested development of pulmonary alveolae.  We 
hypothesized that heme oxygenase (HO-1) and its byproduct carbon monoxide (CO), 
which are thought to be cytoprotective against redox stress, mitigate lung injury and 
alveolar simplification in hyperoxia-exposed neonatal mice, a model of BPD.  Three-day 
old C57BL/6J mice were exposed to air or hyperoxia (FiO2 = 75%) in the presence or 
absence of inhaled CO (250 ppm for 1 h twice daily) for 21 days.  Hyperoxic exposure 
increased mean linear intercept, a measure of alveolar simplification, whereas CO 
treatment attenuated hypoalveolarization, yielding a normal-appearing lung. Conversely, 
HO-1 null mice showed exaggerated hyperoxia-induced hypoalveolarization. CO also 
inhibited hyperoxia-induced pulmonary accumulation of F4/80+, CD11c+ and CD11b+ 
monocytes and Gr-1+ neutrophils. Further, CO attenuated lung mRNA and protein 
expression of pro-inflammatory cytokines including the monocyte chemoattractant CCL2 
in vivo, and decreased hyperoxia-induced lung epithelial cell CCL2 production in vitro. 
Accordingly, we tested the requirement of CCL2 for hyperoxia-induced lung injury.  
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Hyperoxia-exposed CCL2 null mice, like CO-treated mice, showed attenuated alveolar 
simplification and lung infiltration of CD11b+ monocytes. We conclude that, in 
hyperoxia-exposed neonatal mice, inhalation of CO suppresses CCL2-dependent 






An estimated 30% of premature infants with a birth weight between 500-1500 g 
will develop respiratory distress syndrome, with many proceeding to develop 
bronchopulmonary dysplasia (BPD). Pathological features of BPD include interstitial 
fibrosis and abnormal cellular proliferation, as well as arrested alveolar development. 
Infants with BPD are at high risk for morbidity and mortality during the first years of life 
including increased medication use, hospital readmissions 1 and lung function 
abnormalities which persist into childhood and even early adulthood.  2, 3 
The pathophysiological mechanisms underlying BPD are likely multifactorial and 
not completely clear.  Recent studies implicate lung inflammation as a potential 
contributor to the development of BPD. Infiltrates of leukocytes and inflammatory 
mediators have been detected in the lungs of patients with BPD 4, 5.  Neutrophils and cells 
of the monocyte/macrophage lineage appear to play a particularly important role in 
chronic lung disease in preterm infants The development of BPD has been associated 
with increased lung levels of pro-inflammatory cytokines, including IL-1β, IL-6, tumor 
necrosis factor-α, as well as CXC and CC-chemokines 6, 7, 8.  Treatment of hyperoxia-
exposed neonatal lungs with antibodies or antagonists against the neutrophil chemokines 
CXCL1 or CXCL2 prevents lung inflammation and alveolar simplification 9, 10, 11.  
Oxidative stress has also been implicated as one of the major causes of pulmonary 
injury leading to the development of BPD.  Prolonged exposure to sublethal hyperoxia in 
animal models recapitulates some of the processes observed in BPD, such as arrested 
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alveolar development, marked by a paucity of α-actin-positive myofibroblasts at the 
alveolar septal tips, and a corresponding increase in the number of interstitial 
myofibroblasts 12, 13, 14, 15. Importantly, rodents exhibit at birth a saccular stage of lung 
development that is completed after 2 weeks of postnatal alveolarization, thus closely 
resembling the stage of lung development in premature infants between 26 and 28 wk 
gestation requiring intensive care 16.  In newborn animals, hyperoxia has been shown to 
be a strong inducer of various proinflammatory cytokines in airway cells and pulmonary 
tissue 17.  Reactive oxygen species may be produced by resident lung epithelial cells 
under hyperoxic conditions, or from neutrophils and macrophages invading the lungs as 
part of the inflammatory process induced by hyperoxia 18.   
Organisms faced with hyperoxic stress have evolved sophisticated and redundant 
mechanisms to ensure survival. Emerging evidence has highlighted a crucial role for 
stress-inducible heme oxygenase (HO)-1 and its catalytic byproducts, carbon monoxide 
(CO) and biliverdin, in cytoprotection against hyperoxic and ischemic forms of tissue and 
cellular injury 16, 19, 20, 21, 22, 23, 24, 25, 26, 27.  Although the precise mechanisms whereby CO 
modulates the inflammatory milieu remain under study, there is some evidence that it 
does so by tilting the milieu towards the production of the anti-inflammatory cytokine IL-
10 21, 25, 26, while at the same time blunting expression of TNF-α and IL-1β 27.  In 
immature rodents, HO-1 expression is induced during lung maturation and following 
exposure to hyperoxia, consistent with adaptation to extrauterine conditions of increased 
oxidative stress and inflammation 28, 29.  It has recently been shown that HO-1 and CO 
mitigate hyperoxia-induced pulmonary inflammation in neonatal mice 16.  However, 
arrested alveolar development was minimally affected by CO administration, and the 
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mechanisms by which CO reduced pulmonary inflammation were not explored.    
We hypothesized that inhalation of low dose episodic CO mitigates the effect of 
neonatal hyperoxia on alveolar development and the developing lung by an anti-
inflammatory mechanism.  We report here that inhalation of CO suppresses CCL2-
dependent inflammatory cell trafficking, pro-inflammatory cytokine expression and 





Experimental animals.  All animal experiments were performed accordingly to 
protocols approved by and carried out in accordance with the University of Michigan 
Institutional Animal Care and Use Committee. Timed pregnant C57BL/6J mice were 
either purchased from Jackson Laboratories (Bar Harbor, ME) or bred at the University 
of Michigan animal facility. Murine alveolar development begins on postnatal day 3, and 
saccular division is completed by the 14th postnatal day 30.  This sequence and relative 
timing of alveolarization resembles human lung development 31. After birth, three day-
old (P3) newborn pups from six different litters were subdivided into four groups within 
24 h of birth: normoxia (21% O2); hyperoxia (75% O2); carbon monoxide (CO 250 ppm) 
+ normoxia; and CO (250 ppm) + hyperoxia.  Selected experiments also employed 
B6.129S4-Scya2tm1Rol CCL2 null mice (Jackson Laboratories, Bar Harbor, ME). In 
addition, we obtained HO-1 null mice (C57BL/6J background) from Dr. Mu-En Lee 
(Harvard School of Public Health) 32. Colonies of HO-1 gene null mice were maintained 
by breeding HO-1-/- males with HO-1+/- females. Offspring were genotyped at the time of 
birth using PCR to amplify the wildtype and mutant alleles of genomic DNA from tail 
biopsies 33. For all experiments, HO-1+/+ and HO-1-/- mice were age-matched at postnatal 
(PN) day 3. Each litter consisted of 8-10 pups per group to control for the effects of litter 
size on nutrition and growth.  All animals were either exposed to room air or various gas 
mixtures, for up to three weeks.  
 To achieve 75% O2, 100% O2 was delivered at a flow rate of 0.5 L/min into a 
custom-made 1.5 m3 plastic chamber. Oxygen concentrations were monitored 
continuously with an oxygen analyzer (Neutronics, Exton, PA), gas lines were filtered 
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with activated charcoal to remove excess ammonia and calcium chloride was used to 
maintain CO2 levels below 0.05%. Animals were exposed to 250 ppm CO at a flow rate 
of 10 L/min into the same custom-made plexiglass chamber. A CO analyzer (Ntron 
model 1100, Neutronics, Exton, PA) was used to measure CO levels continuously in the 
chamber.  CO was administered at a concentration of 250 ppm for 1 h twice daily. CO 
levels were monitored and recorded daily. Dams were rotated between normoxia and 
hyperoxia conditions, or CO + normoxia and CO + hyperoxia conditions daily to 
minimize oxygen toxicity to the dams and to remove potential confounders of milk 
production induced in the various environments.  Relative humidity in the chamber was 
measured using a standard humidity and temperature monitor and was maintained at 45-
50%. Dams and pups were given food and water ad libitum and maintained on a 12 h 
dark:light cycle. For measurement of body weight, mice pups were weighed at 24 and 48 
h intervals until completion of time course.  Mice were euthanized with an overdose of 
ketamine and xylazine followed by thoracotomy after exposure for the indicated time 
periods and experimental conditions. 
Histological analysis.  Lungs were perfused with phosphate buffered saline (PBS) with 
20 mM EDTA through the right ventricle at a constant pressure of 20 cm H2O for 3-5 
min. Lungs were then intratracheally inflated with 10% formalin, fixed overnight at 4oC, 
then stored in 70% ethanol prior to embedding in paraffin. Five µm sections were stained 
with hematoxylin and eosin. Stained sections were visualized under light microscopy and 
images were captured using MetaMorph version 7.0r3 software (Molecular Devices, 
Sunnyvale, CA) on an Eclipse TE2000-E microscope (Nikon Instruments, Melville, NY). 
Morphometric analysis.  To assess alveolarization, mean alveolar diameter was 
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determined by measurement of mean linear intercept (MLI). MLI, equal to the mean 
interalveolar distance, was measured by dividing the total length of a line drawn across 
the lung section by the number of intercepts encountered, as described 34. Briefly, three 
representative lung sections for each animal were photographed at 200x magnification. A 
grid with parallel lines spaced at 60 µm was overlaid onto the image and the length of 
each cord was defined by the intercept with the alveolar walls.  Fifteen non-overlapping 
fields for each section were examined. Metamorph image analysis software was used for 
morphometric analysis. 
Cytospin preparation and lung inflammation.  To quantify inflammatory cells, lung 
cells were obtained by mincing the tissue, subjecting it to proteolysis in collagenase type 
IV (Invitrogen, Carlsbad, CA), and straining it through a 70 µm nylon mesh (BD Falcon, 
San Jose, CA). The resulting pellet was treated with RBC lysis buffer (BD Biosciences, 
San Diego, CA), and leukocytes were enriched by spinning the cells through 40% Percoll 
(Sigma-Aldrich). The cell suspension was cytocentrifuged at 500 g for 5 min using a 
Cytospin 4 (Thermo Fisher Scientific, Waltham, MA). Lung leukocytes were stained with 
Diff-Quick (Dade Behring, Newark, DE) and differential counts were determined from 
10,000 cells.  
Bronchoalveolar inflammatory and differential cell counts.  Bronchoalveolar lavage 
fluid (BAL) fluid was obtained through intratracheal instillation of 3 x 1 mL ice-cold 
PBS and filtered via a 70 µm cell strainer to exclude contamination from clustered 
epithelial cells. Erythrocyte contaminants were lysed using RBC Lyse (BD Biosciences, 
San Diego, CA). BAL fluid was centrifuged at 2000 rpm for 15 min, and supernatants 
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were removed and stored in -80oC until further analysis. The cell pellet was resuspended 
in PBS, and total infiltrating cells (neutrophils and macrophages) were counted using a 
HEMAVET 950FS cell hemocytometer (Drew Scientific, Dallas, TX).  
Immunohistochemistry and fluorescence microscopy. Paraffin blocks were sectioned 
at 500 µm intervals at a thickness of 5 µm.  After deparaffinization, rehydration and 
antigen retrieval, endogenous peroxidase was blocked using a rodent serum block. Serial 
sections were probed with fluorophore-labeled mouse anti-α-smooth muscle actin (clone 
1A4, Sigma-Aldrich), Alexa Fluor (AF)-conjugated donkey anti-goat IgG (Molecular 
Probes, Portland OR), rat anti-mouse F4/80 (AbD Serotec, Raleigh, NC), anti-CD11b 
(R&D systems, Minneapolis, MN) and rat anti-mouse Gr-1 (R&D systems, Minneapolis, 
MN). Slides were subsequently incubated with secondary antibody, ABC reagent (Vector 
Laboratories, Burlingame, CA) and diaminobenzidine (DAB). Nuclei were 
counterstained with 4',6-diamidino-2-phenylindole-DAPI (Molecular Probes, Portland 
OR) and immunofluorescence (DAPI). In addition, sections were incubated with Alexa 
Flour (AF)-555-conjugated goat anti-mouse JE/MCP-1 (R&D), AF633-rat anti-mouse 
CD68 (AbD Serotec, Raleigh, NC) or AF conjugated isotype control IgGs. To examine 
endogenous HO-1 staining, we used a rabbit polycolonal to rat HO-1 (StressGen; Vicoria, 
British Columbia, Canada). Images were visualized using an Axiovert 100M inverted 
fluorescent microscope (Carl Zeiss, Thornwood, NY). 
Focused gene array analysis of neonatal mouse lung lysates. Lung RNA from mice 
exposed to  normoxia, hyperoxia or episodic low-dose CO in the presence of hyperoxia 
were subjected to a targeted PCR array examining 84 mouse inflammatory cytokines (SA 
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Biosciences, Frederick, MD). Total RNA extraction was performed using the Qiagen 
Animal Spin protocol (Valencia, CA). Total RNA was quantified using the Nanodrop N-
1000 (Agilent Biosystems, Santa Clara, CA).  After verification of RNA quality and 
integrity, first-strand cDNA synthesis was performed on an Eppendorf Mastercycler 
using a Reaction Ready First-Strand cDNA Synthesis kit (SA Biosciences). The cDNA 
template was combined with RT2 Real-Time SYBR Green/Rox Master Mix (SA 
Bioscience) and RNAse-free water.  A final reaction volume of 25 µL was added to each 
well of PCR array. Finally, pathway-focused mRNA was amplified on a 7300 Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA) following the manufacturer’s 
protocol.  Genes were plotted as heat maps by hierarchical clustering using the 
correlation coefficient as a distance measure and the average of each cluster for cluster 
formation of the genes using Amap software (Bioconductor, Fred Hutchinson Cancer 
Research Center, Seattle, WA). Expression values are visualized with color ranging from 
red (high expression) over white (intermediate expression) to blue (low expression).   
RNA isolation and real-time reverse transcriptase-polymerase chain reaction (RT-
PCR). Quantitative RT-PCR was performed on 8 genes with increased or decreased 
expression following the different exposure conditions in C57BL/6J (n=10-18 
samples/condition). Lung total RNA was extracted using an RNAeasy Mini kit (Qiagen, 
Gaithersburg, MD). First strand cDNA (500 ng) was reverse-transcribed with a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real 
time PCR was performed with an ABI PRISM 7000 sequence detection system with 
TaqMan Universal PCR Master Mix and Assay-on-Demand gene expression probes 
(Applied Biosystems). The following primers were used in the PCR reaction: IL-1β, 
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TNF-α, IL-10, IL-13, IL-6, CCL-2, CxCL-2 and CxCL-1.  β-actin served as 
housekeeping gene. All primers and probe sets were purchased from Applied Biosystems. 
All samples were analyzed in quadruplicate.  mRNA expression was normalized to β-
actin level by the 2-ΔΔCt method. 
Protein extraction and cytokine expression.  Whole lung samples were homogenized 
with lysis buffer containing 1 mM Tris-HCl, pH 7.4, 0.5M EDTA, 5M NaCl, 1% 
TritonX-100, 1% sodium deoxycholate and 10% SDS supplemented with protease 
inhibitors (Complete Protease Inhibitor Cocktail, Roche, Indianapolis, IN). Supernatants 
were analyzed for IL-1β, IL-6, IL-10, IL-13, KC/CXCL1, MCP-1/CCL2, TNF-α, MIP-
2/CXCL2, MCP-1 protein abundance using a multiplex mouse immunoassay kit (BioRad, 
Hercules, CA) using the Luminex 200 System (Luminex Corporation, Autsin TX), 
following the manufacturer’s instructions. Supernatants were analyzed in triplicate.   
Flow-cytometric analysis of infiltrating leukocyte populations.  Lung tissues were 
harvested and single cell suspensions were obtained by digestion with collagenase IV 
(Gibco Life Technology, Grand Island, NY) for 1 h at 25oC while shaking. FACSlyse 
buffer (BD Bioscience, Franklin Lake, NJ) was used to lyse erythrocyte contaminants. 
Total lung cell counts were assessed by Hemavet hemocytometer (Drew Scientific) and 
reconfirmed by flow cytometry analysis using FITC-anti mouse CD45 antibody (BD 
Bioscience, Franklin Lakes, NJ) and flow cytometry absolute count standard beads (BD 
Bioscience). Viable cells were identified by the absence of DAPI (Molecular Probes, 
Portland OR) staining.  Nonspecific antibody staining was inhibited using Fc Block (BD 
Bioscience). Analysis of whole lung total alveolar leukocytes was performed using APC-
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anti-mouse CD11b and PE-anti-mouse Ly6G/Ly-6C (Gr-1) (both from BD Bioscience). 
In order to detect infiltrating alveolar macrophages, cells were purified and identified in 
four stages. First, the leukocyte population was gated using FITC-conjugated anti-mouse 
CD45. Second, infiltrating monocyte/macrophages, double positive for staining with 
APC-Cy7-conjugated anti-mouse F4/80high and PE-conjugated anti-mouse CD11c were 
then positively gated. Third, cells were gated using PerCPCy5.5-conjugated anti-mouse 
CD11b (all from BD Bioscience).  For calculation of total cell numbers in tissue, 
normalization to weight of tissue was performed. Data were acquired on a BD FACS 
CantoTM flow cytometer and analyzed with FlowJo v.9.4.11 (Tree Star, Ashland, OR).  
In vitro cell culture and CO exposure.  A549 human respiratory epithelial cells were 
obtained from ATCC (Manassas VA). The cells were maintained in Ham’s F-12K 
Nutrient Mixture Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum  (HyClone, Thermo Fisher Scientific, Waltham, MA), 10 mM L- 
glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin. Cell culture was 
maintained in humidified incubators (5% CO2, 95% air) at 37oC. Cells were grown to 60-
80% confluence and rendered quiescent in medium containing serum-free medium.  
Selected cultures were exposed to 95% O2 or 250 ppm CO + 95% O2 in  an incubator 
chamber (Biospherix, Lacona, NY). Control cells were cultured in standard tissue culture 
conditions (95% air, 5% CO2).  
Statistical analysis.  All results were expressed as mean ± SEM, with the number of 
experiments performed provided in the figure legends. Comparison of results between 
different groups with more than 2 conditions were compared using a one-way analysis of 
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variance (ANOVA) or Mann-Whitney U test, as appropriate, using GraphPad Prism 
software (LaJolla, CA).  To pinpoint differences between specific groups, Newman-






CO partially mitigates the effects of hyperoxia-induced lung injury on body weight 
and survival.   
Prolonged neonatal exposure to hyperoxia adversely affected somatic growth 
(Figure 1A). Hyperoxic exposure resulted in a significantly decreased weight at the end 
of the exposure period compared to air-exposed littermates.  Hyperoxic mice weighed an 
average of 6% less at day 7, 10% less at day 10, 13% less at 2 week and 21% less at 3 
week compared with normoxic mice; p<0.05). This was true for all experiments under 
hyperoxic conditions despite rotation of dams. Intermittent exposure to CO at 250 ppm 
during hyperoxic exposure tended to increase body weight, with the difference reaching 
statistical significance on day 21 (p <0.05). We constructed survival curves for the four 
groups (Figure 1B).  In this set of experiments, 72% of neonatal mice exposed to 
hyperoxia survived, with the majority of deaths occurring between 3 and 7 days of life.  
Administration of 250 ppm CO with 75% O2 treatment increased survival to 89%, with 
the results approaching statistical significance (p=0.07, Log-rank Mantel Cox test).  
Normoxia-exposed pups did not show signs of illness and all survived the first 3 weeks 
after birth. 
CO mitigates hypoalveolarization in hyperoxia exposed neonatal mice.  
  Premature mice are born at the saccular stage of lung development. Sacculi are 
transformed into alveoli within the first 2 weeks after birth by septal thinning and 
secondary septation. Histological analysis in untreated postnatal 3-day (p3) hyperoxia-
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exposed mice revealed markedly underdeveloped lungs at the saccular stage of 
development (Figure 1C). After 7-21 days of exposure, hyperoxic mice exhibited a 
significant structural delay in alveolar development compared to age-matched normoxia-
exposed counterparts. Alveolar simplification in hyperoxia-exposed mice was 
accompanied by increased collagen deposition in the alveolar walls (not shown). Lungs 
of mice intermittently exposed to 250 ppm CO for 1 hr twice daily were structurally 
similar to normoxic control mice.  Mice exposed to 75% oxygen and CO showed partial 
mitigation of hypoalveolarization compared with mice exposed to hyperoxia alone. To 
quantitate these differences, morphometric measurements of the mean linear intercept 
(MLI) were compared between study groups (Figure 1D). Compared to air-exposed 
mice, mean MLI for hyperoxia-exposed mice was significantly increased at 10, 14 and 21 
days of exposure.  When neonatal pups were exposed to 250 ppm CO in the setting of 
hyperoxia, we observed a significant decrease in MLI on day 10 of exposure in 
comparison with hyperoxia-exposed mice (P < 0.001).  Similar decreases in MLI were 
observed at other timepoints, though the differences were not statistically significant. 
Together, these data demonstrate that chronic neonatal hyperoxic exposure results in 
markedly decreased alveolarization, which is mitigated by intermittent CO treatment.  
CO suppresses hyperoxia-induced lung leukocyte recruitment.   
We hypothesize that CO mitigates the effect of hyperoxia on the developing lung 
via an anti-inflammatory mechanism. To quantify inflammatory cells, cells were obtained 
from minced lung tissue, enriched for leukocytes using a 40% Percoll gradient, 
cytocentrifuged and stained with Diff-Quick.  Hyerpoxic exposure increased the number 
of monocyte/macrophages on days 7, 10 and 14 of exposure, and these changes were 
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mitigated by CO treatment (Supplemental Figure S1A; data for day for 14 are shown 
in Figure 2A).   Similar effects were observed for lung neutrophils (Figures 2A, S1A). 
We also examined the inflammatory cell response in the BAL fluid (Figures 2B, 
S1B).   The number of BAL polymorphonuclear cells and monocyte/macrophages was 
significantly increased in hyperoxia-exposed pups at 7 days, reaching a peak at 14 days 
of hyperoxia exposure. Macrophages from hyperoxia-exposed mice showed a larger, 
foamy appearance, indicative of activation (data not shown), concordant with their 
previously reported apperance 19. CO treatment decreased the number of neutrophils and 
monocyte/macrophages in the BAL fluid. Together, the above findings indicate that CO 
treatment may confer significant protection against hyperoxia-induced pulmonary 
inflammation in developing lungs.  
Using flow cytometry to quantify leukocyte infiltration, we isolated whole lungs 
from neonatal pups after 7-21 days of exposure to air, air + CO, hyperoxia and hyperoxia 
+ CO, as described in the Materials and Methods. We employed antibodies against Gr-1 
(Ly6C/G) and CD45 to identify infiltrating neutrophils (CD45high Gr-1+) (Figures, S1C, 
D).  Following hyperoxic exposure, the number of CD45high Gr-1+ cells increased 
compared to normoxic littermates (P <0.001).  Exogenous CO decreased infiltrating 
neutrophils at all time points compared to hyperoxia-exposed mice.   
Immunofluorescent staining confirmed the localization of CD11b-positive (red), 
F4/80-positive (green; colocalization, yellow) macrophages in the alveolar septae and 
alveolar spaces of lungs from hyperoxia-exposed mice (Figure 2C).  Intermittent CO 
exposure during hyperoxia significantly decreased macrophage infiltration into the 
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alveolar space.  Hyperoxic exposure also induced a significant increase in infiltrating Gr-
1-positive neutrophils compared with normoxic control littermates. Exogenous 
application of CO to hyperoxic neonatal mice attenuated the infiltration of neutrophils, as 
it did for macrophages.  
To further understand the role of HO-1/CO in neonatal lung injury, we measured 
lung HO-1 mRNA expression in hyperoxia-exposed mice.  Hyperoxia significantly 
increases HO-1 expression (Figure 3A). HO-1 null mice exposed to hyperoxia showed 
exaggerated alveolar simplification compared to wild-ype mice (Figure 3B).  
Exaggerated hypoalveolarization was confirmed by mean linear intercept measurements 
(Figure 3C).  Immunohistochemistry showed that hyperoxia increases HO-1 expression 
in alveolar macrophages (Figure 3D).  As expected, HO-1 expression was not detectable 
in hyperoxia-exposed HO-1 null mice.  Finally, compared to wild-type hyperoxia-
exposed mice, HO-1 null mice showed a significant increase in BAL macrophages.  
Together, these data demonstrate that HO-1 deficiency is sufficient to exacerbate the 
effects of hyperoxia on the newborn lung.     
To characterize the inflammatory (monocyte/macrophage) response to hyperoxic 
exposure and CO treatment, neonatal pups were exposed hyperoxia and treated with 
intermittent CO for up to 21 days.  More than 90% of the isolated whole lung 
inflammatory cells were CD45-positive cells. By day 7, the percentage of cells 
expressing the monocyte/macrophage cell surface markers F4/80+ and CD11c+ 19 
significantly increased under hyperoxic exposure. The total number of F4/80+ and 
CD11c+ double positive cells peaked at 10-14 days of hyperoxic exposure (Figures 4A, 
4C S2A).   CO treatment tended to decrease the accumulation of cells infiltrating in the 
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hyperoxic exposed lungs.  On the other hand, hyperoxia-exposed HO-1 null mice showed 
increased F4/80+ and CD11c+ double positive macrophages.  
Recent studies suggest that, unlike resident alveolar macrophages, freshly 
recruited macrophages express low levels of CD11c and high levels of CD11b, which is 
required for their successful migration to inflamed tissues 35, 36. We therefore analyzed 
CD45-positive lung cells for both CD11c and CD11b (Figure 4B, 4C). We found three 
distinct subpopulations of cells.  CD11c+ CD11blow cells (population A) increased early 
during hyperoxic exposure.  Backgating of these cells showed them to be small, low 
complexity cells, probably lymphocytes (Figure S2B).  CD11chigh CD11bhigh cells, 
presumably representing exudative macrophages (population B), increased significantly 
early during hyperoxic exposure.  CD11clow CD11bhigh cells (population C), which 
presumably represent a transitional population of inflammatory monocytes, were also 
increased throughout the hyperoxic exposure period.  Both CD11bhigh populations 
backgated to the large, high complexity region typical of macrophages (Figure S2C).  
Administration of CO dramatically reduced the number of cells in populations A, B and 
C (Figure 4B, 4C).  Interestingly, lungs of air/CO-exposed mice also showed smaller but 
significant increases in population C cells.  Finally, compared to hyperoxia-exposed wild-
type mice, lungs from HO-1 null mice showed increased lung macrophages, in particular 
CD11clow CD11b high cells.  
Exogenous CO administration regulates the expression of pro- and anti-
inflammatory cytokines/chemokine under hyperoxic conditions.   
To determine the cytokines responsible for hyperoxia-induced macrophage/monocyte 
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lung infiltration, we performed a gene array focusing inflammatory markers.  Lung 
mRNA from day 3 normoxia-exposed mice, day 14 normoxia-exposed mice, day 14 
normoxia-exposed mice, day 14 hyperoxia-exposed mice and day 14 hyperoxia + CO 
exposed mice was subjected to a targeted PCR array examining mouse inflammatory 
cytokines (Figure 5).  Hierarchical clustering revealed a group of 12 genes, which were 
downregulated during normal development, increased by hyperoxic exposure, and 
decreased by concomitant CO exposure. This group of genes included Ccl2, Cxcl1 and 
Il1b.  We therefore examined the mRNA and protein levels of these and other cytokines 
by qPCR and multiplex immune assay, respectively.  Lung samples from 14 days post-
exposure were studied (Figure 6A-H).  Expression of mRNAs encoding the pro-
inflammatory cytokines IL-1β, TNF-α, IL-6, the monocyte chemoattractant CCL-2, and 
the neutrophil chemoattractants CXCL1 and CXCL2 were significantly greater in the 
lungs of hyperoxia-treated mice compared with lungs from air-exposed mice.  Similar 
increases were observed on the protein level. CO treatment under hyperoxia effectively 
suppressed all pro-inflammatory markers measured.   
In addition to examining pro-inflammatory cytokines/chemokines, experiments 
were also performed to determine the expression levels of two “anti-inflammatory” 
cytokines, IL-10 and IL-13 (Figure 6G, H).  IL-10 and IL-13 were decreased in the lungs 
of hyperoxia-treated mice.   Concordantly, the protein levels of both cytokines were also 
decreased after hyperoxic exposure.  CO tended to increase IL-10 and significantly 
increased IL-13 mRNA and protein levels during both air and hyperoxic exposure.  
CCL2 is required for hyperoxia-induced macrophage/monocyte infiltration and 
hypoalveolarization.   
	  
 68 
Based on the strong induction of CCL2 demonstrated by our microarray data, we 
chose to evaluate in depth the functional consequences of its expression in the 
development of BPD. CCL2 is a critical monocyte chemoattractant protein, also called 
MCP-1 (or JE in humans), which binds to its cognate ligand CCR2 expressed on 
monophagocytes, recruiting them to sites of inflammation. To further characterize 
hyperoxia-induced CCL2 expression, we performed immunofluorescence staining of lung 
sections for CCL2 and CD68, a macrophage marker (Figure 7A).  Hyperoxia increased 
the number of CD68-positive cells, indicating macrophage infiltration.  CCL2 expression 
was also increased, primarily in CD68-negative cells of the airway and alveolar 
epithelium.  CO administration decreased hyperoxia-induced CCL2 expression.    We 
tested whether hyperoxia increases respiratory epithelial CCL2 expression in vitro.   
A549 cells were cultured in an incubator chamber containing a normoxic or hyperoxic 
atmosphere in the absence or presence of 250 ppm CO (Figure 7B).  Hyperoxia caused a 
rapid increase in CCL2 mRNA expression, which was attenuated by CO treatment.   
Taken together, these data suggest that CO attenuates hyperoxia-induced lung 
inflammation by decreasing respiratory epithelial cell CCL2 expression.   
To test the hypothesis that CCL2 is required for hyperoxia-induced 
macrophage/monocyte infiltration and hypoalveolarization, wild-type and CCL2 null 
mice were exposed to air or hyperoxia, as described above.   As shown previously, 
hyperoxia blocked alveolar development, as evidenced by an increase in mean linear 
intercept (Figure 8A, 8B).  In contrast, CCL2 null mice showed no increase in mean 
chord length.   CCL2 null mice showed reduced BAL neutrophils and a trend toward 
reduced BAL monocytes (Figure 8C, 8D). In CCL2 null mice exposed to hyperoxia, 
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flow cytometry showed a reduction in F4/80+ CD11c+ macrophages, CD11chigh CD11bhigh 
(population B) exudative macrophages, and CD11clow CD11bhigh (population C) 






In this report, we show for the first time that: 1) brief episodic exposure to low-
dose CO significantly mitigates the deleterious effects of hyperoxia on alveolar 
development; 2) HO-1 deficiency exacerbates hyperoxia-induced lung injury; and 3) 
CCL2 is required for hyperoxia-induced alveolar simplification. Taken together, these 
studies indicate that, in hyperoxia-exposed neonatal mice, inhalation of the HO-1 product 
CO suppresses CCL2-dependent inflammatory cell trafficking, pro-inflammatory 
cytokine expression, and alveolar simplification.    
Previous studies have examined the role of neutrophils and macrophages in the 
pathogenesis of neonatal hyperoxic lung injury.  In neonatal rats, hyperoxia induces 
neutrophil influx and hypoalveolarization, which is attenuated by neutralizing antibodies 
against the neutrophil chemoattractants CXCL19 or CXCL2 10. Neutrophilic 
inflammation in hyperoxia is also prevented by a selective chemical antagonist of 
CXCR2 11. Neutralizing antibodies against MCP-1/CCL2, a monocyte chemoattractant, 
also decrease lung hypoalveolarization, as well as lung macrophage and neutrophil 
counts, in hyperoxia-exposed rats 37.    
In our study, we extend these observations by demonstrating that hyperoxia 
induces the accumulation of different F4/80-positive macrophage subsets into the lung, 
specifically CD11clow CD11bhigh and CD11chigh CD11bhigh cells. Previously, it was shown 
that, during influenza infection 38 and bleomycin exposure 39, CD11c- CD11b+ 
inflammatory monocytes are recruited to the lung and develop into a CD11chigh CD11b+ 
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activated macrophage population known as exudative macrophages.  On this basis, we 
speculate that the CD11clow CD11bhigh cells (our population C) represent inflammatory 
monocytes, and that CD11chigh CD11bhigh cells (our population B) represent exudative 
macrophages, a major source of inflammatory cytokines and chemokines in the lung.   
In addition to lung inflammation, hyperoxia increased the size of airspaces in the 
lung, indicating hypoalveolarization of the developing lung. Murine alveolar 
development begins on postnatal day 3, and saccular division is completed by the 14th 
postnatal day 30.  This result is in agreement with previous work showing that exposure of 
the perinatal lung to supraphysiological levels of oxygen confers profound 
hypoalveolarization 40, 41, and are consistent with the notion that oxygen exposure may be 
a contributing factor in the pathogenesis of BPD. .  
Next, we examined the effects of one-hour, twice per day CO treatment on lung 
development and inflammation.   CO treatment during hyperoxia significantly reduced 
hyperoxia-induced hypoalveolarization.   In addition, CO decreased the number of 
exudative macrophages and inflammatory monocytes in the lung.  Conversely, compared 
to wild-type mice, HO-1 null mice exposed to hyperoxia showed increased alveolar 
simplification and lung infiltration with CD11b(+) cells.  Overall, these data are 
concordant with the hypothesis that CO protects against lung injury, and is facilitative for 
alveolar development, even under hyperoxic stress conditions.  Unexpectedly, we found 
that CO treatment tended to increase the number of lung inflammatory cells in normoxia-
treated mice.  This may relate to CO’s anti-apoptotic effects 42, 43, which may prevent 
normal clearance of leukocytes from the lung.  
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In our previous work, we demonstrated that HO-1-deficient mice have 
significantly decreased survival upon ischemic lung injury, and that CO can rescue these 
mice 44. Recent reports have demonstrated the cytoprotective role of HO-1/CO in in vivo 
models of acute lung injury. Intravenous hemoglobin, a potent inducer of HO-1 (a major 
heme degradative enzyme), prevented lung injury in a rat model of sepsis 45. In a separate 
report, intratracheal administration of hemoglobin protected rats from hyperoxia-induced 
lung injury46. It was subsequently shown that adenoviral gene transfer of HO-1 conferred 
protection against hyperoxic-induced lung injury47. Inhaled CO at low concentrations 
(50-500 ppm) protected against hyperoxia-induced lung injury in adult rats 22.   Recently, 
the effects of HO-1 overexpression and CO administration (250 ppm for 1 h daily) were 
examined in a model of neonatal hyperoxic lung injury 16.  HO-1 overexpression and CO 
each attenuated hyperoxia-induced arterial remodeling, right ventricular hypertrophy 
pulmonary edema and hemosiderosis, while increasing blood vessel number.  HO-1 
overexpression and CO administration had modest effects on alveolar architecture and 
BAL , but the mechanisms driving inflammatory changes were not further explored.  
To determine the mechanism of hyperoxia- and CO-mediated changes in lung 
inflammation, we examined the mRNA and protein levels of candidate cytokines by gene 
array, followed by qPCR and multiplex immune assay.   Increases in lung leukocyte 
subpopulations with hyperoxia and mitigation of this response by CO were reflected in 
lung cytokine mRNA and protein levels.   Lungs of hyperoxia-exposed mice showed 
increased levels of CCL2 mRNA and protein, which were reduced by CO treatment.  We 
found a similar pattern for the type I cytokines IL-1β, TNF-α, CXCL1, and CXCL2.  
CCL2 is a chemoattractant for exudative macrophages 38.   We therefore tested the 
hypothesis that respiratory epithelial cells produce CCL2 in response to hyperoxic 
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exposure, leading to monocyte and macrophage infiltration of the lung.  First, we found 
that hyperoxia increased epithelial CCL2 protein expression in vivo, and that CO 
attenuated this response.  Second, we exposed A549 cells to hyperoxia in vitro.   We 
found that hyperoxia increased A549 cell CCL2 mRNA expression, and that expression 
was inhibited by CO treatment.  Finally, we exposed CCL2 null mice to hyperoxia in 
vivo, and found that these mice were protected from alveolar simplification.  In addition, 
the lungs of hyperoxia-exposed CCL2 null mice showed significantly reduced exudative 
macrophages and inflammatory monocytes, reproducing the effects of exogenous CO.  
Taken together, these data are consistent with the notion that inhalation of the HO-1 
product CO suppresses CCL2-dependent inflammatory cell trafficking, pro-inflammatory 
cytokine expression and alveolar simplification.    
The precise mechanisms by which inflammation inhibits alveolar development 
are not completely known.  Using a fetal lung explant model, it was recently shown that 
IL-1β-producing tissue macrophages mediate the inflammatory response to 
lipopolysaccharide and that macrophage activation inhibits airway morphogenesis 48. 
Conversely, macrophage depletion protected airway branching.  Further, tissue-specific 
macrophage activation induced by overexpression of IκB kinase inhibited lung 
development in vivo.  We propose that CO protects against hyperoxia-induced alveolar 
simplification by blocking macrophage infiltration and activation.  It is also conceivable 
that hyperoxia retards the growth of blood vessels in the lung needed for alveolar 
development 13, 49, 50, and that CO promotes angiogenesis 51, 52.  
In summary, we have provided a detailed in vivo analysis of lung inflammation 
and development after hyperoxic exposure in neonatal mice.  Our studies demonstrate a 
direct link between CO, the CCL2-dependent control of leukocyte migration into 
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hyperoxic lung tissue, and alveolar growth.  Inhibition of inflammatory cell infiltration by 
either CO or CCL2 gene deletion was associated with the attenuated alveolar 
simplification. Improved understanding of the mechanisms regulating macrophage 
recruitment into the developing lung could lead to new insights into the pathogenesis of 
BPD.  Finally, these data suggest that additional studies exploring low dose CO as a 
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FIGURE II.1: LOW INTERMITTENT DOSE CO PARTIALLY MITIGATES 
THE EFFECTS OF HYPEROXIA ON BODY WEIGHT, SURVIVAL AND 
ALVEOLAR ARREST IN NEONATAL MICE. 
(A) Group mean body weight at 3, 7 10 14 and 21 days of life under conditions of 
normoxia (n=167), hyperoxia (n=106), CO+normoxia (n=52) and CO+hyperoxia (n=64).  
Hyperoxic exposure decreased body weight compared to normoxia.  On day 21, mice of 
the hyperoxia+CO group were significantly larger than mice of the hyperoxia group 
(*p<0.05, ANOVA).  (B) Survival curves are plotted for all experimental groups as 
determined using the Kaplan-Meyer method. Compared to the hyperoxia group, there 
was a trend towards increased survival in the CO+hyperoxia group (all groups n=21; 
hyperoxia survival, 76.9%; hyperoxia+CO survival, 93.7%, Log rank test p=0.072). (C) 
Representative images of hematoxylin and eosin stained lungs of neonatal mice exposed 
to normoxia (21% oxygen), hyperoxia (75% oxygen), intermittent exposure to 250 ppm 
carbon monoxide plus compressed air for 1 hr twice daily (normoxia+CO) or 75% 
oxygen and 250 ppm CO for 1 hr twice daily (hyperoxia+CO).  Compared to air-exposed 
mice, hyperoxia-exposed mice demonstrated increased alveolar size indicative of alveolar 
development arrest. CO-treated mice exposed to hyperoxia showed attenuated alveolar 
simplification compared to hyperoxia-exposed mice. CO-treated mice exposed to 
normoxia showed similar alveolar architecture as normoxia-treated mice. Solid bar scale 
represents 200  µm and all panels are (200x). (D). Corresponding group mean linear 
intercepts (MLIs) of all groups. Data are reported as mean±SEM.  N =17-24 per group, 
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FIGURE II.2: EPISODIC CO TREATMENT SUPPRESSES LEUKOCYTE  
TRAFFICKING TO THE LUNGS OF HYPEROXIA-EXPOSED NEONATAL 
MICE.   
(A). Lungs were digested and cytospins were stained with Diff-Quik.  Cell counts of 
monocyte/macrophages (left) and neutrophils (right) are shown (mean±SEM, n= 3-8 per 
group, *p<0.05, ANOVA). (B) Bronchoalveolar lavage fluid (BALF) from 17 day-old 
pups exposed to normoxia or hyperoxia in the absence or presence of CO for 14 days. 
Total BALF cells (left), monocyte/macrophages (middle) and neutrophils (right) were 
measured by Hemavet.  N = 12-17 per group, *p<0.05, ANOVA).  (C) 
Immunofluorescent stains of 14-day lung sections from normoxia- hyperoxia- 
CO+normoxia- and CO+hyperoxia-exposed mice.  Macrophage staining panels include 
F4/80 (green) and CD11b (red).  Colocalization (yellow) indicates CD11b-positive 
macrophages (arrows).  Neutrophil panels show Gr-1 (green, arrows) and α-actin (red).  
Nuclei were counterstained with DAPI (black).  Original magnification is 200X, scale bar 






























































































































































































FIGURE II.3:  HO-1 KNOCKOUT EXACERBATES HYPOALVEOLARIZATION 
AND INCREASES LEUKOCYTE INFILTRATION IN HYPEROXIA-EXPOSED 
NEONATAL MICE. 
(A) Whole lung HO-1 mRNA expression from wild-type mice exposed to either 
normoxia (n= 20-26 mice per group) or hyperoxia (n = 19-23 mice per group) for up to 
21 days.  Hyperoxic exposure increased mRNA expression, as measured by qPCR 
(*p<0.05, ANOVA).  (B) Three-day-old wild-type or heme oxygenase-1 null mice were 
exposed to air or 75% oxygen for 14 days. As previously, hyperoxia-exposed wild-type 
mice showed alveolar arrest with large airspaces.  Hyperoxia-exposed HO-1 null mice 
showed exaggerated alveolar simplification compared to wild-type mice. (C)  Group 
mean chord length data (n = 4-9 per group, *p<0.05, ANOVA). (D) Hyperoxia-induced 
HO-1 expression is observed in lung alveolar macrophages (arrows). 
Immunohistochemistry was performed with an antibody against murine HO-1 (scale bar 
= 100 µm). (E-F). Hyperoxia-induced inflammatory cell influx in neonatal mouse lungs 
is exacerbated by HO-1 deletion. BALF monocytes (E) and neutrophils (F) were counted 
14 days after exposure to room air (21% O2) or hyperoxia (75% O2).  Compared to wild-
type mice, HO-1 null mice showed a significant increase in macrophages and a trend 
towards increased neutrophils (n = 4-7 mice per group, mean±SEM, *different from 
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FIGURE II.4:  HYPEROXIC EXPOSURE INDUCES ALVEOLAR 
MONOCYTE/MACROPHAGE INFILTRATION INTO NEONATAL LUNGS 
THAT IS AMELIORATED BY CO INDUCED TREATMENT.   
Representative flow cytometric scattergrams of monocyte/macrophage subpopulations 
within the  lungs of wild-type and HO-1 null mice exposed to normoxia and hyperoxia 
for 14 days.  Wild-type mice were also exposed to  normoxia+CO or hyperoxia+CO. 
Each dot plot is representative of four independent experiments). (A) CD45+, CD11c+, 
F4/80+ macrophages. (B) Gating scheme used in subsequent flow cytometric analysis. 
Whole lung live CD45+ cells were  analyzed for expression of CD11c and CD11b.  (C-E)  
Comparison of cell counts for F4/80 and CD11c double positive macrophages (panel C), 
CD11chigh CD11bhigh exudative macrophages (subpopulation B, panel D) and 
CD11clowCD11bhigh inflammatory monocytes (subpopulation C, panel E). Hyperoxia 
increased the trafficking of macrophage subpopulations into the neonatal lung and CO 
treatment attenuated macrophage recruitment.  HO-1-/- mice showed increases lung 
macrophages.  N = 4-10 per group, mean±SEM, *compared to hyperoxia alone, P <0.05, 
ANOVA. 






























FIGURE II.5:  HIERARCHICAL CLUSTERING DIAGRAM OF 
DIFFERENTIAL INFLAMMATORY GENE EXPRESSION IN NEONATAL 
MICE LUNGS ON 14DAYS POST HYPEROXIC-INDUCED LUNG INJURY.   
Gene expression was measured by focused mRNA array and analyzed by hierarchical 
clustering and plotted on a heat map using R software.  Each lane represents the 
expression profile of 84 unique probe sets.   Lane 1 compares gene expression from two 
P3 normoxia and two 14 day normoxia-exposed mice.  Lane 2 compares gene expression 
from two P3 normoxia and two P17 hyperoxia-exposed mice.  Lane 3 compares two P3 
normoxia and two P17 hyperoxia+CO mice. Red and blue colors indicate up- and 


















































































































































































































expression level.  The bracket indicates a group of genes that were downregulated with 
development (lane 1), increased with hyperoxic exposure (lane 2) and suppressed by CO 







FIGURE II.6 EXOGENOUS CO ADMINISTRATION REGULATES THE 
EXPRESSION OF PRO- AND ANTI- INFLAMMATORY CYTOKINES UNDER 
HYPEROXIC CONDITIONS.   
mRNA and protein levels were measured by quantitative PCR and multiplex immune 
assay at 14 day post-exposure. (A-F) Hyperoxia increased the mRNA and protein 
expression of IL-1β, TNF-α, IL-6, CCL-2, IL-10, IL-13, CxCL-1 and CxCL-2 (A-F).  
.CO administration significantly reduced IL-1β, TNF-α, IL-6, CCL-2, CxCL-1 and 
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CxCL-2 mRNA expression as well as IL-1β, CCL-2, CxCL-1 and CxCL-2 protein 
expression.  (G, H). IL-10 and IL-13 were downregulated by hyperoxic treatment and 
increased with CO exposure.  The data pool at least three independent experiments 
(mean±SEM,  n=10-18 animals per group for mRNA analysis, n = 4 per group for protein 



























FIGURE II.7: HYPEROXIA EXPOSURE IS ASSOCIATED WITH AN 
INCREASE IN RESPIRATORY EPITHELIAL CELL CCL2 EXPRESSION. 
Lung sections were stained for CCL2 (red) or CD68 (green); colocalization appears 
yellow.  Compared to normoxia-exposed mice, hyperoxia-exposed mice show an increase 
in CCL2 expression primarily in the epithelium as well as an increase in CD68-positive 
macrophages.  Episodic CO treatment the presence of hyperoxic exposure suppressed 
CCL2 expression (line segment = 50 µm, results are typical of three individual 
experiments). (B) A549 respiratory epithelial cells were exposed to 250 ppm CO or room 
air in the absence or presence of high oxygen tension (>95% O2) for a duration of 2, 6 or 















































































FIGURE II.8:  CCL2 DELETION DECREASES HYPEROXIA-INDUCED 
ALVEOLAR SIMPLIFICATION AND INFLAMMATORY CELL 
TRAFFICKING.   
(A)  Representative lung sections from wild-type and CCL2 null mice exposed to 
normoxia or hyperoxia for 14 days were stained with hematoxylin and eosin.  (B).  
Alveolar size, as measured by mean chord length, confirmed features noted on lung 
histology (n= 15-18 mice per group, *P <0.05, ANOVA).  (B). Bronchoalveolar lavage 
cells were measured Hemavet.  Compared to hyperoxia-exposed wild-type mice, CCL2 
null mice tended to show decreased neutrophils (C) and macrophages (D).  (N = 5-8 mice 














































FIGURE II.9:  CCL2 DELETION DECREASES ALVEOLAR 
MONOCYTE/MACROPHAGE INFILTRATION INTO HYPEROXIA-EXPOSED 
NEONATAL LUNGS. 
Representative flow cytometric scattergrams of monocyte/macrophage subpopulations 
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14 days.  Each dot plot is representative of four independent experiments. (A) CD45+, 
CD11c+, F4/80+ macrophages. (B) The gating scheme used for CD11c and CD11c 
staining was explained in Figure 4 and is briefly shown here.   Each dot plot is again 
representative of four independent experiments.  Comparison of cell counts for F4/80 and 
CD11c double positive macrophages (panel C), CD11chigh CD11bhigh exudative 
macrophages (subpopulation B, panel D) and CD11clowCD11bhigh inflammatory 
monocytes (subpopulation C, panel E). Hyperoxia increased the trafficking of 
macrophage subpopulations into the neonatal lung and CCL2 deletion attenuated 
macrophage recruitment.(n = 8-14 mice per group, mean±SEM, *different from 
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FIGURE II.10 GRAPHICAL REPRESENTATION SUMMARIZING THE 
MECHANISM(S) POTENTIALLY INVOLVED IN THE ANTI-
INFLAMMATORY ACTIVITIES OF HO-1/CO VIA SUPRESSION OF MCP-
1/CCL-2 IN HYPEROXIA INDUCED BRONCHOPULMONARY DYSPLASIA 
The precise mechanisms by which inflammation inhibits alveolar development are not 
completely known. In our current study we used a neonatal hyperoxic induced mouse 
model to depicted our proposed mechanism of an activated alveolar macrophage during 
hyperoxia induce bronchoplumonary dysplasia and CO treatment. During hyperoxia 
exposure and in the absence of HO-1, exudative and activated macrophages secrete 
Carbon monoxide + Hyperoxia
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proinflammatory cytokine and chemokines, which ultimately lead to mitochondrial 
dysfunction and an increase in reactive oxygen species. However, when these cells are 
treated with low dose of pulsatile carbon monoxide and in the absence of CCL-2, there is 
an increase in anti-inflammatory cytokine IL-10 and IL-13 and a subsequent increase in 
anti oxidants, which lead to protection of alveolar damage. Our studies demonstrate a 
direct link between CO, the CCl-2-dependent control of leukocyte migration into 
hyperoxic lung tissue, and alveolar growth.  Inhibition of inflammatory cell infiltration by 






































































































































SUPPLEMENTAL FIGURE II.1: TIME COURSE FOR CO-INDUCED 
SUPPRESSION OF LEUKOCYTE MIGRATION TO THE LUNGS OF 
HYPEROXIA-EXPOSED NEONATAL MICE.  
The effect of CO on lung infiltration by leukocytes was assessed using cytospins from PN 
days 7, 10 and 21 days. Cell counts of monocyte/macrophages (A) and neutrophils (B) 
are depicted (y-axis indicates cell number x 1000). Data represent mean±SEM, n = 12-17 
per group, *different from hyperoxia-exposed group, P <0.05, ANOVA. (C) Hyperoxia-
induced neutrophil inflammation in neonatal mouse lungs is attenuated by exogenous CO 
exposure.  DAPI-negative (live), CD45-positive, Gr-1+ neutrophils were identified by 
flow cytometric analysis. Representative histogram showing Gr-1+ staining from 7, 10 
and 21 days of hyperoxic exposure in the presence and absence of CO.  Effects of the 
various treatments on Gr-1 mean fluorescent intensity (MFI, y-axis indicates MFI x 
1000). Numbers represent mean±SEM, n = 12-17 per group; *different from hyperoxia-
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SUPPLEMENTAL FIGURE II.2:  TIME COURSE OF 
MONOCYTE/MACROPHAGE INFILTRATION INTO NEONATAL LUNGS 
EXPOSED TO HYPEROXIA IN THE PRESENCE OR ABSENCE OF EPISODIC 
CO TREATMENT.  
 (A) Flow cytometric analysis of viable (negative for DAPI) alveolar 
monocyte/macrophages from neonatal mouse lungs of wild-type or HO-1 null mice after 
7, 10 or 21 days of normoxic or hyperoxic exposure, in the presence and absence of CO. 
Flow cytometry plots show the expression of CD45+, CD11c+/F4/80+ macrophages.  CO 
treatment tended to decrease percentage and total number of F4/80+/CD11c+ double 
positive cells. HO-1 deletion tended to increase in F4/80+/CD11c+ double positive cells.  
Group mean data are also shown.  Results are depicted as mean±SEM, n = 4-10 per 
group, *different from hyperoxia alone, P <0.05, ANOVA.   (B).  Back-gating analysis of 
CD11c and CD11b cells in hyperoxic exposed mice.  Back gating analysis showed that 
cells isolated from population A were located in the lymphocytic region based on side 
and forward scatter. Population B CD11chigh CD11bhigh cells tended to be large cells with 
varying granularity.  Population C CD11clow CD11bhigh were smaller with moderate 
granularity, reflecting recruited monocytes.    C.  Time course of alveolar 
monocyte/macrophage subpopulations after exposure to hyperoxia or CO treatment. 
More than 85% of the viable live cells isolated (gated for side and forward scatter) were 
CD45+ cells. More than 65-75% of CD45+ cells expressed varying levels of cell surface 
antigens CD11c and CD11b. Dot plot analysis showed three distinct subpopulations of 
monocyte/macrophages under conditions of normoxia, hyperoxia, CO+normoxia and 
CO+hyperoxia. Data for 7, 10 and 21 day time points are shown; these plots are 
representative of four independent experiments.  Plots of group mean data for 
subpopulations B (CD11chigh CD11bhigh) and C (CD11clowCD11bhigh) are shown.  HO-1 
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null mice exposed to hyperoxia had significantly more infiltrating cells compared to wild-
type hyperoxia-exposed mice. Hyperoxia increased the amount of CD11chigh CD11bhigh 
macrophages infiltrating into the neonatal lung in both hyperoxia-exposed wild-type and 
hyperoxia-exposed HO-1-/- mice. CO treatment attenuated macrophage recruitment 
starting at day 7 of exposure. These data are from three independent time course 
experiments, n=5-10 per group at each time point.  Results are depicted as mean±SEM; 
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HEME OXYGENASE-1/CARBON MONOXIDE (HO-1/CO) SUPPRESSES 
THROMBUS MASS AND PLATELET-LEUKOCYTE AGGREGATION IN A 




Deep venous thrombosis (DVT) formation instigates an inflammatory response, resulting 
in vessel wall damage and an increase leukocyte infiltration. The objective of this study 
was to understanding venous thrombosis and the relationship between thrombosis and 
inflammation during acute verses chronic venous thrombosis. Heme oxygenase-1 (HO-1) 
and its byproduct carbon monoxide (CO) are strongly induced in injured tissues are 
thought to have anti-inflammatory and anticoagulant properties by augmenting 
fibrinolysis and inhibiting platelet aggregation. Vascular injury activates endothelial cells 
and promotes expression of P-selectin (P-sel), von Willebrand factor (vWF) on vein wall 
of endothelial cells during stasis-induced DVT. However, whether HO-1/CO, P-sel and 
vWF plays a role in platelet recruitment in DVT remains elusive. We hypothesize that 
HO-1/CO modulates venous thrombosis through a combination of anti-inflammatory and 
anti-thrombotic effects in part through mitigating the expression of vWF and P-sel. We 
employed an inferior vena cava (IVC) ligation mouse model of venous thrombosis. HO-
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1+/+ and HO-1-/- mice underwent IVC-ligation for 48 hrs. WT animals were also exposed 
to 250ppm of CO for 7 days post-IVC ligation. Mouse blood was drawn via cardiac 
puncture and the infra-hepatic thrombus containing IVC was removed in toto. We 
examined serum levels of a soluble form of vWF and P-sel. vWF, P-selectin and 
inflammatory cytokine levels were measured in the venous wall by ELISA and qRT-
PCR. Flow cytometry was used to measure expression of platelet and leukocyte surface 
markers, in order to determine the relative activation and binding of platelets and 
leukocytes in whole blood. Compared to HO-1+/+, thrombus weights increased 
significantly in HO-1-/- mice and episodic low dose of CO treatment had a modest 
inhibitory effect on thrombus weight. We also showed P-sel and vWF levels in HO-1-/- 
IVC ligated mice plasma was significant increase compared to IVC-ligated HO-1+/+ mice. 
Additionally, compared to IVC-ligated HO-1+/+ mice, platelet-leukocyte aggregates were 
significantly increased in IVC-ligated HO-1-/- null mice. Furthermore, pro-inflammatory 
cytokines and chemokine (IL-6, CCL-2, CxCL-1 and CxCL-2) mRNA levels increased in 
IVC ligated HO-1 null mice. The application of low-dose CO for 7 days after IVC 
ligation decreased expression of these proinflammatory modulators in the venous wall 
and thrombus as well as leukocyte infiltration into the clot. These findings suggest that 
platelets binding to activate leukocytes contribute to the inflammatory milieu in thrombi 
of IVC-ligated mice.  DVT strongly induce vascular-protective enzyme HO-1, the actions 
of which may mitigate inflammatory upregulation of leukocyte adhesion receptors such 
as P-sel and vascular modulator, vWF. Exogenous CO may also mitigate thrombosis by 






Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is the third most common cardiovascular disease in the United 
States.1 Current therapy primarily involves anticoagulation with heprin, followed by a 
vitamin K antagonist.2 Although anticoagulant therapy is efficacious when used 
prophylactically, it carries a significant major bleeding when used for long-term therapy.3 
There is increasing evidence that inflammatory process and DVT are closely interrelated.4 
It is known that during vascular injury, the endothelium is activated and promotes Weibel-
Palade body (WPB) release and facilitates blood coagulation.5,6 WPB stores P-selectin, 
von Willebrand factor (vWF) and other vascular modulators. vWF, a multimeric protein 
that mediates platelet adhesion to the vessel wall and platelet recruitment to the growing 
thrombus.7 In arterial thrombosis, the role of vWF in the developing thrombus has been 
repeatedly demonstrated, and more recently the role of vWF in platelet recruitment in a 
mouse model of venous thrombosis was reported.8 Research in various animal models 
suggests an integral association between inflammation and thrombosis. Specifically, a 
proinflammatory environment, which is mediated by cell adhesion molecules such as P-
selectin and E-selectin.9,10,11,12 The expression of P-selectin on the endothelial and platelet 
surface plays an important role in perithrombothic inflammation.12 P-selectin allows for 
the interaction and recruitment of leukocytes and monocyte to thrombotic sites with fibrin 





Recent clinical and basic science studies have revealed that heme oxygenase-1 (HO) is 
involved in modulating a number of disease processes.14,15 Heme oxygenases are the rate-
limiting enzymes in the catabolism of heme into bilirubin, free iron, and carbon 
monoxide (CO), and exist in different isoforms.16 HO-2 is thought to be constitutive, 
whereas HO-1 is inducible by various stimuli, such as cytokines and oxidants.16 HO-3 is 
also involved in heme degredation, but is a less efficient heme catalyst than the other 
isozymes. Recently, compelling studies have shown that products of HO-1 activity 
possess antithrombotic properties, and impairment of HO-1 activity may contribute to 
thrombus formation.17 Although the beneficial roles of HO-1 are not completely 
understood, these cytoprotective and anti-inflammatory effects of HO-1 are related to the 
formation of its end-products. CO, an odorless gas that is commonly viewed as an 
environmental poison, is produced endogenously by mammalian cells as a product of 
heme degradation by HO enzyme, of which HO-1 plays a homeostatic role in host 
defense and inflammation.18 Several, experimental studies have also shown that non-
toxic, low doses of CO exert anti-coagulant effects by affecting fibrinolysis19, platelet 
aggregation20,21 and by maintaining the integrity of the vessel wall.22,23 Exogenous CO 
might prove beneficial in deep venous thrombosis by attenuating pro-inflammatory 
cytokines and chemokine production as well as neutrophil recruitment. However, the 
progression and time course of endothelial injury by stasis-induced venous thrombosis 
are not well represented by the models previously used in experimental studies evaluating 
CO and HO-1’s cytoprotective effects. Therefore, the aim of this study was to examine 
the effects of pulsatile low-dose exogenous CO on stasis-induced venous thrombosis and 
delineate the role of HO-1 in leukocyte recruitment during acute and chronic thrombus 
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formation. In addition, we examined the effects of HO-1/CO on key inflammatory 
modulators (p-selectin and vWF), cytokine and chemokine levels and peripheral whole-
blood leukocyte-platelet aggregation. The results demonstrated that pulsatile CO 
treatment acutely reduced leukocyte recruitment to the vessel wall post-IVC ligation and 
endogenous CO production attenuates the inflammatory response and leukocyte-platelet 
aggregates. These studies provide a basis for further investigation of HO-1/CO treatment 









A colony of homoxygous male HO-1–deficient mice (HO-1-/-) bred on a C57BL/6 
background for more than fifteen backcrosses was established at the University of 
Michigan.24 Age- and sex-matched specific pathogen-free 8–10-wk-old male C57BL/6 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). HO-1-/- generated 
by targeted disruption of the HO-1 gene was used25 with HO-1+/+ progeny serving as 
littermate controls. Colonies of mice were maintained by breeding HO-1-/- males with 
HO-1+/- females and genotype was confirmed by genomic PCR analysis of DNA 
extracted from tail clippings. All animals were housed in specific pathogen-free 
conditions within the University of Michigan Animal Care Facility. All animal 
experiments preceded in accordance with National Institutes of Health policies on the 
human care and use of laboratory animals and were approved by the University 
Committee on Use and Care of Animals at the University of Michigan. 
 
Inferior vena cava stasis model of deep venous thrombosis  
Experiments were performed in a recently described IVC ligated stasis mouse model for 
studying deep venous thrombosis.26,27 In brief, animals were anesthetized using 
continuous flow of 5% isoflurane gas and 100% oxygen and placed on a temperature-
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regulated heatpad to maintain body temperature at 37oC. Following a midline laparotomy 
to access the IVC and exteriorize the bowel and intestines, anesthesia was maintained 
using an inhalation mixture of 2% isoflurane and 100% oxygen. All dorsal branches were 
cauterized and venous side branches caudal to the left renal vein were ligated using 7–0 
Prolene suture (Ethicon, Inc, Somerville, NJ). The abdominal wall was closed in a bilayer 
fashion with 5–0 Vicryl (Ethicon, Inc, Somerville, NJ) for abdominal muscles and 
Vetbond tissue adhesive (3 M Animal Care Products, St. Paul, MN) for the skin. 
Following euthanasia, the IVC containing the thrombus was carefully removed, weighed 
in miligrams (mg). The thrombus was then removed from the IVC and the vein wall and 
thrombus were weighed individually in miligrams (mg). All animals were euthanized at 
specific time points, post-thrombosis, for tissue harvest and blood collection.  
 
Episodic administration carbon monoxide  
Mice were intermittently treated with exogenous CO gas as follows.  Cages were placed 
in a plexiglass exposure chamber immediately after competition of IVC ligation and 
exposed to 250ppm for 1 hour twice daily (balanced with air) or 21% oxygen and 
continuing for up to 7 days. This concentration of CO was based on previous reports of 
their use in different model systems.24,28,29,30,31 Flow into the 5.70-ft2 plexiglass chamber 
was maintained at rate of 12L/min. The final CO levels in the chambers (250 ppm) were 
monitored using a CO analyzer (Interscan Corporation). There were no fluctuations in the 
CO concentrations after the chamber had equilibrated. Ventilation was adjusted using an 
Oxycycler controller (Biospherix, Lacona, NY) to remove CO2 so that it did not exceed 
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0.5%. Ammonia was removed by ventilation and activated charcoal filtration through an 
air purifier. At the end of the exposure period, mice were killed and IVC tissues were 
harvested for further analysis.   
 
Thrombus containing Inferior vena cava weight measurement 
After stasis induced IVC liagtion of HO-1+/+ and HO-1-/- mice or empirically 
administered CO at 250ppm in air for 1 hour twice a day in breathing chamber, groups of 
mice were analyzed for different experimental conditions at each time point. This 
technique is an indirect measure of thrombus content. At sacrifice, IVC (including 
contents) was removed, weight and length were measured in milligrams (mg) and 
centimeter (cm), respectively, and then IVC was carefully stripped from the thrombus 
and both were weighed independently.  
 
Histopathological evaluation, immunocytochemistry and morphometric analysis  
Thrombus containing IVC were excised, fixed in 10% formalin for 2 hrs, then stored in 
70% ethanol prior to embedding in paraffin. Five µm sections were cut and stained with 
hematoxylin and eosin, visualized under light microscopy and images were captured 
using MetaMorph version 7.0r3 software (Molecular Devices, Sunnyvale, CA) on an 
Eclipse TE2000-E microscope (Nikon Instruments, Melville, NY) at 400x magnification. 
Morphometric measurements of cross-sectional areas were performed to assess vein wall 
inflammatory cell infiltrate (total inflammatory cells, polymononucleated (PMNs), 
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monocte/macrophage, or lymphocytes). To ensure our result were unbias, a board-
certified veterinary pathologist blinded to experimental conditions using a previously 
described thrombus surface organization scoring criteria27 chose five representative high-
powered fields  (5HPFs) from a least three different sections from each experimental 
group were examined. Results from each 5HPF were added together for each section 
studied, and mean ± SEM was calculated for each experimental group. 
Immunocytochemistry for P-selectin and vWF was performed by immersion in 4% 
formalin, incubation with blocking serum, followed by incubation at 4oC overnight with 
rabbit polyclonal stained for CD62P (Ab 59738 - Abcam, Cambridge, MA or vWF 
(A0082 – Dako, Carpinteria, CA) at as a primary antibody. A secondary antibody 
conjugated to a horseradish peroxidase-labeled polymer (EnVision+, HRP, Rabbit, 
catalog no. K4003, Dako, Carpinteria, CA) was further used. Slides were counterstained 
with hematoxylin, and images acquired with a 400x objective, and analyzed using 
MetaMorph image analysis software (Molecular Devices, Sunnyvale, CA) on an Eclipse 
TE2000-E microscope (Nikon instruments Inc).  
 
Hematology 
Blood was drawn from each experimental group via direct cardiocentesis into EDTA 
microtainer tubes (BD, Franklin Lakes, NJ). A complete hematological blood profile was 
run on 30µL using the CDC Technologies HEMAVET® Multispecies Hematology 
Analyzer (Drew Scientific, Inc. Oxford, CT). The hematologic parameter examined at 
outline on Table 1.  
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vWF and P-selectin analysis by enzyme-linked immunosorbent assay 
Following IVC ligation and blood cell count analysis, EDTA (Becton Dickinson, and Co. 
Franklyn Lakes, NJ) treated whole blood samples were spun down and plasma was 
processed according to the manufacturer’s instructions. Aliquots of plasma from varying 
experimental groups were measured for vWF (Perkin Elmer, Waltham, MA) and soluble 
P-selectin (R&D systems Minneapolis, MN) post-thrombus induction and exogenous 
carbon monoxide exposure. Plasma vWF antigen levels were determined by AlphaLISA 
custom designed kit, using a polyclonal anti-human vWF antibody (DAKO, Glostrup, 
Denmark) conjugated to Alphalisa acceptor beads and well as biotinylated anti-human 
VWF antibody (also DAKO) to interact with streptavidin coated donor beads. 
AlphaLISA signals were determined on an EnSpire 2300 Multimode Plate reader (Perkin 
Elmer), and VWF levels were calculated by comparing signals to a dilution series of 
C57BL/6J plasma.  All vWF levels are reported as a percent of C57BL/6J plasma and   
samples were assayed at least 3 times.  
 
Flow cytometry 
To assess platelet-leukocyte aggregates a 6-color flow cytometry assay was used to 
measure the interdependence of both platelets and leukocytes in this model. Whole blood 
from each animal was collected from the retro-oribital plexus of each experimental group 
and assayed for flow cytometry by standard techniques. Total cell counts were assessed 
by Hemavet hemocytometer (Drew Scientific) and reconfirmed by flow cytometry 
analysis using PerCPCy5.5-anti mouse CD45 antibody (BD Bioscience, Franklin Lakes, 
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NJ) and absolute count standard beads (BD Bioscience). Neutrophils were stained using 
APC-Cy7-anti-mouse Ly6G/Ly-6C (Gr-1) and monocyte/macrophage were detected 
using APC-anti-mouse CD11b. Within the CD11b/CD45 and Gr-1/CD45 positive-double 
events, subpopulation was identified using rat anti-mouse CD41 (platelet glycoprotein 
(GP) IX)- PE antibody to label platelets; the activation of platelets bound to leukocytes 
was assessed by counting CD62P (P-selectin) – fluorescein isothiocyanate (FITC)- 
positive events. Activated platelet –monocyte (CD11b-APC/CD41-PE/CD62P-FITC) and 
activated platelet–neutrophil (GR-1-APC-Cy7/CD41-PE/CD62P-FITC) aggregates were 
calculated from CD41-PE/CD62P double positive gates. Antibody specificity was 
verified using an appropriate isotype-labeled antibody (anti–rat IgG2a or anti–rat IgG2b). 
Erythrocytes were depleted from the preparations with BD FACS lysing solution (BD). 
Flow cytometric measurement was performed on a FACSCanto (BD) using DIVA 
software. All antibodies were purchased from BD Bioscience. Dead cells were excluded 
with DAPI (Sigma-Aldrich, St. Louis, MO). Files were analyzed in FlowJo (Tree Star, 
San Carlos, CA). 
 
Quantitative reverse-transcription PCR 
RNA was isolated from the whole IVC using the RNEasy MicroKit (Qiagen, Valencia, 
CA) or TRIzol (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. 
cDNA was prepared with Superscript II (Invitrogen). Quantitative PCR was performed 
with TaqMan (Applied Biosystems, Carlsbad, CA) per manufacturer’s instructions, and 
the ABI Prisim 7500fast sequence detection system (Applied Biosystems, Carlsbad,CA). 
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Real-time PCR was run on the cDNA template according to the manufacturer's protocol 
for β-actin (house keeping gene). Relative expression was calculated using the ΔΔ 
threshold cycle method. All the primers used for qRT-PCR were purchased from 
Invitrogen. 
 
Statistical analysis.   
Representaive data was displayed as mean ± SEM, with the numbers of experiments 
performed provided in the figure legends. Comparison of results between different groups 
with more than 2 conditions were compared using a one-way analysis of variance 
(ANOVA) or a Mann-Whitney U test, as appropriate, using GraphPad Prism software 
(LaJolla, CA).  To discern differences between specific groups, Newman-Keuls test was 








Pulsatile exposure of low dose carbon monoxide decrease thrombus mass and 
inflammatory cells in the vein wall post IVC-ligation. 
We previously reported an essential role for CO during an orthotopic lung transplant 
model 32 and double-lumen airway transplant model for studying chronic airway 
rejection.24 To assess if carbon monoxide decreases thrombus mass and mitigates 
inflammatory cell trafficking into the vein wall, we used C57BL/6 mice as wildtype 
control group and performed a time course and exposed mice to empirical low dose twice 
a day of 250ppm of CO in 21% oxygen to determine at which time point CO decrease 
thrombus weight. Thrombus size was smaller in the CO+N exposed wild type mice as 
compared with normoxia exposed wild type mice at 7day of exposure (Fig 1A). We then 
performed hematoxylin and eosin staining on the thrombus containing inferior vena cava 
sections 7-day post IVC-ligation and exposure of CO+N. In the 7-day CO+N exposed 
wildtype group, we observed decreased vein wall and inflammatory cells and compared to 
the 7day N exposed wild type (Fig 1B,C). Morphometric analysis revealed at day 7 in 
shams (N and CO+N) and IVC-ligated (N and CO+N) groups, CO treatment significantly 
decreased vein wall monocytes and lymphocytes post-IVC ligation compared to normoxic 
exposed mice. In contrast, vein wall polymorphonuclear cells (neutrophils) show a trend 
towards a decrease during CO+N treatment (Fig 1D-G). These data demonstrate that 
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exogenous CO shown to have a remarkable salutary effect on the thrombus formation, 
reduce expression of inflammatory cells especially leukocyte traffic, and thrombus mass.  
 
Heme oxygenase -1 deficiency is affected by thrombogenesis and leukocyte 
infiltration into the vein wall 
 
Since arterial thrombosis only occurred in HO-1-/- mice and CO, a product of HO-1, has 
been implicated in venous thrombosis17, we further investigated the role of endogenous 
CO production via absence of HO-1 in acute venous thrombogenesis model in which 
HO-1 null mice subjected up to 7 day of IVC-liagtion and thrombus mass and 
inflammatory cell accumulation in the vessel wall was measured (Fig 2). Quantitative 
RT-PCR measurement show an increase in HO-1 mRNA and thrombus mass at 48hrs 
post-IVC ligation in wild type C57BL/6 mice  (Fig 2 A, B). Our finding is in accordance 
with previous report that demonstrated HO-1 mRNA was strongly induced at 24hrs and 
48hrs following IVC-ligation.17 Using 48hrs IVC-ligated acute venous thrombosis model 
we performed all ligations in HO-1 null mice using 48hr model. Fig 2C depicts an 
enlarged thrombus containing IVC for HO-1-/- stasis-induced venous thrombosed mice 
compared to HO-1+/+ IVC-ligated mice. In addition, thrombus mass was also markedly 
increased in HO-1 null mice compared to HO-1+/+ IVC-ligated mice Fig 2D. Thus, 
ligation of the inferior vena cava at 48hrs promotes increase in thrombogenesis by 
increasing expression of HO-1, thereby causing an increase in thrombus mass in HO-1 
deficient mice. To evaluate the inflammatory cells in the vein wall at 2day post IVC-
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ligation, similar to Fig 1B,C we evaluated thrombus containing IVC histologic and 
morphometric profiles using H&E and selecting five high powered field around the vein 
wall to assess leukocyte accumulation, respectively (Fig 3). H&E analysis revealed 
significant thicker vessel wall and more prominent inflammatory cell infiltration in HO-1-
/- compared to HO-1+/+ 48hrs post IVC-ligation  (Fig 3A-D). Morphometric evaluation of 
vein wall showed statistically more neutrophils (12.8±.47 vs 6.2±.25 cells/5HPFs, 
P<0.05) and total inflammatory cell (14.7±.3 vs 9.8±.15 cells/5HPFs, P<0.05 ) in the vein 
walls of HO-1-/- 48hrs compared to HO-1+/+ animals (Fig 3 E, G). In contrast, vein wall 
monocyte/macrophages and lymphocytes were not increased at 48hrs following IVC-
ligation (Fig 3 F, H). These data indicate that heightened inflammatory response is 
primarily due to neutrophil influx not the monocytes macrophages. It is possible to 
conclude that monocytes may recruited to the vein wall/thrombus interface at a later time 
point following thrombus.  
 
Peripheral whole-blood hematology profile following IVC-liagtion  
To verify exaggerated inflammatory accumulation observed in HO-1-/- mice subjected to 
IVC-ligation, we examined hematological profile of all 4 groups. The normal reference 
range previously reported for mice for peripheral blood cell counts were normal between 
the sham-operated HO-1+/+ and HO-1-/- animals. In contrast, peripheral neutrophil, 
monocyte, lymphocyte, and red blood cell were significantly different between IVC-
ligated HO-1+/+ and HO-1-/- mice (Table 1). Interestingly, HO-1-/- showed a trend towards 
an increase in circulating platelet counts (282±41 vs 195±37 K/µL p=ns, respectively) 
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and also showed significant increase in mean platelet volume  (7.5± .35 vs 6.2±.29 fL 
p<0.05, respectively) compared to HO-1+/+ IVC-ligated animals (Fig 4A, B).  
 
Circulating and vein wall P-selectin and vWF following IVC-ligation are increased 
in HO-1-/- mice and decreased during treatment to low dose of carbon monoxide  
To test wether P-selectin or vWF play a role in the development of DVT, we employed 
our model of venous thrombosis on HO-1+/+ and HO-1-/- mice and treated wildtype mice 
with empirically low dose of CO to measure levels of these two inflammatory mediators. 
Immunocytochemical staining indicated P-selectin and vWF were both localized in vein 
wall of HO-1+/+ and HO-1-/- IVC-ligated mice (Fig 5A-D). Interestingly, HO-1-/- IVC-
ligated animals had larger vessel wall and slightly modest increase in localized staining 
of both P-selectin and vWF compared to HO-1+/+ mice (Fig 5B,D). One of the major 
precursors during an inflammatory response is the release of vWF and P-selectin from 
weibel-Palade body (WPB). The interaction of P-selectin, its receptors PSGL-1 and vWF 
facilitate platelet rolling leukocytes and thrombus amplification. Therefore, we 
hypothesized that exogenous CO treatment or endogenous CO release from HO-1 null 
mice may reduce the release of these vascular mediators caused by IVC-ligation. We 
measured soluble levels of P-seletin and vWF using ELISA. We show that in HO-1-/- 
IVC-ligated mice had a modest increase in P-selectin (4.2±0.59 vs 3.7±0.7 ng/mg 
p<0.05) expression and as well as a significant increase in vWF (263±18.4 vs 151± 21.7 
ng/mg p<0.05) compares to HO-1+/+ IVC-ligated animals (Fig 6A,B). Concordantly, 
pulsatile dose of CO administered twice a day for up to 7days, resulted in significant 
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decrease in both P-selectin (0.42±.09 vs 0.72±0.14 ng/mg p<0.05) and vWF (102±13 vs 
187±19.5 ng/mg p<0.05) levels compared to normoxic exposed wild type mice (Fig 
6C,D). Taken together, our results demonstrate that absence of HO-1 or exogenous 
treatment of carbon monoxide plays a role in mitigating leukocyte infiltration into the 
vessel wall by regulating P-sel and vWF. 
 
IVC-ligation enhances the accumulation of platelet-leukocyte aggregates following 
ligation of IVC in HO-1+/+ and HO-1-/- mice.   
Previous work in venous thrombosis has showed recruitment of inflammatory leukocytes 
also can involve thrombosis.17 Animal studies utilizing rat and mouse thrombosis models 
have demonstrated the upregulation of P-selectin in the vein wall as early as six hours 
after thrombus induction.26 P-selectin on activated platelets is a major mediator of 
adhesion to leukocytes.33 Because the role of P-selectin in venous thrombosis was 
previously reported, we sought to investigate the role of platelet-leukocyte interactions in 
our model of venous thrombosis in the absence of HO-1 by using a 5-color flow 
cytometry. The percentage of monocyte/macrophage and neutrophils found aggregated 
with platelets in blood obtained from IVC-ligated HO-1-/- vs HO-1+/+ mice was 
approximately 3.2 fold and 5 folds higher, respectively (Fig 7A,B). The number of P-
selectin-positive platelets in the blood of thrombus induced HO-1-/- mice was not 
different from that of HO-1+/+ mice (data not shown). However, the absolute cell counts 
for platelet-monocyte (595±13.7 vs 302±14.8, P<0.05) and Platelet-neutrophils 
(196±24.2 vs 92±15.7, P<0.05) was significantly greater in HO-1-/- vs HO-1+/+ IVC-
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ligated mice. These data indicates HO-1 null mice subjected to IVC-ligation had an 
increase in the number of leukocytes, particularly monocytes and neutrophils, and 
thrombosis resulted in accumulation of aggregation of leukocytes to platelets. 
 
Effects of thrombogenesis on vein wall proinflammatory cytokines and chemokine 
mediators on IVC mRNA expression 
We examined the effects of HO-1 knockout on IVC-ligation by isolating total IVC 
mRNA and measured levels of pro inflammatory cytokines and chemokine via 
quantitative RT-PCR. Following IVC-ligation HO-1-/- mice showed an increase in IL-6, 
CCL-2, CxCL-1 and CxCL-2 (Fig 8A-D). Pulsitile treatment of CO twice a day to wild 
type mice, demonstrated no significant decrease in IL-6 and CxCL-2 (Fig 8E,H).  
However, two genes related to macrophage and neutrophil recruitment to the vessel wall 
during injury (CCL-2 and CxCl-1), were significantly downregulated by CO treatment 
(Fig 8F,G). As reported previously17, in a chronic model of venous thrombosis in the 
absence of HO-1, thrombosis increased the expression of these key proinflammatory 
mediators that we examined, suggesting exogenous and endogenous CO production 







The dynamic and complex balance that exists between thrombosis and 
inflammation during thrombogenesis plays a pivotal role in the pathogenesis of DVT. 
Using a well-established and widely employed model of stasis-induced venous 
thrombosis, the present study demonstrates that stress-induced enzyme HO-1 and its 
byproduct CO, attenuates thrombus formation and mitigates leukocyte influx into the 
vessel wall. Absence of HO-1 was associated with significantly increased thrombus size 
and leukocyte influx. The increase in thrombus cellularity with deletion of HO-1 is 
consistent with other experimental model of venous thrombosis.34,17,35,8 Our findings also 
showed that platelets binding to activate leukocytes might contribute to the inflammatory 
milieu in thrombi of HO-1 deficient IVC-ligated mice. This increase of vascular wall 
thrombogenicity may directly result from the marked upregulation of leukocyte adhesion 
receptors P-selectin and the induction of prothrombotic modulator, von Willebrand factor.  
 
Thrombus formation initiates a local inflammatory response.36,37 During the acute 
stages of inflammation, neutrophils are the predominant cellular responder. Over time, 
monocytes increase at the site of thrombosis and are important in proteolytic digestion 
and resolution of the thrombus components.38,39,40 The differential role of the monocytes 
in the vessel wall response and thrombus resolution after IVC-ligation has been 
previously reviewed.41,36 Counterintuitively; a greater monocyte number is not 
necessarily associated with greater vein wall injury. In a rat model of stasis induced 
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venous thrombosis, P-selectin inhibition was associated with increased vein wall 
monocyte accumulation, but decreased stiffness and fibrosis.42 Monocyte subtypes may 
confer a pro- or antiinflammatory state depending on the local environmental ques.43 
Using morphometric analysis of leukocyte cell migration through the vein wall during 
thrombosis, we demonstrated that acute and chronic inflammatory patterns in both HO-1 
null mice and wildtype mice exposed to empirical low dose of CO for up to 7days in this 
study. In this study, HO-1 deficient mice increased the recruitment of PMN in the vessel 
wall 48hrs post-IVC ligation. In addition, neutrophil migration through the vein wall 
show a trend towards decrease during pulsatile CO administration. In contrast, in the 
absence of HO-1, monocytes showed a gradual but not significant increase in migration 
48hrs post- IVC ligation, compared to HO-1+/+ mice. The increase in vein wall monocyte 
extravasation occurred by day 7, surpassing neutrophil levels by 7days post-IVC ligation 
in HO-1 null mice (data not shown). These results demonstrate that induction of HO-1 
can modulate the early, and acute inflammatory response to a direct vascular injury post 
venous thrombosis.  
 
In previous studies, in which arterial thrombosis was induced in HO-1 deficient 
mice under conditions of oxidative stress, hemin administration resulted in arterial clot 
formation, which was hastened in HO-1-/- mice.44 Similar to our results, one study 
demonstrated that genetic deficiency of HO-1 impaired thrombus resolution and 
exaggerated the inflammatory response to thrombus formation 10 day post stasis induced 
thrombosis and they also show that clot size at day 2 was not different in HO-1+/+ and 
HO-1-/- mice.17 The investigators also suggested that the exaggerated clot size that was 
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observed in the HO-1-/- mice following stasis induced venous thrombosis may not be 
ascribed to an inherent, pre-existing, hemostatic defects present in the mutant strain.17 In 
acute stasis-induced venous thrombosis, IVC-ligated HO-1 deficient model used in our 
study demonstrated a significantly larger thrombus and increase neutrophil recruitment at 
48hr post IVC-ligation. With this model, neutrophil, monocytes, lymphocytes and 
platelets count in hematologic profiles represented in Table 1, contributes significantly to 
the pro-thrombotic milieu 48hrs post- IVC ligation. The increase in mean platelet volume 
observed in HO-1 null mice post IVC-ligation provided a concordant increased supply of 
P-selectin, and vWF, which results in a pro-thrombotic environment within these mice. 
Mean platelet volume has been identified as a prognostic marker for inflammatory 
conditions and thrombosis.45 Taken together, this finding suggests that increase in platelet 
number in the HO-1 IVC ligated animals may occur during inflammatory events where 
platelets are being consumed.   
 
When HO-1 activity is suppressed, proinflammatory heme would accumulate and 
trigger endothelial cell activation and the expression of proinflammatory genes 
presumably involved in the pathogenesis of DVT.46 One possible explanation for the 
requirement of HO-1 to suppress venous thrombosis is that HO-1 enzymatic function is 
necessary to eliminate proinflammatory free heme as it accumulates through release of 
oxidized hemoglobin post-IVC ligation. An alternative but not mutually exclusive 
explanation would be that HO enzymatic activity is needed to generate one or more of the 
end-products of heme catabolism, e.g. bilirubin, free iron that leads to ferritin expression, 
and/or CO. These antiinflammatory molecules would then abrogate the proinflammatory 
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responses that lead to DVT. Our study favored the second hypothesis and tested directly 
whether the exogenous treatment of CO would account for the protective effect of HO-1 
in preventing thrombus formation and leukocyte accumulation. CO has been shown to be 
protective in multiple models of injury, including vascular injury47, transplantation48 and 
ischemia-reperfusion.19  
 
Experimental studies have rarely addressed the effects of CO on the relatively 
acute and chronic development of injury in response to vascular insult to the vein wall 
during venous thrombosis. Leukocyte trafficking is dependent on a number of factors 
affecting activation, chemoattraction, and attachment of the cells. The specific 
mechanisms by which CO can affect neutrophil migration from the peripheral blood to 
the vein wall have not been fully characterized. Previous reports have documented that 
the expression of adhesion molecules including P-selectin17 is modulated by HO-1 and 
that CO-releasing molecules mediated anti-thromboic effects in vivo by inhibition of 
platelet mediated thrombus formation.49 The results of our studies suggested that 
exposure to pulsatile low dose of CO fully suppressed P-selectin and vWF plasma levels. 
This data suggests that CO can fully substitute for the protective effect of HO-1 in this 
model. This data also suggests that the major mechanism by which HO-1 prevents 
inflammatory cell infiltration may not involve elimination of free heme but rather the 
generation of one of the end products of heme catabolism by HO-1, e.g., CO. We do not 
exclude that other end products of HO-1 activity, e.g., iron/ferritin and bilirubin, may 
contribute to prevent venous thrombus formation as well. However, our present data 




To address the question weather HO-1 deficiency would affect platelet-leukocyte 
aggregation, we employed a 5-color flow cytometry system to define interdependence 
between circulating platelets and inflammatory cells in a stasis model of venous 
thrombosis. In our study, we were able to consistently show that platelet specific marker, 
CD41, binds to neutrophils and monocytes in the peripheral blood, which likely promote 
adhesion to endothelial cells and the induction of vascular injury in IVC-ligated HO-1 
deficient mouse model. The analysis of platelet-leukocyte aggregates revealed more 
platelets bound to monocytes than neutrophils in the absence of HO-1 post IVC-ligation. 
These observations provide some evidence that P-selectin-positive platelet-leukocyte 
aggregates tether and roll on endothelial cells with higher avidity than single leukocytes, 
thereby exacerbating endothelial inflammation. Thus the binding of multiple platelets 
associated with the increased monocytes adhesive and oxidative activities may represent 
a newly recognized mechanism contributing to monocyte/macrophage activation in the 
peripheral blood in vivo. 
 
To further distinguish the role of HO-1 and CO in this model, we studied key 
inflammatory cytokine and chemokine’s post IVC ligation in HO-1 deficient mice and 
episodic CO administration in WT mice. One of the main inflammatory cytokines that we 
studied, IL-6 has been demonstrated to play a role in stasis induced venous thrombosis.50 
Systemic neutralization of IL-6 during early stages of venous thrombosis, using the IVC 
ligation mouse model, modulates CCL-2 (also known as monocyte chemotactic protein-1 
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(MCP-1)) expression and is responsible for monocyte recruitment and ultimately 
modulates thrombus resolution.50 Based on this information, we hypothesized that HO-1 
deficiency would upregulate IL-6, CCL-2 and other inflammatory chemokine’s post 
venous thrombosis.  Our study further substantiates, the absence of HO-1 regulates the 
expression of IL-6, CCL-2, CxCL-1 (KC) and CxCl-1 (MIP-2). In contrast, episodic low 
dose of CO decreased expression of these key inflammatory mediators. All together, our 
findings suggest that intermittent administration of CO over short exposure times would 
be beneficial and we also demonstrated that the degree of vascular injury also dictated the 
relative efficacy of CO treatment. However, it is important to note that inflammatory 
response may also vary with the age, gender, and genetic background of the mouse51, 
suggested that a number of additional studies would be required to completely understand 
the effectiveness of CO treatment post IVC ligation. The present studies cannot rule out 
the possibility that CO would be even more effective in models producing less 
inflammation or more focal injury. In any case, it would appear important to examine the 
effects of CO treatment at early and later time points to fully evaluate HO-1/CO role in 
acute venous thrombosis.  
 
In conclusion, vascular HO-1 with the release of CO attenuates thrombus 
formation, most probably via the modulation of P-selectin and vWF expression on 
endothelial cells. HO-1 and CO have differential roles in leukocyte infiltration post IVC-
ligation and HO-1 deficiency appears to promote platelet-leukocyte aggregates by a CO-
independent mechanism as HO-1 induces key adhesion molecules. These data suggest 
several possible mechanisms, including other byproduct of heme oxygenase. The 
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protective effects are likely to be multifactorial. Although new therapies are on the 
horizon for DVT treatment, these all primarily target the coagulation cascade, and the 
bleeding risk remains.2 Indeed, a concern of those new agents is the lack of antidotes.52 
The next generation of DVT therapy should have rapid onset, require little monitoring, 
and have little bleeding risk. Further delineation of mechanisms associated in HO-1/CO 
anti-inflammatory and anti-thrombotic effects holds promise as a therapeutic adjunct in 
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FIGURE III.1: PULSATILE EXPOSURE OF LOW DOSE CARBON MONOXIDE 
DECREASE THROMBUS MASS AND INFLAMMATORY CELLS IN THE VEIN 
WALL POST IVC-LIGATION.  
(A) Thrombus were harvested from C57BL/6 mice, exposed to normoxia (N - 21% 
Oxygen) or carbon monoxide (CO+N - 250ppm and 21% Oxygen) and thrombus weight 
were compared between days 1 to 7 post IVC-ligation. Thrombus size was smaller in the 
CO+N exposed wild type mice as compared with normoxia exposed wild type mice at 
7day of exposure. All mice C57BLK6: 1d, n = 4-5; 2d, n = 11-20; 4d, n = 8-9; 7d, n = 8-
11 per group. (B-C) Representative hematoxylin and eosin stained inferior vena cava 
sections of 7-day wild type samples exposed to either N or CO+N. Note the decreased 
vein wall and acellularity in the 7 day CO+N compared to the 7day N exposed wild type. 
Original magnification is 400X, scale bar = 50 µm. (T-Thrombus and W- vein wall). (D-
G) Morphometric evaluation of inflammatory cells in the vein wall of five high-powered 
fields (5HPFs) at day 7 in Shams (N and CO+N) and IVC-ligated (N and CO+N). CO 
exposure significantly decreased vein wall inflammatory cells post-IVC ligation 
compared to normoxic exposed mice (N =17-25 per group). All results represents mean ± 
SEM of tissue harvested from indicated number of mice. *Different from normoxia, 





FIGURE III.2: HEME OXYGENASE -1 DEFICIENCY IS AFFECTED BY 
THROMBOGENESIS.  
(A) Real-time reverse transcriptase polymerase chain reaction of HO-1 mRNA in WT 
mice exposed to normoxia from 1-7 days following IVC ligation. HO-1 mRNA is 
significantly increased at 2dy. (N =8-11 per group) TC, true controls (mice that did not 
receive ligation). *Different from WT 1 day IVC ligated P<0.05. (B) Thrombus weight in 
WT mice at 1-7 days following the thrombogensis was significantly different at 2dy post- 



































































































ligated thrombus (left) and HO-1-/- stasis-induced venous thrombosis (right). D, Weight, 
in miligrams of thrombus harvested from sham-operated and stasis-induced venous 
thrombosis in HO-1+/+ and HO-1-/- mice at 48 hours (Sham: HO-1+/+, n = 11; HO-1-/- n = 
9. IVC-ligated: HO-1+/+, n = 13; HO-1-/- n = 14). Bars represent mean ± SEM from tissue 
harvested from indicated number of mice. *Different from HO-1+/+ IVC ligated P<0.05. 

































































































































FIGURE III.3: VEIN WALL HISTOLOGICAL EXAMINATION SHOWING THE 
AFFECT OF THROMBOGENESIS AND INFLAMMATORY CELL 
ACCUMULATION 48 HR POST-IVC LIGATION.  
Representative hematoxylin and eosin stained inferior vena cava section of 48 hr sham 
operated (A and C) and thrombosed IVC (B and D) of HO-1+/+ and HO-1-/- mice. (D) The 
venous wall of thrombus containing IVC of HO-1-/- mice show a markedly increase in 
leukocyte accumulation compared to HO-1+/+ mice. (Magnification = original x400; scale 
bar = 50 µm. (T-Thrombus and W- vein wall). (E-H) Morphometric evaluation of 
inflammatory cell counts of five high-powered field in the vein wall of HO-1+/+ and HO-
1-/- mice 48h post IVC ligation and sham-operated controls. Total inflammatory cell (E), 
Monocyte/macrophage (F), Polymorphonuclear cells (neutrophils) (G), and lymphocytes 
(H) (n = 9-14 all groups). Bars represent mean ± SEM from tissue harvested from 
indicated number of mice. *Different from HO-1+/+ IVC ligated P<0.05. All data were 










TABLE III.1: HEMATOLOGICAL PARAMETERS OBTAINED FROM HO-1+/+ 
AND HO-1-/- MICE. 
 
Blood samples from four mice were analyzed for each profile, and data are represented as 
mean ± SEM. Hematology values displayed as ranges and means. Bold numbers are 
arrows represent increase (upward arrow) seen in HO-1+/+ and HO-1-/- 48 hrs post-IVC 
ligated mice.   
 
WBC= White Blood Cells, NE = Neutrophils, MO = Monocytes, LYM = Lymphocytes, 
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FIGURE III.4: CIRCULATING PLATELETS AND MEAN PLATELET 
VOLUME IN HO-1+/+ AND HO-1-/- MICE 48 HR POST-IVC LIGATION.  
(A-B) Circulating platelets and Mean platelet volume (MPV) levels at day 2 in sham-
operated and IVC ligated HO-1+/+ and HO-1-/- mice. HO-1-/- mice showed a trend towards 
increase in circulating platelet levels and MPV. (N = 5-8 per group) *Different from    
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FIGURE III.5: IMMUNOHISTOCHEMISTRY IMAGES OF THROMBUS 
CONTAINING IVC STAINED WITH P-SELECTIN AND VWF 48HR POST-IVC 
LIGATION.  
(A, B) IVC-ligated HO-1+/+ and HO-1-/- mice stained with P-selectin (C, D) IVC-ligated 
HO-1+/+ and HO-1-/- mice stained with vWF. Cells expressing P-selectin and VWF appear 
dark brown in color (indicated by dark arrows). Original Magnification x 200; scale bar = 

























FIGURE III.6: ELISA MEASUREMENT OF SOLUBLE P-SELECTIN AND VWF 
FOLLOWING LIGATION OF THE INFERIOR VENA CAVA.  
(A-D) Soluble P-selectin (sP-sel) and vWF was measure 48hrs post thrombogenesis in 
HO-1+/+, HO-1-/- mice and wildtype mice exposed to normoxia (21% Oxygen) or episodic 
low dose of carbon monoxide (twice a day 1 hr exposure of 250ppm of CO and 21% 
normoxia) using ELISA based assay. (A) Sham – operated and IVC ligated HO-1+/+ and 
HO-1-/- mice measuring sP-sel or vWF (B). (C) Sham – operated and IVC ligated wild 
type mice exposed to normoxia and carbon monoxide measuring sP-sel or vWF 7 days 




























































































post-IVC ligation and exposure. (D). The trends show increase levels of sP-sel and vWF 
in plasma of HO-1-/- mice 48hrs post-IVC ligation. Concordantly, plasma from thrombus 
containing IVC shows sP-sel and vWF was significantly decreased in CO+N compared to 
N exposed wildtype mice. HO-1+/+ and HO-1-/- mice: N = 6-10 per group and Normoxia 
and CO+N: N = 3-5 per group. Bars represent mean ± SEM from tissue harvested from 
indicated number of mice. *Different from HO-1+/+ IVC ligated or wildtype normoxia 














FIGURE III.7: THROMBOGENESIS ENHANCES THE ACCUMULATION OF 
PLATELET-LEUKOCYTE AGGREGATES FOLLOWING LIGATION OF IVC 
IN HO-1+/+ AND HO-1-/- MICE.   
Pre-gating strategy: forward and side scatter were used to identify ganulocyte and 











































































































B) Representative dot plot of percentage of whole-blood platelet-granulocyte (neutrophils 
– Gr-1+) (A) and platelet-monocyte (CD11b+) (B) aggregates in HO-1+/+ and HO-1-/- 
sham operated or IVC-ligated mice 48hrs following IVC ligation. The percentage of 
neutrophils and monocytes found in heteroaggregates with P-selectin (CD62P+) and 
platelets (CD41+) is greater in HO-1-/- compared to HO-1+/+ IVC-ligated mice. (C, D) 
Quantitative cell count analysis of Gr-1 and CD11b-CD41+/CD62P+ cells in HO-1+/+ and 
HO-1-/- sham operated or IVC-ligated mice. N = 3-5 per group. Bars represent mean ± 
SEM from tissue harvested from indicated number of mice. *Different from HO-1+/+ IVC 
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FIGURE III.8: EFFECTS OF THROMBOGENESIS ON VEIN WALL 
PROINFLAMMATORY CYTOKINES AND CHEMOKINE MEDIATORS IN 
HO-1+/+ AND HO-1-/- MICE. 
 (A-D) mRNA from IVC was measured by quantitative PCR of sham-operated and IVC-
ligated HO-1+/+ and HO-1-/- mice 48 hr post thrombosis. (E-H) mRNA from IVC was 
measured by quantitative PCR of sham-operated and IVC-ligated of wildtype exposed to 
normoxia (21% Oxygen) or episodic low dose of carbon monoxide (twice a day 1 hr 
exposure of 250ppm of CO and 21% normoxia). We examined mRNA expression of IL-
6, CCL-2 (MCP-1), CxCL-1 (KC), and CxCL-2 (MIP-2). (n = 5-11 per group). Fold 
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changes (y-axis) were normalized to β-actin. Results are shown as the mean ± SEM and 
*different from HO-1+/+ IVC ligated or wild type normoxia P<0.05. All data were 








































FIGURE III.9 GRAPHICAL REPRESENTATION SUMMARIZING THE 
MECHANISM(S) POTENTIALLY INVOLVED IN THE ANTI-
INFLAMMATORY ACTIVITIES OF HO-1/CO IN ACUTE VS. CHRONIC 
VENOUS THROMBOSIS 
The dynamic and complex balance that exists between thrombosis and inflammation 
during thrombogenesis plays a pivotal role in the pathogenesis of DVT. Using a well-
established and widely employed model of stasis-induced venous thrombosis, we depicted 
above a proposed hypothesis of HO-1/CO activity after stasis induced DVT in the 
mouse. During the acute stages (right panel) of inflammation, neutrophils are the 
predominant cellular responder. The left panel depicts during administration of episodic 
low dose of carbon monoxide (chronic stages), monocytes increase at the site of 
CHRONIC DVT (WT mice) 
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thrombosis and are important in proteolytic digestion and resolution of the thrombus 
components. This increase of vascular wall thrombogenicity may directly result from the 
marked upregulation of leukocyte adhesion receptors P-selectin and the induction of 
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CONCLUSIONS AND FUTURE DIRECTIONS 
SUMMARY 
 
The work presented in this thesis explores our evolving understanding of the role 
of heme oxygenase-1 (HO-1) and carbon monoxide (CO) in pulmonary and 
cardiovascular disease. All cells catabolize heme using one of the two heme oxygenase 
(HO), HO-1 or HO-2, which are the inducible and consitutitive isoforms, respectively.1 
The primary focus of this thesis is on heme oxygenase-1 and one of its cytoprotective 
byproduct carbon monoxide, and its modulation of disease pathologies that have an 
inflammatory component driven by tissue injury. Several studies have reported that CO 
independently influences cellular functions in unique and succinct immunological 
modalities that optimize the ability of the cell to respond to the needs of the tissue. HO-1 
is usually activated within hours of exposure to a host of cellular stressors including 
pathogens, fluctuations in oxygen, endothelial damage, oxidants, growth factors and 
chemokine mediators.2 CO generated by HO-1 regulates, either positively or negatively, 
inter and intracellular networking and communication within the tissue and organ 
systems, allowing them to respond appropriately to the stressor or changes in 
environmental cues. The absence of HO-1 gene in mice or humans leads to chronic, 
multi-organ systemic inflammation, emphasizing the crucial importance of this enzyme 
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in regulating fundamental physiology and requisite immune response.3,4 One conundrum 
that has besieged the field is how HO-1/CO, as a heme-catabolizing enzyme, mediates 
such potent and broad-reaching salutary effects in contexts ranging from vascular to 
pulmonary diseases. Thus, the principal goal of this work was to elucidate how HO-1 and 
its cytoprotective by product CO provide cellular and tissue protection in an 
inflammatory environment. Carbon monoxide holds a prominent place in the history of 
the contemporary biological sciences. CO functions similarly to other signaling 
molecules, such as nitric oxide and hydrogen sulfide, by amplifying a signal 
intracellularly that leads to changes in cellular function locally. However, CO is unlike 
other signaling molecules because it propagates effects pericellularly as well as distally to 
remote cells and tissues through its high diffusivity, its portability using hemoglobin, and 
its biochemical stability (integrity). CO is perhaps the smallest signaling molecule, it can 
easily transverse through lipid bilayers and bind to its targets, much like oxygen and 
carbon dioxide as they are mobilized throughout the body. With such characteristics, CO 
facilitates the behavior of a matrix of interactions among cell types that, in turn, 
facilitates rapid responses both to stressors and danger signals.  
 
In chapter II, we developed a novel flow cytometry technique to examine the 
amount of leucocyte cell populations that trafficked through a developing lung during 
hyperoxic insult. In addition, the application of pulsatile CO to exert its anti-
inflammatory and cytoprotective effects on developing lung. The precise mechanisms by 
which inflammation inhibits alveolar development are not completely known.  However, 
in this chapter, we begin by exploring the role of heme oxygenase (HO-1) and its 
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byproduct carbon monoxide (CO), which are thought to be cytoprotective against redox 
stress, mitigate lung injury and alveolar simplification in hyperoxia-exposed neonatal 
mice, a model of bronchopulmonary dysplasia (BPD). Furthermore, we tested the 
requirement of CCL2 for hyperoxia-induced lung injury.  Hyperoxia-exposed CCL2 null 
mice, like CO-treated mice, showed attenuated alveolar simplification and lung 
inflammatory infiltrate. This work showed for the first time that: 1) brief episodic 
exposure to low-dose CO significantly mitigates the deleterious effects of hyperoxia on 
alveolar development; 2) HO-1 deficiency exacerbates hyperoxia-induced lung injury; 
and 3) CCL2 is required for hyperoxia-induced alveolar simplification. Taken together, 
this work demonstrated that, in hyperoxia-exposed neonatal mice, inhalation of the HO-1 
product CO suppresses CCL2-dependent inflammatory cell trafficking, pro-inflammatory 
cytokine expression, and alveolar simplification.    
 
HO-1/CO autonomous regulation of leukocytes and inflammation can be paired 
with monocyte chemoattractant (MCP-1/CCL-2) to suggest a novel therapeutic approach. 
The work of our lab and others has previously shown that exogenous CO treatment is 
profoundly protective in hyperoxia induced BPD.5 The importance of HO-1 during 
hyperoxia induced lung injury is perhaps best exemplified by observations of the HO-1 
deficient mouse3,6 and the effects of exogenous CO to mimic its HO-1 cytoprotective 
properties.  In chapter II we explored the anti-inflammatory and cytoprotective properties 
of HO-1/ CO in HO-1-/- and HO-1+/+ neonatal animals. Up to this point, only a few 
studies have examined the role of neutrophils and macrophages in the pathogenesis of 
neonatal hyperoxic-induced lung injury. In some of the studies, hyperoxia induces 
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neutrophil influx and hypoalveolarization, which is attenuated by neutralizing antibodies 
against the neutrophil chemoattractants CXCL17 or CXCL2.8 Neutrophilic inflammation 
during hyperoxia is also prevented by a selective chemical antagonist of CXCR2.9 
Neutralizing antibodies against MCP-1/CCL2, a monocyte chemoattractant, also decrease 
lung hypoalveolarization, as well as lung macrophage and neutrophil counts, in 
hyperoxia-exposed rats.10 We propose that CO protects against hyperoxia-induced 
alveolar simplification by blocking macrophage infiltration and activation. In many 
instances, the exogenous addition of CO can substitute for HO-1 deficency.11,12 CO 
preserves cellular and tissue survival in vivo, which is likely to reflect the participation of 
disparate signaling pathways in regulating inflammatory sequelae.  
 
Our studies demonstrate a direct link between CO, the CCL2-dependent control of 
leukocyte migration into hyperoxic lung tissue, and alveolar growth.  Inhibition of 
inflammatory cell infiltration by either CO or CCL2 gene deletion was associated with 
the attenuated alveolar simplification. Furthermore, we extend these observations by 
demonstrating that hyperoxia induces the accumulation of different F4/80-positive 
macrophage subsets into the lung, specifically CD11clow CD11bhigh and CD11chigh 
CD11bhigh cells. Previously, it was shown that, during influenza infection13 and 
bleomycin exposure14, CD11c- CD11b+ inflammatory monocytes are recruited to the lung 
and develop into a CD11chigh CD11b+ activated macrophage population known as 
exudative macrophages.  On this basis, we speculate that the CD11clow CD11bhigh cells 
(our population C) represent inflammatory monocytes, and that CD11chigh CD11bhigh cells 
(our population B) represent exudative macrophages, a major source of inflammatory 
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cytokines and chemokines in the lung.  This paradigm is somewhat unique for leukocyte 
trafficking and for the first time provides critical information about the link between HO-
1 derived CO and CCL-2, with studies of exogenously administering pulsatile CO in a 
model of hyperoxia-induced bronchopulmonary dysplasia.   
 
With the techniques employed in this work, we have begun to parse the effects of 
HO-1/CO modulation of leukocyte trafficking in the neonatal lung. Some major 
limitations in our present study lie in reconciling the timing of CO treatment. It is also 
possible that the timing of CO exposure is critical. Specific studies varying this timing 
may have to be done. In our unpublished study on cardiac preconditioning, two phases of 
preconditioning are known to exist, early and late (the former does not require de novo 
protein synthesis, whereas the latter does). Furthermore, It is possible that a longer 
duration of CO given during either post-hyperoxia or during recovery might result in 
benefits over and above those shown in the this chapter. Thus we have tried to guard 
against drawing our conclusions too firmly. It is likely that other mechanisms of CO 
delivery could be employed to exogenously administer CO in this model such as 
methylene chloride15 or carbon monoxide releasing molecules16. As arterial pH does not 
change with the levels of CO, which are used, it is unlikely that inhaled CO causes tissue 
asphyxia, although at longer episodic exposure and higher concentrations, this remains a 
possibility. Even though this was not the focus of our study in this chapter, we cannot 
rule out the possibility that the inducibility of HO-1 might be regulated at the level of 
post-transcription and/or post-translation processing. In order to verify this hypothesis, 
we could test the activity of activator protein 1(AP-1), a transcription factor that is an 
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important regulator of HO-1 transcription in hyperoxia17. If there is a lack of AP-1 
binding to neonatal lung DNA during hyperoxia, this might partially explain the 
resistance to HO-1 hyperoxic induction. However, a confounding limitation such as 
inconsistent mRNA and protein induction will tell us that experiments need to be 
conducted at the posttranscriptional and posttranslational level in order to understand 
what proteins regulate the inducibility of HO-1/CO during maturation. 
 
Chapter III takes a different look at the role of HO-1/CO in cardiovascular 
disease, Venous thromboembolism (VTE) a chronic and multicausal disease.18 Defined 
clinically as inappropriate clotting of the blood presenting as either deep vein thrombosis 
(DVT), pulmonary embolism or both, VTE is estimated to affect approximately 1 in 1000 
individuals per year in the U.S. alone. Despite great advancements in the treatment and 
prevention of VTE in the twentieth century, the burden of this disease is increasing. The 
inflammatory process is increasingly being recognized as an important mechanism 
regulating thrombus formation and resolution.19,20 Platelet activation has recently 
emerged as a therapeutic target for limiting cardiovascular diseases.21,22 Identification of 
new mechanisms, which contribute to thrombus formation and resolution could lead to 
new insights into its disease pathogenesis and new therapeutic options. With this concept 
in mind, Chapter III explores the endogenous protection of HO-1 and the application of 
low therapeutically dose of CO to mitigate leukcosequetsration into the vessel well. In 
doing so, we employed a long-established and widely used model of venous thrombosis 
and one based on the ligation of intra-renal inferior vena cava (IVC).23,24,25,26,27,28 
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In chapter III, we highlight the effects of pulsatile low-dose of exogenous CO 
treatment on stasis-induced venous thrombosis and delineate the role of HO-1 in leukocyte 
recruitment during acute thrombus formation. In addition, we also examined the effects of 
endogenous CO production and key inflammatory modulators (p-selectin and vWF), 
cytokine and chemokine levels and peripheral whole-blood leukocyte-platelet aggregation. 
The results demonstrated pulsatile CO treatment acutely reduced leukocyte recruitment to 
the vessel wall post-thrombus induction and endogenous CO production exacerbates the 
inflammatory response and leukocyte-platelet aggregates. The physiological significance of 
increased formation of platelet-leukocyte aggregates in the peripheral blood during 
inflammatory disease still remains uncertain, however, our studies suggest that platelets at 
the thrombo/inflammatory interface may play an active role in DVT. All together, our 
findings suggest that intermittent administration of CO over short exposure times would be 
beneficial and we also demonstrated that the degree of vascular injury also dictated the 
relative efficacy of CO treatment. We provide evidence that HO-1 deficiency promotes 
inflammation and results in the increased extravasation of key inflammatory cells and 
activation of vascular coagulant reactions at the blood/vessel interface 48 hrs post-IVC 
ligation. Absence of HO-1 further pushes the balance towards a proinflammatory vascular 
wall phenotype. However, it is important to note that inflammatory response may also vary 
with the age, gender, and genetic background of the mouse29, suggested that a number of 
additional studies would be required to completely understand the effectiveness of CO 
treatment post IVC ligation. The present studies cannot rule out the possibility that CO 
would be even more effective in models producing less inflammation or more focal injury. 
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In any case, it would appear important to examine the effects of CO treatment at early and 
later time points to fully evaluate HO-1/CO role in acute venous thrombosis. 
Understanding the complex interplay of vascular injury, stasis and coagulation and how 
this is modulated by HO-1/CO would lead to new therapies for DVT or other disorders at 
the nexus of inflammation and platelet aggregation. 
The leukocentric focus taken in this chapter was not meant to preclude the idea 
that HO-1 could only confer protection through the regulation of platelet activation. In 
fact the answer likely lies somewhere in the middle; a potential synergy may exist 
between the populations of leukocytes and platelets leading to co-activation and 
heteraggregation. Ultimately, to address these questions effectively, new molecular tools 
and genetic mouse models will need to be developed. The classic paradigm of 
inflammatory cell signaling has primarily focused upon the recruitment and activation of 
leukocytes, with concomitant release of soluble mediators (cytokines and chemokines) 
that may amplify and accelerate the inflammatory process during stasis-induced venous 
thrombosis.  
The experiments in this thesis tested whether the HO-1/CO axis regulates 
inflammatory cell trafficking in vivo.  Since HO-1/CO is likely to have pleiotrophic 
effects, the only clear way to dissect the mechanisms that underlie increase leukocyte 
infiltration and thrombus formation of HO-1 deficient animals is to design in vitro 
experiments that have only one cellular variable at a time.  For example, if CO suppresses 
leukocyte infiltration into the vessel wall in vivo, but leukocyte adhesion molecules and 
transmigration are not affected by the silencing HO-1 in macrophage specific cell line 
(i.e. RAW264.7), then leukocyte accumulation in the vessel wall may be attributed to the 
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fact that mechanism other than leukosequestration are also playing a role and could 
contribute to stasis-induced venous thrombosis. If HO-1/CO regulates inflammatory cell 
trafficking and the expression of adhesion molecules and chemokines, we could directly 
test the role of the identified adhesion molecules and chemokines by determining whether 
the relevant knockout mice are protected from thrombus formation.  For example, we 
could cross adhesion receptor null mice or CXCR2 (the receptor for CXC chemokine 
neutrophil chemoattractants) null mice with HO-1 null mice. If HO-1/CO mitigates the 
effect of leukocyte accumulation and thrombigenesis thru the inhibition of PECAM 
expression, then the expected outcome that may result in the HO-1 null mice may not 
occur in the double knockout. Similar arguments can also be made for the other adhesion 
receptors null mice (ICAM-1, VCAM-1, P/E selectin). The majority of these null mice 
are all commercially available via Jackson laboratories. This does not diminish the value 
of the current studies, which were critical for demonstrating HO-1/CO is a powerful 
endogenous protector against venous thrombogenesis, and identifying this field as an area 










The road towards effective HO-1/CO based therapies to study pulmonary and 
cardiovascular diseases are fraught with technical challenges and will provide 
conversation for years to come. Throughout this thesis, I have outlined the possible 
limitations of our methods and the gaps that remain in our present knowledge. At the 
point where this research concludes, there are a number of important and exciting 
questions that remain to be answered.  
 
Macrophages play a crucial role in innate and adaptive immunity in response to 
oxidative stress and are major mediators of the inflammatory response. During infection, 
macrophage effectors functions are critical for the elimination of pathogens, however 
uncontrolled inflammatory responses can induce injury of the tissue environment and 
must be repressed to allow the process of repair Figure 1. During the stages of disease, 
tissue and cytokine microenvironment induce, in vivo, a heterogeneous macrophage 
population that displays an appropriate inflammatory phenotype.30 In vitro, two major 
macrophage populations are characterized. Classically activated (M1) or type I 
macrophage, induced in particular by IFNγ,31 display a pro-inflammatory profile whereas 
alternatively activated (M2) or type II macrophage (AAMφ), induced by Th-2 cytokines, 
express anti-inflammatory and tissue repair properties32 Figure 2.  In Chapter II, we 
successfully demonstrated the anti-inflammatory effect of HO-1/CO in neonatal 
hyperoxia-induce BPD model. One of the exciting projects that has arose from this work 
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is we found that hyperoxia polarized the population of alveolar macrophages toward an 
M2 phenotype and that this regimen of intermittent CO administration of hyperoxia-
exposed neonatal mice decreased the number of M2 cells. Work in chapter II of this 
thesis has shown a relationship between exogenous CO administration and alternative 
activation of key macrophage markers. Yet to this point, we still do not understand what 
role CO plays in modulating the trafficking of AAMφ into the lung. 
 
As part of the work for this thesis, I have already begun to investigate the process 
of leukosequestration in the developing lungs and the mechanism by which CO mitigates 
lung inflammatory, macrophage type 1 (M1) and type 2 (M2) markers. We found that 
hyperoxic exposure increased the percentage of M1/M2 macrophages and exogenous 
administration of CO attenuated this change. In addition to flow cytometric analysis, we 
also found a significant upregulation in the mRNA levels of canonical M2 markers 
(CD301b, FIZZ-1, Arg-1, Ym-1) during hyperoxic exposure. Similar modulation of 
FIZZ-1, Arg-1 and Ym-1 expression was noted following hypoxia-induced pulmonary 
hypertension 33. Upregulation of Arg-1 may be of particular physiologic importance. Arg-
1 has been shown to contribute to vascular damage and remodeling, and elevated Agr-1 
in the lungs of hypoxic mice has been associated with increased severity of pulmonary 
hypertension 34, 35. Thus, although both hyperoxia alone and CO alone appear to stimulate 
M1 to M2 conversion, hyperoxia leads to a faster degradation of macrophage infiltrates, 
probably due to a higher degree of oxidative stress than that induced by CO alone (Fig 3-
8). Furthermore, the phagocytic activity of alternatively-activated macrophages may be 
associated with the clearance of cellular debris, of damaged or dying cells, and of 
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infiltrating neutrophils, thus resulting in the elimination of several potentially cytotoxic 
substances 5, 30, 33, 36. In addition, we also briefly examined the role of HO-1 and 
alternatively-activated macrophages in this model. We show that hyperoxia exacerbates 
the expression of M2 markers CD206 and CD301. CCL-22 a macrophage-derived 
chemokine that induces migration of Th2 lymphocytes through specific receptors CCR4 
was significantly increased in the absence of HO-1 during hyperoxia exposure (Fig 9,10). 
CCL-24 a small cytokine that belongs to the CC chemokine family was decreased in the 
absence of HO-1. CCL24 interacts with chemokine receptor CCR3 to induce chemotaxis 
in eosinophils. This chemokine is also strongly chemotactic for resting T lymphocyte and 
slightly chemotactic for neutrophils.  Some of the findings in this studies was puzzling, 
however, it would be of great interest to explore in the future how HO-1/CO modulates 
the trafficking of AAMφ into the interstitium of neonatal lung exposed to hyperoxia.  
 
It is tempting to speculate that CO may play a critical role in the switch of a 
macrophage from an M1 to an M2 state during inflammatory resolution but future ex-
vivo studies of expression levels of alternatively-activated macrophage markers are likely 
to provide insight into weather intermittent CO in the presence of a hyperoxic 
environment may have a critical function in the switch of a macrophage from an M1 to an 
M2 state during inflammatory resolution in an acute lung injury. 
 
Another pressing question that arose from this work is the role CO plays in the 
signaling of mitochondrial reactive oxygen species (ROS) production. Among the earliest 
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events in cells and tissues exposed to low dose of CO is the rapid production of ROS 
such as superoxides, H2O2 and hydroxyl radicals.37,38,39,40 Although superoxides anions 
(O2-) and hydrogen peroxide (H2O2) are generally considered to be toxic byproducts of 
respiration, recent evidence suggests that ROS are important regulators of eukaryotic 
signal transduction regulating biological processes as diverse as immune cell activation 
and vascular remodeling in mammals.40 Recent report suggests, the generation of ROS at 
nondetrimental amounts in response to exogenous administration of low-dose CO might 
affect cellular respiration eventually resulting in adaption.41,42 Mitochondria are the only 
organelles to provide cells with energy. It has been reported that mitochondrial function 
is essential for normal growth in pulmonary epithelial-like cells in culture.43 
Compromised mitochondrial oxidative phosphorylation has been implicated in 
pathogenesis of genetic diseases presenting with developmental and growth restriction of 
different organs.44 Clearly, well-functioning mitochondria are needed to convert 
nutritional substrates into energy to maintain growth and development. Figure 11 depicts 
the different cytochromes contained within the mitochondrial respiratory chain ultimately 
provide electrons to cytochrome c oxidase, which catalyzes electron transfer from 
cytochrome c to reduced O2 to H2O. CO binds to complex IV (cytochrome c interacts 
with CO by competing with O2) in the electron transport chain and promotes reduction of 
respiratory carriers in complex III thereby increasing mitochondrial H2O2 production.45,46 
The primary effect of CO on the mitochondria is to retard the rate of electron transport 




To explore the physiological effects of CO-induced ROS in hyperoxia-induced 
BPD or stasis-induced venous thrombogenesis, we need to use more precise tools that 
utilized isolation of mitochondria from neonatal lung or inferior vena cava. Isolation of 
mitochondria from HO-1 null mice should allow endogenous CO-induced ROS effects to 
be separated from ROS burst. Mitochondrial isolation could be as an initial technique to 
selectively compare the morphological differences between a naïve mitochondria isolated 
from neonatal lung compare to hyperoxia-exposed lung and compared to CO exposed 
neonatal lung using electron microscopy and complex IV activity assay as measured by 
spectrophotometric analysis (The follow experiments outlined above can also be applied 
to isolation of wildtype IVC (absence or presence of CO) compared to HO-1 deficient 
IVC). Some of the pressing questions that could be answered by using these techniques 
are as follows: Is CO-induced mitochondrial biogenesis related to the ability of CO to 
promote further ROS generation or is it related to effects on respiration and the simple 
need to provide additional ATP for the cells? Or is there a yet to be defined molecular 
mechanism that drives additional homeostatic cellular response?  
 
As part of this thesis, I have also begun to measure the changes in mitochondrial 
bioenergetics using XF Cell mitochondrial stress kit. We exposed RAW264.7 cell to CO 
and normoxia for up to 24 hrs. We measured the changes CO induces upon the oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR). Using this 
technique we were able to measure 4 key parameters of mitochondrial function such as 




Our preliminary data show, CO greatly increased the baseline OCR and reduced 
the spare respiratory capacity compared to norrnoxia control cells (Fig 13). When we 
analyzed baseline percentage we chose ideal cell density (~100K) for both normoxia and 
CO exposed RAW264.7 cell (RAW). OCR baseline percentage was 40-50% spare 
respiratory capacity in normoxia exposed cells, which was significantly reduced in CO 
exposed cells (Fig 14).  In addition to OCR measurements, we also measure the ECAR. 
We injected Oligomycin (ATP Coupler), FCCP (Electron Transport Chain Accelerator), 
Antimycin A (Mitochondrial Inhibitor A) and Rotenone (Mitochondrial Inhibitor B) –
ANTI/ROT at specific time points during the experiments. In Figure 15 and 16, we show 
normoxia and CO exposed cells had the same baseline ECAR. However, once 
oligomycin (a mitochondrial ATP synthase inhibitor) was injected the ECAR increased, 
as well as baseline Oligo, FCCP and ANTI/ROT in the CO exposed RAW cells.   
 
Taken together, this preliminary study demonstrated that when measuring the OCR, 
RAW control cells and RAW CO exposed cells had differential mitochondrial function as 
determined with the Cell Mito Stress Test at most of the densities tested. Based upon the 
basal OCR readings, dynamic range of the XF24, and response to drugs, chiefly FCCP, 
100,000 cells per well would be the best density to use in future experiments. Raw cells 
incubated overnight in our in vitro CO chamber have increased baseline OCR rates 
compared to the RAW control cells. In addition, RAW cells exposed to CO have reduced 




Interestingly, we also show that Oligomycin caused increased ECAR under both 
conditions with 400k, which is a fivefold increase in RAW cell density with CO 
exposure. Oligomycin, a mitochondrial ATPase inhibitor, cause a large increase in 
glycolysis as cells compensate for loss of mitochondrial ATP. Some cells do this quite 
well, and under hyperoxic conditions, cells can become more glycolytic as well. RAW 
cells incubated overnight in a CO chamber have similar baseline ECAR rates compared 
to the RAW control cells, suggesting CO has no effect on baseline ECAR rates.  
However, RAW cells exposed to CO have an increase in ECAR rates after the 
administration of the stress test. 
 
 
It is critical that future experiments focus on HO-1/CO attenuates the amount of 
oxidants in the cells via an increase in mitochondrial ROS and subsequent cellular 
signaling events.39, 47 One possible future experiment could be to isolation the 
mitochondria from a hyperoxic –exposed neonatal lung or mitochondrial inferior vena 
cava. This might be technically challenging due to the amount of mice needed to get a 
sufficient amount of mitochondria for these experiments or lack of reagents that might be 
needed to assess the integrity of mitochondria. Once the method is established, however, 
particular attention should be paid to conditioning role of CO by modulating 
mitochondrial ROS production or metabolic changes following hyperoxia exposure 




Lastly, many reports have ignored events that occur during CO pretreatment 
period, instead focusing on the direct effect of CO upon a subsequent stimulus.48,49,39 The 
key observation that administration of exogenous CO leading to a transitory burst of ROS 
would not have been appreciated if investigators continued to think a along the lines that 
CO is benign in cells and tissues unless there is an inflammatory stimulus present. This 
rapid increase in ROS likely leads to concomitant induction of antioxidant enzymes and 
protective genes such that upon the addition of pro-oxidant stimuli, further production of 
ROS is attenuated. Thus, CO is not acting as an antioxidant molecule; rather, it forces the 
cell to undergo oxidative conditioning leading to cytoprotective gene expression, which 
indirectly modulates the ensuing cellular response to the stimulation. While these are 
valid and important studies, conclusions on mechanisms of CO need to be carefully 
considered.   
 
In closure, CO is a molecule that has come full circle after being studied for over 
a century and classified as hazardous. Like other molecules CO has to be re-evaluated, 
not as a toxic molecule, but rather as a critical signaling molecule akin to nitric oxide. 
The beneficial effects of CO as an inhaled gas or through the use of CO-releasing 
molecules have been demonstrated in cell culture and animal models of a number of 
diseases.16,5,50,51 As the results of inhaled CO treatment from clinical trials52 have become 
available, the utility of this therapy to facilitate pulmonary and cardiovascular diseases 
will need to be investigated. Taken together, the studies in this thesis has only begun to 
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scratch surface and hope that in time, further cellular functions can be ascribed to the 
signaling processes initiated by CO. Our continued understanding of molecular 
mechanisms of various gaseous mediators and their relationships to one another must be 


























FIGURE IV.1: PARADIGM OF MACROPHAGE ACTIVATION: 
 Depicted above is a schematic model of macrophage activation modified from Gordon et 
al. Cell Immunity Review 2010.53 The first stage, differentiation, depends on the growth 
factors such as GM-CSF or M-CSF (Macrophage colony-stimulating factor (M-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The second, priming by 
IFN-gamma (CAM), IL-4 or IL-13 (AAM) -- switching M1 and M2 phase can occur and 
the third is a localizing stimulus delivered by a TLR. This stimulus promotes induction of 
a full complement of classical or alternative activation functions. In the case of AAMs, 
this may arise in a Th2 cell bias environment. The fourth stage (resolution and repair) is 
counteracts the negative effects even though the macrophage pro-inflammatory potential 











is deactivated, it could undergo functional changes allowing it to clear debris and express 
repair functions.  
 
FIGURE IV.2: TWO SIGNAL MACROPHAGE ACTIVATION MODEL: 
 Classically activated (M1) or type I macrophage, induced in particular by IFNγ display a 
pro-inflammatory profile whereas alternatively activated (M2) or type II macrophage 
(AAMφ), induced by Th-2 cytokines, express anti-inflammatory and tissue repair 
properties. M2 macrophage have been implicated in the pathogenesis of lung and other 
disorders via their ability to promote trophic, profibrotic ,and angiogenic function. 
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FIGURE IV.3: GATING STRATEGY 
 Hyperoxia induced lung injury results in the influx of alternatively activated macrophage 
and pulsatile CO treatment attenuates AAMφ infiltration. Cells were gated on CD45+ and 
then double positive cells were gated CD11chigh/F4/80+/CD11b+ then subgated on 















































FIGURE IV.4: HYPEROXIA UPREGULATES ALTERNATIVE ACTIVATION 
OF MACROPHAGES AND CO TREATMENT AMELIORATES M2 
MACROPHAGE MARKER EXPRESSION ASSOCIATED WITH HYPEROXIA-

















 M2 expression profile of hyperoxia induced mice show an increase in expression of 
CD206+CD301+ macrophages and CO treatment attenuates infiltration of M2 




FIGURE IV.5: HYPEROXIA UPREGULATES ALTERNATIVE ACTIVATION 
OF MACROPHAGES AND CO TREATMENT AMELIORATES M2 
MACROPHAGE MARKER EXPRESSION ASSOCIATED WITH HYPEROXIA-
INDUCED LUNG INJURY. 
 Results from percent double positive population and cell number of CD206+CD301+ 
macrophages are shown here. The data are from day 7 up to day 21 from five to eight 
mice at each time point with two repeats. Numbers represent mean± SEM.* P <0.05 as 
compared to hyperoxia alone. One-way ANOVA. 
 
 


























































































FIGURE IV.6: HYPEROXIA UPREGULATES ALTERNATIVE ACTIVATION 
OF MACROPHAGES AND CO TREATMENT AMELIORATES M2 
MACROPHAGE MARKER EXPRESSION ASSOCIATED WITH HYPEROXIA-
INDUCED LUNG INJURY. 
 (A-E) mRNA was measured by qPCR at 14 day post exposure of hyperoxia and CO 
treatment. Hyperoxic lung alveolar macrophage mRNA expression show decreased 
expression of macrophage activation Th2 related cytokine (MgL-2 (CD301), Fizz-1, Arg-
1 and Ym-1) 10days post CO administration. (B) The mRNA levels of Mrc-1 (CD206) 
had no significant decrease after with or without intermittent CO treatment. Numbers 
represent mean±SD at least n=8-13 mice per group. ** P <0.05; ***P < 0.0001, one way 
ANOVA. 
 









































































































***p< 0.001 **p< 0.05



































































































FIGURE IV.7: HYPEROXIA UPREGULATES ALTERNATIVE ACTIVATION 
OF MACROPHAGES AND HO-1 DEFICIENCY EXACERBATES M2 
MACROPHAGE MARKER EXPRESSION ASSOCIATED WITH HYPEROXIA-
INDUCED LUNG INJURY. 
 M2 expression profile of hyperoxia induced mice show an increase in expression of 
CD206+CD301+ macrophages and absence of HO-1 exacerbates the expression of M2 
macrophage into the injured lung from day 7 up to day 21 in wild type animals. Cells 




















FIGURE IV.8: HYPEROXIA UPREGULATES ALTERNATIVE ACTIVATION 
OF MACROPHAGES AND HO-1 DEFICIENCY EXACERBATES M2 
MACROPHAGE MARKER EXPRESSION ASSOCIATED WITH HYPEROXIA-
INDUCED LUNG INJURY. 
 Results from absolute cell number of CD206+CD301+ macrophages are shown here. The 
data are from day 7 up to day 21 from five to eight mice at each time point with two 






































FIGURE IV.9: HYPEROXIA UPREGULATES AAMφ  CHEMOKINE MRNA 
EXPRESSION. 
 mRNA was measured by qPCR for CCL-22 and CCL24 at 14 day post exposure of 
hyperoxia. Hyperoxic lung alveolar macrophage mRNA expression shows increase in 
expression in CCL22 in HO-1-/- animals compared to HO-1+/+ mice. The mRNA levels of 
MPIF-2 (CCL-24) had no significant increase post hyperoxia exposure in the absence of 
HO-1. Numbers represent mean ± SEM at least n=4-7 mice per group. ** P <0.05 as 















































FIGURE IV.10: HYPEROXIA UPREGULATES AAMφ  M2 MACROPHAGE 
MARKER MRNA EXPRESSION. 
mRNA was measured by qPCR at 14 day post exposure of hyperoxia. Hyperoxic lung 
alveolar macrophage mRNA expression showed a significant increase in Fizz-1 and Arg-
1 in the absence of HO-1 compared to wild type. The mRNA levels of Mrc-1 (CD206), 
Ym-1 (Chi313) and Mrc-1 (CD206) was not significant in the absence of HO-1 compared 
to wild type. Numbers represent mean ± SEM at least n = 6-14 mice per group. * P <0.05 
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FIGURE IV.11: SCHEME ILLUSTRATING THE EFFECTS OF CARBON 
MONOXIDE INHIBITION OF THE MITOCHONDRIAL ELECTRON 
TRANSPORT CHAIN. 
 CO slows the rate of electron transport (solid arrows), enabling electrons to accumulate, 
including at complex III. As a consequence, the lifetime of the ubisemiquinone state of 
Coenzyme Q (Q) is prolonged which is prone to reduce O2 to superoxide (O2-). 
Superoxide could then be converted enzymatically to other ROS that collectively induce 
a conditioning response by altering signaling pathways. FMN Flavinmononucleotide, 
FeS: iron-sulfur cluster, Cyt cytochrome. The area of CO signaling through the 
mitochondria ROS production is still in its early stages, and the issues of how much CO 
binding occurs physiologically and what the role of H2O2 egress from mitochondria is in 





FIGURE IV.12: SCHEMA ILLUSTRATING THE XF CELL MITOCHONDRIA 
STRESS TEST PROFILE. 
 The XF Cell Mito Stress Test Kit makes it easy to measure the four key parameters of 
mitochondrial function in a microplate: basal respiration, ATP production, proton leak, and 
maximal respiration, revealing critical information not evident in basal metabolism measurements 
alone. There are 4 different reagents that are important to measure OCR and EACR: Oligomycin 
(ATP Coupler), FCCP (Electron Transport Chain Accelerator), Antimycin A (Mitochondrial 






FIGURE IV.13: OCR MEASUREMENTS 
. (Top) RAW264.7 cell exposed to normoxia for up to 24hrs. (Bottom) RAW264.7 cell exposed 
to CO + normoxia for up to 24hrs using Cell Mito Stress Test 
 
RAW264.7	  Cell	  –	  CO	  +	  Normoxia	  
RAW264.7	  Cell	  –	  Normoxia	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FIGURE IV.14: OCR BASELINE PERCENTAGE CHANGES MEASUREMENTS 
. (Top) RAW264.7 cell exposed to normoxia for up to 24hrs. (Bottom) RAW264.7 cell exposed 
to CO + normoxia for up to 24hrs using Cell Mito Stress Test.  
 
RAW264.7	  Cell	  –	  Normoxia	  




FIGURE IV.15: ECAR MEASUREMENTS 
. (Top) RAW264.7 cell exposed to normoxia for up to 24hrs. (Bottom) RAW264.7 cell exposed 
to CO + normoxia for up to 24hrs using Cell Mito Stress Test. There are 4 different reagents that 
RAW264.7	  CELL	  –	  NORMOXIA	  
RAW264.7	  Cell	  –	  CO	  +	  Normoxia	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are important to measure OCR and EACR: Oligomycin (ATP Coupler), FCCP (Electron 
Transport Chain Accelerator), Antimycin A (Mitochondrial Inhibitor A) and Rotenone 





FIGURE IV.16: ECAR MEASUREMENTS 
. (Top) RAW264.7 cell exposed to normoxia for up to 24hrs. (Bottom) RAW264.7 cell exposed 
to CO + normoxia for up to 24hrs using Cell Mito Stress Test. There are 4 different reagents that 
RAW264.7	  Cell	  –	  Normoxia	  
RAW264.7	  Cell	  –	  CO	  +	  Normoxia	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are important to measure OCR and EACR: Oligomycin (ATP Coupler), FCCP (Electron 
Transport Chain Accelerator), Antimycin A (Mitochondrial Inhibitor A) and Rotenone 
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Leukocyte flux is thought to contribute to thrombus formation in deep venous structures 
under pathologic conditions, but little is known of the driving mechanisms or 
mechanisms which inhibit venous thrombosis during quiescence.  Ectonucleoside 
tri(di)phosphohydrolase 1 (CD39), an ectoenzyme which catabolizes adenine nucleotides, 
is embedded on the surface of endothelial cells (EC), leukocytes and platelets.  To 
determine whether CD39 regulates thromboinflammation at the vein/blood interface, 
mice were subjected to experimental inferior vena cava (IVC) ligation and deep venous 
thrombus formation examined. Mice homozygous null for the CD39 gene developed 
significant larger thrombi and more vein wall leukocytes (particularly neutrophils) at 48 
hours than wild type mice expressing a normal complement of CD39. Gene expression 
profiling of CD39 gene-null mice (in comparison to controls) revealed three 
differentially-expressed inflammatory genes groups (group I, II and III – total of 76 
genes) that were significantly upregulated during venous thrombosis and CD39 deletion; 
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qRT-PCR validation experiments confirmed high expression of 10 of these key 
inflammatory mediators.  From this group, P-selectin and vWF, were chosen for further 
study due to their proximal involvement with inflammatory and thrombotic events, 
respectively.  Circulating levels of both P-selectin and vWF were strikingly higher 
following IVC ligation in mice lacking CD39, with a corresponding increment in platelet-
leukocyte heteroaggregates. Taken together, these data indicate a cardinal role for CD39 






Deep vein thrombosis (DVT) and its major complication, pulmonary embolism 
(PE) is the third leading cause of cardiovascular death in the United States. DVT and PE, 
collectively referred to as venous thromboembolism (VTE) affect > 500,000 individuals 
and cause up to 180,000 deaths each year in the United States alone.1, 2, 3 In spite of high 
disease burden of DVT, much of the underlying etiology and pathophysiology remains 
unclear. A growing body of evidence supports the paradigm of intertwined roles of 
inflammation and thrombosis in the pathogenesis of DVT.  
 
In humans, systemic inflammatory conditions such as sepsis, inflammatory bowel 
disease and rheumatoid arthritis are associated with an increased risk of venous 
thrombosis.4 Inflammation in an animal model of DVT drives thrombosis by increasing 
tissue factor derived from the vessel wall and leukocytes. Inflammation also increases 
platelet reactivity, fibrinogen synthesis, and decreasing thrombomodulin, thereby 
increasing thrombosis. Inflammation or hypoxia-driven inflammation increases 
plasminogen activator inhibitor (PAI-1) by suppressing fibrinolysis. In concert, these 
changes set out to substantiate accumulated thrombus burden.5, 6, 7, 8, 9 Early stages of 
venous thrombosis in animal models are characterized by increased leukocyte 
recruitment, adhesion and infiltration into the vessel wall.10, 11, 12 The molecular 
mechanisms by which thrombosis occurs in DVT have not been fully elucidated. 
Activation of the vessel wall, vascular tissue factor, disturbed flow, stasis, hypoxia and 
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activated circulating leukocytes and platelets play significant roles as triggers for 
thrombus formation.13, 14, 15, 16, 17, 18, 19   
 
Selectins, expressed on the surface of endothelial cells (E-selectin and P-selectin) and 
platelets (P-selectin) have been shown to be important mediators of inflammation and 
DVT formation.19, 20 Recent work has shown the role of endothelial, neutrophil, 
monocyte and platelet cell-cell interactions as facilitators and potentiators of venous 
thrombus formation and propagation.19 Though there is some uncertainty as to the role of 
platelets in thrombosis related to venous stasis, the position of platelets at the thrombosis 
and inflammatory interface suggested they might play an active role in DVT. von 
Willebrand Factor (vWF), a multimeric adhesive ligand for platelet (GPIb), serves as a 
critical endothelial mediator of venous thrombosis by providing binding sites on the 
luminal surface for leukocyte and platelet adhesion. The observation that thrombi do not 
form in the absence of vWF in a mouse model of DVT highlights its critical role in 
venous thrombogeneis.21, 22 Additionally, diffuse fibrin accumulation serves as a mesh for 
platelet agglutination. More recently, neutrophil extracellular traps released from 
activated neutrophils have been implicated as key modulators of venous thrombus 
propagation, serving as a prothrombotic scaffold and a trap for leukocytes, platelets and 
red blood cells. In fact, studies in humans with DVT have shown an increase in 
circulating activated leukocyte-platelet heterodimers.23 Understanding drivers of, the 
interaction between innate immune cells and platelets in DVT propagation forms the 




Though found in abundance within cells purine nucleotides (ATP, ADP and 
AMP) are released extracellularly upon injury or death, where they form an extensive cell 
communication system with central roles in modulating endothelial cell activation, 
thrombosis, inflammatory cell trafficking and activation, apoptosis and 
vasoconstriction.24, 25, 26, 27, 28, 29, 30 Extracellular ATP and ADP metabolism is regulated 
by an ecto-apyrase (ecto-nucleoside triphosphate diphosphohydrolase-1, CD39), a 
transmembrane enzyme with a luminal-facing active site, which catalyzes the terminal 
phosphohydrolysis of ATP and ADP. CD39 thereby plays a critical role in 
thromboregulation and inflammation. CD39 is located on the surface of endothelial cells, 
leukocytes and platelets, where it tonically suppresses platelet aggregation by dissipating 
ADP, the chief agonist for the P2Y12 class of purinergic receptors on the platelet 
surface.31, 32 CD39 deficiency causes deleterious outcomes in various models of end-
organ injury, such as stroke33,34, Ischemia reperfusion injury35 and transplantation as graft 
survival in xenograft heart transplantation36 which could be caused by unopposed ATP 
toxicity. Our previous work demonstrated the protective thromboregulatory function of 
CD39 in mice 34,37 and in rats38 with stroke.
37
 Through its equally potent ability to 
dissipate a cloud of ATP released as an injury or danger signal, our group has shown that 
surface CD39 enables leukocytes to autoregulate their own flux into ischemic tissue.34 
This ectoenzyme therefore has a critical role at the nexus between inflammation and 




The objective of this study was to test the hypothesis that CD39 diminishes 
venous thrombogenesis. To test this hypothesis initially in an agnostic manner, mice 
(CD39+/+ or CD39-/-) were subjected to experimental procedure to create venous 
thrombosis, and gene expression profiling was used to monitor differential gene 
expression in inferior vena cava post thrombus induction compared to sham-operated 
control. Comprehensive bioinformatics analyses were used to enrich databases for Gene 
Ontology and pathway information to provide a deeper insight into candidate genes 
identified by expression profiling to elucidate inflammatory mechanisms involved during 
venous thrombogenesis. Using this approach we were able to show CD39 attenuates 









Targeted disruption of CD39 and generation of CD39-deficient mice.  
The CD39flox/flox mice used in this work were on C57BL/6J background and generated 
using vector pFlox-Flp-Neo as a backbone for generating a targeting vector with LoxP 
sites flanking the first exon of CD39 gene. CD39 global knockout mice were generated 
by crossing the floxed allele to a ubiquitously expressed Cre (EIIA) recombinase 
promoter. The presence of the EIIA promoter ensured less extraneous genetic material 
was present in the CD39 global deficient mice. Quantitative RT-PCR analyses confirmed 
the absence of CD39 mRNA in various adult mouse organs tested (Figure 1A and B).  In 




The control mice used for these experiments were CD39flox/flox, designated as CD39+/+ 
mice. Mice which were globally deleted of CD39 utilizing the EIIA cre recombinase 
deletion strategy, are designated here as CD39-/- mice. All mice, CD39+/+ and CD39-/- 
were back bred at least 8 generations into the C57BL/6J background. For all experiments, 
CD39+/+ and CD39-/- mice were aged-matched, males (8-to-10-weeks-old) weighing 25–
30 grams. Animal experiments were approved by and carried out in accordance with the 




Phenotypic characterization of CD39+/+ and CD39-/- mice   
Cardiovascular phenotype was assessed by measuring blood pressure and heart rate and 
by evaluating for baseline differences in overall cardiac function. Blood pressure and 
heart rate were obtained on acclimatized mice by tail cuff. A minimum of 6 
measurements per animal was obtained and averaged. Baseline echocardiographic 
measurements were obtained in the following manner. Induction of anesthesia was 
performed in an enclosed container filled with 4-5% isoflurane. After induction, mice 
were placed on a warming pad to maintain body temperature.  1 – 1.5% isoflurane was 
supplied via a nose cone to maintain anesthesia.  The hair was removed from the upper 
abdominal and thoracic area with depilatory cream.  ECG was monitored via non-
invasive resting ECG electrodes. Transthoracic echocardiography was performed in the 
supine or left lateral position.  Two-dimensional, M-mode, Doppler and tissue Doppler 
echocardiographic images were recorded using a Visual Sonics’ Vevo 700 high 
resolution in vivo micro-imaging system.  
 
Analysis of whole-blood hematology profile and platelet aggregometry 
Mice were anesthetized with isoflurane (2.5% in 10% oxygen) and blood was drawn by 
direct cardiac puncture into ethylenediaminetetraacetic acid (EDTA) microtainer tubes or 
10% sodium citrate (Becton Dickinson, and Co. Franklyn Lakes, NJ). A complete blood 
panel was run on 30 µL using the CDC Technologies HEMAVET 950FS® Multispecies 
Hematology Analyzer (Drew Scientific, Inc. Dallas TX). The hematologic values 
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evaluated included the white blood cell count, neutrophils, monocytes, lymphocytes, red 
blood cell count, platelet count, hematocrit, and mean platelet volume. Prothrombin time 
and partial thromboplastin time were measured by Antech Diagnostics (Irvine, CA). For 
whole-blood aggregation experiments, murine blood was drawn in heparinized capillary 
tubes (Fisher Scientific, Pittsburgh PA) from the retro-orbital plexus. Whole-blood was 
diluted 4-fold with physiologic saline and impedance aggregometry was performed using 
a Chrono-log 560CA with the Aggro/Link 810 software (Haverton, PA) according to 
manufacturer’s instructions. Whole-blood aggregation was stimulated with 5 µM ADP 
(Chrono-log). 
Mouse model of stasis-induced deep venous thrombosis 
The thrombus induced mouse complete stasis model of inferior vena cava thrombosis was 
used to induce thrombogenesis as previously described39,20,40,41 by an operator blinded to 
the genotype of the experimental animal. Eight-to –ten-week- old male mice were 
anesthetized using inhalational 5-7% isoflurane gas and 100% oxygen mixture, and body 
temperature was maintained during surgery at 37oC for 45min – one hour thereafter using 
a temperature –controlled circulating liquid heating pad. After a midline laparotomy to 
access the inferior vena cava (IVC), the intestines were exteriorized and sterile saline was 
applied during the entire procedure. Abdominal contents were protected with moist sterile 
gauze to prevent from drying. A space holder was positioned on the outside of the vessel 
and fascia surrounding the aorta, and the IVC was approached and all venous side 
branches were ligated using 7-0 prolene suture (Ethicon, Inc, Somerville, NJ) 
immediately below the renal veins to obtain complete stasis.   After surgery, the intestines 
were returned to the body cavity, 1.5mL of warm saline was flushed into the peritoneum, 
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and the abdominal wall and skin closed with 5-0 Vicryl (Ethicon, Inc, Somerville, NJ). 
Sham-operated experiments consisted of median laparotomy and intestine manipulation 
without ligation of the IVC. For the initial time course experiment, the thrombus-
containing IVC was carefully removed, weighed and the block was measured. Thrombus 
–containing IVC and IVC of sham-operated mice is widely used in studies of DVT model 
in mice to characterize the weight and size of the clot.39,20,40,41 One – seven days after 
thrombus induction, the entire thrombosed IVC was either 1) weighed in milligrams (mg) 
to assess the clot weight; 2) placed in 10% formalin for fixation and then 70% ethanol for 
storage until the time of histological analysis; or 3) thrombus was carefully separated 
from the IVC wall, snap frozen, and stored at -80oC until used for biochemical analysis.  
Thrombus and Inferior vein wall weight measurement  
Four-eight hours after surgery, mice from the four experimental groups (CD39+/+ sham 
and IVC-ligated and CD39-/- sham and IVC-ligated), CD39+/+ and CD39-/- mice were 
euthanized, IVC (including contents) was removed, weight and length were measured in 
milligrams (mg) and centimeter (cm), respectively, and then IVC was carefully stripped 
from the thrombus and both were weighed independently.  
 
Histological analysis of thrombus-induced IVC/ vein wall morphometric analysis 
Post-thrombus induction, thrombus-containing IVC was excised, fixed in 10% formalin 
overnight at 4oC, then stored in 70% ethanol prior to embedding in paraffin. 5 µm serial 
cross sections of the thrombus-containing IVC were cut using leica RM2235 microtome. 
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Tissue sections were stained with hematoxylin and eosin, visualized under light 
microscopy and images were captured using an Eclipse TE2000-E microscope (Nikon 
Instruments, Melville, NY 400 x magnifications).  MetaMorph image analysis version 
7.0r3 software (Molecular Devices, Sunnyvale, CA) was used for morphometric analysis. 
Morphometric evaluations were made by an experienced pathologist blinded to 
experimental conditions, using a previously described thrombus surface-organization 
scoring criteria.39 Briefly, veins were examined under high-power oil immersion light 
microscopy (1000x). Five representative high-power fields (HPFs) were chosen from 
three different section from each animal, positive cells were examined radially around the 
vein wall, and inflammatory cells (total cells, polymononucleated (PMNs), 
monocytes/macrophages, or lymphocytes (data not shown)) were identified based on 
standard histologic criteria.20 Results from the 5 HPFs were added and mean ± SEM was 
calculated for each experimental group.  
 
Immunohistochemical localization of P-selectin and von willebrand factor 
expression 
Immunohistochemical analysis of P-selectin and vWF expression was performed on 5 µm 
sections prepared from formalin fixed, paraffin-embedded thrombus-induced IVC using 
rabbit polyclonal stained for CD62P (Ab 59738 - Abcam, Cambridge, MA) at 1:200 
dilution or vWF (A0082 – Dako, Carpinteria, CA) at 1:250 dilution as a primary 
antibody. Prior to antibody incubation, thrombus-containing IVC tissues were subjected 
to 30 minutes of antigen retrieval (10mmol/L citrate buffer, pH6.0, 98oC) and 5 minutes 
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of serum-free protein block (Cat X0909 Dako). A secondary antibody conjugated to a 
horseradish peroxidase-labeled polymer (EnVision+, HRP, Rabbit, catalog no. K4003, 
Dako, Carpinteria, CA) was used according to the manufacturer's instructions to localize 
sites where the primary antibody had bound. Color development was performed with 
diaminobenzidine (DAB). Slides were counterstained with hematoxylin, and images 
acquired with a 400x objective, and analyzed  using MetaMorph image analysis software 
(Molecular Devices, Sunnyvale, CA) on an Eclipse TE2000-E microscope (Nikon 
instruments Inc). 
Ectonucleoside Triphosphate Diphosphohydrolase-1 (ENTDP-1/CD39), P-selectin 
and VWF plasma protein quantification via enzyme-linked immunosorbent assay  
To determine soluble CD39, P-selectin and vWF levels in plasma, blood was collected 
from thrombus-induced CD39+/+ and CD39-/- mice and its respective sham-operated mice 
via cardiocentesis and placed in tubes containing EDTA as an anticoagulant (Becton 
Dickinson, and Co. Franklyn Lakes, NJ). Platelet-poor plasma was isolated from whole 
blood by centrifugation (2000xg, 30minutes and 10,000xg, 10minutes at 4o C for the 
solP-selectin and CD39 ELISA and at 25o C for vWF AlphaLISA and snap frozen in 
liquid nitrogen for later analysis. Prior to evaluation, plasma retrieved from the EDTA- 
treated blood samples was processed according to the manufacturer’s instructions in the 
ELISA kit for sP-selectin (R&D systems Minneapolis, MN). We developed an ELISA 
based protocol to detect sol CD39 using recombinant CD39 as a standard and anti-CD39 
(R&D systems Minneapolis, MN). Plasma vWF antigen levels were determined by 
AlphaLISA (Perkin Elmer, Waltham, MA) custom designed kit, using a polyclonal anti-
human vWF antibody (DAKO, Glostrup, Denmark) conjugated to Alphalisa acceptor 
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beads and well as biotinylated anti-human vWF antibody (also DAKO) to interact with 
streptavidin coated donor beads.  Mouse plasma was diluted 1:50 in PBS.  Twenty µL of 
diluted plasma was incubated at room temperature with anti-vWF acceptor beads and 
biotinylated anti-vWF antibody in AlphaLISA buffer (25 mM HEPES, pH 7.4, 1 mg/mL 
Dextran 500, 0.5% BSA, 0.5% Triton X-100 and 0.05% Proclin-300) for one hour.  
Steptavidin-coated donor beads were added for a final concentration of 12.5 µg/mL 
acceptor beads, 5 nM biotinylated antibody and 40 µg/mL donor beads in 60 µL reaction 
volume.  AlphaLISA signals were determined on an EnSpire 2300 Multimode Plate 
reader (Perkin Elmer), and VWF levels were calculated by comparing signals to a 
dilution series of C57BL/6J plasma.  All vWF levels are reported as a percent of 
C57BL/6J plasma, which was considered to be 100 U/dL. All mouse samples were 
assayed at least 3 times and the average CV% of samples was 7.75%. 
Assessment of platelet-leukocyte aggregates in whole blood  
Following thrombosis induction, mouse blood was collected from the retro-oribital 
plexus from CD39+/+ and CD39-/- mice and its respective sham-operated mice and placed 
in cold phosphate buffer saline without magnesium or calcium (PBS) at 4o C. FACSlyse 
buffer (BD Bioscience, Franklin Lake, NJ) was used to lyse erythrocyte contaminants. 
Total cell counts were assessed by Hemavet hemocytometer (Drew Scientific) and 
reconfirmed by flow cytometry analysis using PerCPCy5.5-anti mouse CD45 antibody 
(BD Bioscience, Franklin Lakes, NJ) and absolute count standard beads (BD Bioscience). 
Viable cells were identified by the absence of DAPI (Molecular Probes, Portland OR) 
staining.  Antibody specificity was verified using an appropriate isotype-labeled antibody 
(anti–rat IgG2a or anti–rat IgG2b). Nonspecific antibody staining was inhibited using rat-
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anti mouse CD16b/CD32 antibody to block the FcγIII/II receptor (BD Bioscience). Total 
leukocyte analysis of whole blood was performed using APC-anti-mouse CD11b 
(monocyte/macrophage) and APC-Cy7-anti-mouse Ly6G/Ly-6C (Gr-1-neutrophils) (both 
from BD Bioscience).  
 
In order to evaluate platelet-leukocyte aggregates, a 6-color flow cytometry assay was 
developed to analyze platelets binding to neutrophils or monocytes in whole blood. Cells 
and cell aggregates were purified and identified in four stages. First, the leukocyte 
population was gated using PerCPCy5.5-conjugated anti-mouse CD45. Second, 
infiltrating monocyte/macrophages, double positive for staining with APC-conjugated 
anti-mouse CD11bhigh, and granulocytes, APC-Cy7-conjugated anti-mouse Gr-1. The 
combinations of rat anti-mouse CD11b-activated protein C, CD45-PerCPCy5.5 and 
glucocorticoid receptor (GR)-1- APC-Cy7 antibodies and isotype controls (all from BD 
Bioscience Franklin Lakes, NJ) were used for labeling leukocytes. Neutrophils and 
monocytes were distinguished from other cells by their size and granularity and by anti-
CD11b-activated protein C and anti-GR-1- APC-Cy7 antibody binding. Within the 
CD11b/CD45 and Gr-1/CD45 positive-double events, the third cell subpopulation was 
identified using rat anti-mouse CD41 (platelet glycoprotein (GP) IX)- PE antibody to 
label platelets; the activation of platelets bound to leukocytes was assessed by counting 
CD62P (P-selectin) – fluorescein isothiocynate (FITC)- positive events. Lastly, activated 
platelet –monocyte (CD11b-APC/CD41-PE/CD62P-FITC) and activated platelet–
neutrophil (GR-1-APC-Cy7/CD41-PE/CD62P-FITC) aggregates were calculated from 
CD41-PE/CD62P double positive gates. All antibodies were purchased from BD 
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Bioscience. Platelet- leukocyte aggregates were identified using multispectral BD FACS 
CantoTM flow, at least 1X105 cells were collected from each sample and analyzed with 
FlowJo v.9.4.11 (Tree Star, San Carlos, CA). 
Microarray-based transcriptional profiling and bioinformatics analysis of 
microarray data  
RNA samples from CD39+/+ and CD39-/- mice and their respective sham-operated mice 
(n=4 per group for biological replicates; Technical replication was achieved by pooling 
four samples for each of the four groups for analysis) were were used to detect gene 
expression changes at 48 hrs post – thrombus induction. Total IVC RNA was extracted 
using the TRIzol reagent (GIBCO BRL) and RNeasy spin (Qiagen) columns following 
homogenization. Prior to microarray based gene expression profiling total RNA was 
further purified using RNAeasy reaction cleanup kit (Qiagen). All procedures were based 
on the manufacturer’s RNA amplification protocol. 50 nanogram of total RNA (Ovation 
PicoSL WTA System V2 P/N 3312) was used to synthesize double-stranded cDNA, 
according to the NuGen WT-Pico V2 kit protocol. Biotinylated single-stranded cDNA 
was prepared from 3 µg of cDNA (Encore Biotin Module P/N 4200-12, 4200-60, 4200-
A01). Following fragmentation, 3.7 µg of cDNA was hybridized for 20 hr at 48o C on 
Mouse Gene ST 1.1 strip arrays, using the Affymetrix Gene Atlas system (software 
version 1.0.4.267; Affymetrix, Inc., Santa Clara,CA). Raw intensity data was processed 
and exported using Affymetrix Command Console, after scanning with the Affymetrix 
Gene Atlas system. Subsequent analyses were performed using the R programming 
environment 2.15.0 (R development core team 2011): a language and environment for 
statistical computing with the Oligo bioconductor software packages (Bioconductor, Fred 
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Hutchinson Cancer Research Center, Seattle, WA)42 
 
To assess sample quality, we compared the probe intensity distributions across the 
multiple samples with the expectation that they be similar in shape, location, and scale. 
We also used degradation plots to assess differences in degradation that might appear as 
differences in expression. We next calculated the expression values for each gene using a 
robust multi-array average (RMA)43 which produced pairwise scatterplots of log2 
whereby converting the perfect match (PM) probe value intensities into log2 expression 
values for each sample used quantile normalization and median-polish. (Figure 4A). 
Moreover, the principal component analysis (PCA) was performed using “stats” package 
in R. When visualizing PCA results, the first 2 principal components (coordinates) are 
shown z-transformed and give the overall structure of high dimensional data (Figure 4B). 
Having passed all the manufacturer’s quality control checkpoints, data was normalized 
using RMA as mentioned above.42 Comparisons were made between CD39+/+ and   
CD39-/- mice, and their respective sham-operated mice. Data was filtered using probesets, 
with a fold change greater than 2 with the added constraint that one of the two samples 
had an expression value of 25 or greater, to remove non-informative genes. Variable 
genes were plotted as heatmaps with hierarchical clustering using euclidean distance as a 
distance measure and complete linkage as the clustering method using the “stats” package 
of R. Fold-changes were visualized with color ranging from red (high expression relative 
to sham) over white (intermediate expression relative to sham) to blue (low expression 
relative to sham).  Microarray data generated in this study were deposited in Gene 




Molecular interaction networks and functional analysis 
Using Ingenuity Pathway Analysis (IPA) tool 9.0 software (Ingenuity Systems Inc. 
Redwood City, CA), gene ontology achieved identification of cellular functions affected 
by induction of thrombosis or the deletion of ENTDPase-1/CD39. The “Core Analysis” 
was used to interpret the large datasets in the context of biological functions, disease 
processes, and molecular networks. The gene lists containing Affymetrix IDs, fold 
change, and P values, were mapped in the Ingenuity Pathways Knowledge Base (IPKB). 
The focus genes were then used in the network algorithm to generate scored networks, 
based on the curated list of molecular interactions in IPKB. Pathway and global 
functional analyses were performed using Ingenuity Pathway Analysis 6.0 (IPA; 
Ingenuity® Systems, www.ingenuity.com). A data set containing gene identifiers and 
corresponding expression values was uploaded into the application, and each gene 
identifier was mapped using the IPKB. The IPKB analyses identify the biological 
functions as well as the pathways from the IPA library that are most significant to the 
data set. Genes from the data sets associated with biological functions or with a canonical 
pathway in the IPKB, that met the p-value cutoff of 0.005 were used to build the 
interactome as described above. Fisher's exact test was used to calculate a p-value 
determining the probability that each biological function and/or canonical pathway 
assigned to this data set was not due to chance alone. 
 
Validation by quantitative RT-PCR  
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Differential gene expression identified through microarray analysis was validated via 
quantitative real-time PCR (qRT-PCR), which was performed using TaqMan probe-based 
chemistry (Applied Biosystems, Carlsbad, Calif) per manufacturer’s instructions, and the 
ABI Prisim 7500fast sequence detection system (Applied Biosystems, Carlsbad,CA). 
Briefly, the vein wall was separated from its associated thrombus, placed in a 15 mL 
conical tube filled with 1.5 mL of TRIzol (Invitrogen, Carlsbad, CA), and homogenized 
using the standard homogenization protocol. The RNA was cleaned using the RNAeasy 
reaction cleanup kit (Qiagen Inc, Valencia, Calif) according to the manufacturer's 
protocol. For this procedure, RNA concentrations were verified using the Nanodrop 
spectrophotometer (Thermo Fischer Scientific Inc., Wilmington, DE). Reverse 
transcription of the RNA (500 µg) into cDNA was done using SA Biosciences’ RT 2 First 
Strand kit. Real-time PCR was run on the cDNA template according to the 
manufacturer's protocol for β-actin (housekeeping gene). All the primer used for qRT-
PCR was purchased from Invitrogen. Commercially-available mouse primers sequences 
were derived using validated primer sequences from Affymetrix microarray (Affymetrix, 
Inc., Santa Clara,CA) were all purchased from Invitrogen.  Quantification of 
inflammatory mediators utilizes the cycle threshold (Ct) for the gene of interest 
normalized to the housekeeping gene β-actin. Relative mRNA expression is calculated by 
the formula 2-(Ct target gene-Ct reference gene), and cycle lengths used are within the 
exponential phase of the polymerase chain reaction. Cycle threshold values were 
evaluated with the delta CT method to determine increases or decreases in gene 




All data are represented as mean ± SEM, with the numbers of experiments performed 
provided in the figure legends. Data are expressed as means ± SE. Differences between 
statistical groups were evaluated for statistical significance using the Student’s t-test for 
unpaired data with Welch’s correction. P < 0.05 was considered statistically significant. 
Comparison of results between different groups with more than 2 conditions were 
compared using a one-way analysis of variance (ANOVA) or a Mann-Whitney U test, as 
appropriate, using GraphPad Prism 6 software (LaJolla, CA).  To discern differences 
between specific groups, Newman-Keuls test was used.  Values were considered 
significantly different when P≤0.05 
RESULTS 
 
Generation of ectonucleoside tri (di)phosphohydrolase (cd39)-deficient mice 
To eliminate the cd39 gene product in mice, a targeting vector was prepared 
from the 5’portion of the murine cd39 gene by inserting novel LoxP and Frt sites, 
and a PKG neomycin resistant cassette in the reverse orientation. By interbreeding 
homozygote cd39 flx/flx mice and crossing to a pleiotropic CRE (EIIA) mouse, we were 
able to successfully excise the cd39  gene product. No specific abnormalities in 
development nor reproductive capacity were found in the cd39 flx/flx and cd39−/− mice. 
Using qRT-PCR we detected cd39 transcript in mRNA from multiple organs from cd39 
flx/flx
 and cd39−/− mice. As expected, CD39-deficent mice, no cd39 transcripts were 
detected (Fig 1A). Not only were cd39 flx/flx and cd39−/− mice phenotypically grossly 
identical but hemodynamically they were also similar in terms of heart rate and blood 
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pressure (Fig 1B, C). Circulating total leukocyte and subset population cell counts were 
similar between cd39 flx/flx and cd39−/−mice. In keeping with previous published 
observations, platelet counts were lower in CD39-/- mice compared to cd39 flx/flx (Fig. 1 
D). Both values are nearly within expected normal platelet count range for mice 
Peripheral blood smears of CD39-/- mice showed reduced platelet number with no 
megakaryocytes or platelet clumping (data not shown). CD39-/- mice had similar 
prothrombin and partial thromboplastin time estimates compared to those of cd39 flx/flx 
mice (Fig. 1D). To further characterize coagulation, whole-blood impedance 
aggregometry was performed. Consistent with prior published studies, in which globally 
CD39-deficient mice had significantly impaired platelet aggregation due to platelet 
desensitization 31compared to WT mice (Fig. 2A,B).  
 
CD39-deficient mice generate significantly more thrombus than wild type mice 
Deep venous thrombogenesis was induced in CD39-deficent and WT mice with the use 
of an IVC ligation stasis (absence of flow) model20, 39. In our animal model, thrombus 
mass measurements give a reliable measurement of DVT formation and resolution. This 
technique assesses the entire thrombosed vein, and is performed in a standardized 
fashion. Thrombus weights were evaluated in WT male mice from 1d to 6d after IVC 
ligation. All 44 WT mice developed a thrombus within 24 hrs post-thrombus induction 
(Fig 2C-E). Forty-eight hours post-thrombus induction, IVCs demonstrated a 50% 
increase thrombus mass compared to day 4 and 6 in CD39+/+ mice (P= 0.0072) (Fig 2C). 
Compared to the WT age-matched controls, CD39-/- mice had approximately 47% larger 
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thrombi, (P = 0.0001), 48 hrs post-thrombogenesis (Fig 2D). Fig 2E depicts a 
representative photograph of CD39-/- and CD39+/+ thrombi 48 hrs post-thrombogenesis. 
The data obtained with this model of stasis-induced IVC ligation shows that CD39-/- mice 
have larger thrombi compared to CD39+/+ mice 48 hrs post- thrombogenesis.  
 
Vein wall inflammation is increased in CD39-/- mice 48 hrs post- thrombus induction  
When evaluating the vein wall and the thrombus proper, the total inflammatory cells 
showed a trending increase in CD39-/- thrombi, as compared with CD39+/+ mice (Fig 3). 
Hematoxylin and eosin staining of the thrombosed IVC sections qualitatively confirmed 
that increased leukosequestration in vein wall was present 48 hrs post-thrombogenesis in 
CD39-/- mice compared to wild-type age-matched counterparts (Fig 3A-D). Together 
with histology and thrombus histomorphological evaluation, a significant increase was 
observed in neutrophil migration through the vein wall 48 hrs post- thrombus induction in 
CD39-/- compared to CD39+/+ mice, suggesting that the absence of CD39 exaggerates 
polymorphonuclear neutrophils recruitment into the thrombosed zone (Fig 3B, D, F). 
There was no significant increase in monocyte accumulation in the vein wall 48 hrs post- 
thrombogenesis in CD39-/- thrombi, as compared with CD39+/+ mice (Fig 3G). However, 
there was a significant increase in the vein wall monocyte accumulation at 6 days post-
thrombus induction in CD39-/- mice compared to wild type mice (data not shown).  
 
Microarray quality control analysis revealed strong differences in gene expression 
48 hr post-thrombus induction in CD39-deficient mice. 
	  
 242 
To investigate gene expression profiles that are associated with leukosquestration 48 hrs 
post-thrombrogenesis, mRNA expression in total IVC (from all four groups described 
above) was profiled using Affymetrix gene chip ST1.1 microarray platform. We used an 
n=4 biological replicates to run one array strip and employed several quality control 
parameters prior to analyzing the probeset. Figure 4A depicts a histogram showing the 
distribution of the probes for each chip. One of the underlying assumptions for the 
normalization procedure was that the probe data all come from the same distribution, 
with the only differences being the location and scale. Each expression value for each 
gene used a robust multi-array average.43 Principal component analysis (PCA) was first 
performed to examine the correlations among the different experimental variables. The 
red, green, blue and purple dots represent the overall expression pattern of each IVC 
sample from CD39+/+ sham-operated, CD39+/+ IVC-ligated, CD39-/- sham-operated or 
CD39-/- IVC-ligated mice, respectively (Fig 4B). The first component shown in the x-axis 
includes genes with a high degree of variance within the different genotypes (CD39+/+ 
sham and IVC-ligated vs. CD39-/- sham and IVC-ligated). The second component, 
displayed along the y-axis, encompasses genes that also had a high range of variance 
within the sham and IVC-ligated groups (Sham - CD39+/+ and CD39-/- vs. IVC-ligated- 
CD39+/+ and CD39-/-). The PCA results indicated that the global expression patterns in 
IVC of the same experimental mouse groups were similar, whereas those in IVCs of the 
different mouse groups were different. The PCA analyses also show that the samples 
within the two experimental variables (genotype, and ligation status), were distinctly 
separated, indicating that the quality of the microarray data was excellent. As anticipated, 
when using a Venn diagram to illustrate the number of probe sets common to both sham 
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and DVT groups. The sham vs. DVT experimental group there were 132 common probe 
sets Fig 4C. Conversely in the CD39+/+ IVC-ligated vs. CD39-/- IVC-ligated there were 
722 common probe sets Fig 4D. Between the four different experimental groups, we 
identified 854 probe sets as significantly differentially expressed (Fold change -2≥ to ≥2; 
P≤0.001) in each pairwise comparison (Fig 4C,D). Altogether, we observed a 
considerable increase in the dynamic range of fold differences in microarray data with 
differences spanning six orders of magnitude.  
 
Hierarchical clustering analysis of differentially expressed genes identified unique 
groups of highly upregulated inflammatory genes  
We hypothesized that induction of thrombosis and the deletion of CD39 will heighten the 
expression of inflammatory mediators. We also hypothesized that the increase in 
leukocyte flux seen in the ligated IVCs of CD39-/- mice was due in part to an absence of 
vascular wall CD39 activity, and possibly the loss of CD39 circulating on the leukocytes. 
To examine this, an ANOVA was first performed to identify genes that are differentially 
expressed due to CD39 deficiency or stasis-induced thrombogenesis (Fig 5A-D). After 
ANOVA, 179 inflammatory and immune response genes were found to be highly 
upregulated during stasis-induced thrombosis and CD39 deficiency were analyzed by 
hierarchical clustering and visualized as a heatmap (Fig 5A-B). We focused our analysis 
on three groups of genes (group I, II and III = total 76 unique probe sets) that showed a 
concordant increase in expression in Sham vs. DVT and CD39+/+ IVC-ligated vs. CD39-/- 
IVC-ligated. Fig 5C and D depicts the subset of genes that were categorized as groups I, 
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II, III and visualized as a supervised hierarchical clustering heatmap. By comparing our 
results from the four different groups, we identified ten differentially expressed genes in 
common; Il-6, Nos2, Il-1b, Tnf, Ccl2, Cxcl2, Chi313, Arg1, Selp and VWF. Our data 
show that Selp, vWF and Il-6 were slightly up-regulated. This finding is concordant with 
previous studies using varying models of deep vein thrombosis.44,39,45,46,47,48,21 
Interestingly, Chi313 and Arg1, an M2 alternative macrophage marker, was highly 
upregulated (fold change > 4) during stasis-induced thrombogenesis and also showed a 
concordant increased in the absence of CD39 (fold change > 5). These experiments 
showed that CD39 could regulate key inflammatory mediator expression levels during 
stasis-induced thrombogenesis.  
 
Validation of microarray results by Real-time qRT-PCR of inflammatory mediators 
and chemokine gene expression profiles 48 hrs post-IVC ligation. 
To independently confirm the microarray results, quantitative real-time RT-PCR were 
performed on samples from CD39+/+ and CD39-/- sham operated or IVC-ligated mice 48 
hr post IVC ligation that were used in the microarray. The pattern of dysregulation of 
several genes with prominent proinflammatory functions, as well as several chemokines, 
presented the first evidence that stasis- induced thrombogenesis might mediate 
leukosequestration in CD39-deficient mice. The relative expression levels of ten 
differentially expressed genes identified through the microarray analysis – (Il-6, Nos2, Il-
1b, Tnf, Ccl2, Cxcl2, Chi313, Arg1, Selp and vWF) – were assayed (Fig 6A-J). IL-6 and 
Cxcl2 gene expression were significantly increased (p<0.001) during stasis –induced 
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thrombosis and CD39-deficiency (Fig 6A,F), and TNF-α and CCL-2 (M1 polarized 
inflammatory mediator) and Chi313 and Arg1 (M2 polarized inflammatory mediator) 
were also significantly increased in CD39-/- mice (p<0.05). In addition, during stasis-
induced thrombosis, P-selectin and vWF were enhanced by ~4 fold (p<0.05) and 6-fold 
(p<0.01), respectively, in the absence of CD39 (Fig 6I,J). These findings (P-selectin and 
vWF gene expression) were then followed up at the protein level by ELISA using plasma 
from the four different groups described above (Fig 9A-E), where similar results were 
obtained, confirming the microarray findings.  
 
Functional pathway and network analysis affected by stasis induced thrombogenesis 
and CD39 deficiency   
The differential mRNA expression patterns as revealed by the microarray of CD39+/+ and 
CD39-/- sham operated or IVC-ligated mice 48 hr post IVC ligation were analyzed using 
the Ingenuity System Database, software that includes the Ingenuity Knowledge Base and 
the Global Molecular Network. These databases integrate published findings on 
biologically meaningful genetic or molecular gene/gene product interactions and identify 
functionally related gene networks. 
Ingenuity Pathway functional analysis for pathways and diseases revealed many 
inflammatory and immune response- relevant pathways that were significantly 
overrepresented in CD39+/+ and CD39-/- sham-operated or IVC-ligated mice post-
thrombogenesis, including; atherosclerosis signaling; HIF-1α signaling; hypoxia 
signaling in cardiovascular systems; inhibition of angiogenesis; VEGF signaling; CD40 
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signaling; IL-12 signaling and the production of macrophages; IL-6; IL-10; IL-8 
signaling; iNOS signaling; leukocyte extravasation signaling; NF-κB signaling; p38 
MAPK signaling; cytokine mediating communication between immune response; CCR5 
signaling in macrophages; chemokine signaling; coagulation system; and eNOS signaling 
(Fig 7A). Each functional pathway or disease category defined by Ingenuity Pathway 
Analysis includes sublevel functions, thus the data presented in Figure 7A represent the 
most significant sub-level function in each category. Based on the results obtained by 
Ingenuity canonical pathway analysis, we further investigated the genes involved in 
leukocyte extravasation signaling in CD39+/+ and CD39-/- sham operated or IVC-ligated 
mice 48 hrs post-thrombogenesis (Fig 7B-E). Among the genes that were affected by 
leukocyte rolling and docking on the endothelial surface of capillaries, PSGL-1 (P-
selectin glycoprotein ligand-1) was significantly down-regulated in the sham-operated 
group (Fig 7B). Conversely, during thrombus induction and CD39 deficiency, PSGL-1 
was significantly up-regulated (Fig 7C-E). This finding is concordant with previous 
report showing the interaction of P-selectin with PSGL-1 is an exceptionally effective 
mechanism for mediating leukocyte tethering under flow.49,50,51 It is interesting to note 
that, MMP-9 (matrix metalloproteinases-9), located on leukocyte that has transmigrated 
through a capillary endothelial layer, was also significantly down-regulated under sham 
conditions. Simultaneously, during thrombogensis and absence of CD39, MMP-9 gene 
expression levels were significantly up-regulated (Fig 7B-E). This finding is 
complementary to recent work in which deletion of MMP-9 impaired vein wall fibrosis 




To further investigate the interaction of Selp, vWF and other differentially regulated 
proinflammatory genes with other gene products, pathways, and biological processes, 
molecular networks were formed in Ingenuity Pathway Analysis using functional 
relationships between genes products based on known connections in the literature. These 
networks include genes that are biologically relevant to the pathway but not identified in 
the microarray. Figure 7A-D represents the IPA-generated molecular networks 
assembled from diffentially-expressed genes in CD39+/+ and CD39-/- sham-operated or 
IVC-ligated mice 48 hrs post-thrombogenesis. Each network was identified based on a 
numerical rank score according to the degree of relevance of the network to the 
molecules in the significant genes list and based on the hypergeometric distribution 
calculated as –log (Fisher’s exact test result). A score greater than two indicates a ≥99% 
confidence that a focused gene network was not generated by chance alone IPA. In these 
network illustrations, genes or gene products are represented as nodes, and the biological 
relationship between two nodes is represented as an edge (line). All edges are supported 
by at least one published reference. Focus genes are denoted by red symbols for 
upregulated genes and green symbols indicate downregulated genes. Grey and open 
symbols are intermediate molecules, placed in the network by the Ingenuity software and 
shown in the literature to interact with genes in this dataset. Symbols representing the 
functional categories of the molecules are listed in the legend (Fig 7F-I). These GMN 
findings showed in the sham-operated group the interaction between Selp, vWF and other 
differentially regulated proinflammatory genes caused an upregulation in Selp and down-
regulation of vWF and the proinflammatory cytokine group (Fig 7F). In contrast, 
thrombus induction and CD39-deficiency caused Selp and vWF to be slightly up-
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regulated, and proinflammatory cytokines to be moderately down-regulated (Fig 7G, I).  
 
Vein wall P-selectin and vWF was increased in CD39-null mice 48 hr post-thrombus 
induction 
P-selectin and vWF have previously been shown to be involved in facilitating the initial 
rolling and recruitment of leukocytes during thrombosis.39,45,21 In addition, previous 
studies have suggested a link between inflammation and DVT7,53, yet the precise role that 
CD39, P-selectin, and vWF plays in leuckosequestration during thrombogenesis has not 
been explored. To discern the localization of P-selectin and vWF in CD39 null mice via 
immunohistochemical analysis, we stained tissue sections from CD39+/+ and CD39-/- 
sham operated or IVC-ligated mice 48 hrs post-thrombogenesis (Fig 8A-H), with an 
antibody that recognize murine P-selectin and vWF. Immunohistological examinations 
reveal an increase in expression of P-selectin and vWF in CD39 null mice 48 hrs post-
thrombus induction (Fig 8D-H). Interestingly, there were a large number of inflammatory 
cells recruited to the thrombus milieu that were stained with P-selectin antibody in CD39-
/- IVC-ligated, compared to CD39+/+ IVC-ligated thrombus induced group (Fig 8B, D). 
Furthermore, the increased staining of vWF was significantly greater on the endothelium 
in CD39-deficient mice compared to their wild type counterparts (Fig 8F, H).  
Circulating P-selectin and VWF was significantly enhanced in CD39-deficient mice 
48 hr post-thrombus induction 
Soluble P-selectin is an established biomarker for deep venous thrombosis as confirmed 
in both patients54,55 and mice that have deep venous thrombosis56,57, vWF-null mice are 
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protected from DVT.21 To determine whether soluble P-selectin and vWF play a role in 
modulating the leuckosequestration in CD39-deficient animals post-thrombosis, a series 
of time course experiments was performed in CD39+/+ IVC-ligated animals. ELISA 
analysis show at 48 hr soluble CD39 was significantly higher compared to the other time-
points (Fig 9A). Conversely, soluble P-selectin and vWF were increased at 48 hr, 
however, were not significantly differed compared to the other time-points (Fig 9 B, C). 
In a separate set of experiments, traditional ELISA and alphaELISA assays58 were used 
to examine circulating levels of P-selectin and vWF (respectively) in CD39+/+ and CD39-/- 
sham-operated or IVC-ligated mice 48 hrs post-thrombus-induction. Data demonstrated 
that both soluble P-selectin and soluble VWF were significantly higher in CD39-/- IVC-
ligated mice compared to CD39+/+ IVC-ligated animals soluble P-selectin (Fig 9D, E).  
 
CD39 regulates platelet-leukocyte trafficking and aggregation 48 hrs post- 
thrombus induction 
P-selectin on activated platelets is a major mediator of adhesion to leukocytes.59 Utilizing 
flow cytometry to quantify platelet-leukocyte aggregation, we analyzed CD39+/+ and 
CD39-/- sham operated or IVC-ligated mice 48 hrs post-thrombus -induction mouse 
peripheral blood was assessed by 6-color flow cytometry. Antibody against CD45 and 
CD11b characterized the monocyte subpopulation (CD45hi/CD11b+) and CD45 and Gr-1 
characterized the neutrophil subpopulation (CD45hi/Gr-1+) were gated respectively and 
subsequently sub-gated into two distinct groups; Platelet - monocyte heteroaggregates 
(CD45hi/CD11b+/CD41hi/CD62Phi) and Platelet – granulocyte (neutrophil) 
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heteroaggregates (CD45hi/Gr-1+/CD41hi/CD62Phi). Although we were not able to detect 
platelet-monocyte aggregates in all mice studied, in four of nine mice we were able to 
detect them. In these mice, platelet-monocyte aggregates of IVC ligated CD39-deficient 
mice were more abundant compared to CD39+/+ IVC-ligated mice 48 hrs post-IVC 
ligation (76.3 ± 12.3 vs. 52.6 ± 10.2 p<0.001 n=3-4). Conversely, Platelet – granulocyte 
heteroaggregates demonstrated 42% more total aggregates in CD39 null mice as 
compared with CD39 wild type (13.7%) 48 hrs post-thrombus-induction (Fig 10A, B). In 
addition to examining representative platelet-leukocyte aggregate dotplots, we calculated 
the absolute levels of recruited platelet-leukocytes populations in mice in which we 
detected them. Absolute numbers of both platelet-monocyte and platelet – granulocyte 
hetroaggregates were significantly increased 48 hrs post-thrombogenesis in CD39-
deficient animals as compared to their wild type counterparts (Fig 10C, D). These data 
show for the first time that CD39 regulates leukosequestration and attenuates venous 
thrombogenesis by down-regulating soluble vWF and soluble P-selectin expression in a 










As links between local thrombosis and inflammation are likely to serve as underpinnings 
for the development and propagation of a DVT, we proposed to examine a potentially 
relevant molecular mechanism. Although there are a number of intersection points in the 
nexus between coagulation and inflammation, one in particular stands out as being 
particularly important. CD39, an ectoapyrase expressed on endothelium and leukocyte 
subpopulation60, rapidly metabolizes ATP to ADP and AMP, which are released by 
platelets and other activated cells, inhibiting platelet recruitment into an evolving 
thrombus. In this current study, our laboratory successfully engineered a globally 
deficient CD39 mouse using the Cre EIIA system. We sought to determine the role of 
CD39 in DVT by employing a mouse model of venous thrombosis in which we ligated 
the inferior vena cava. Our data reveal for the first time that CD39 plays a critical role in 
mitigating venous thrombogenesis by squelching inflammatory and coagulant reactions at 
the blood/vessel interface.  
 
Our current studies show that CD39 plays an important, protective role in the recruitment 
of inflammatory vascular mediators to the vessel wall post thrombus induction. The 
CD39-/- mice engineered by our group had an apparently normal phenotype at baseline, 
with the exception of platelet hyporeactivity, as previously reported.31  
Several investigators have reported a bidirectional relationship that exists between 
thrombosis and inflammation39,20,40,41. To test this relationship, we used a long-
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established and widely employed model of infra-renal inferior vena cava venous 
thrombosis.39,20 We studied the effects of deletion of CD39 on thrombus formation in 
IVC-ligated mice at baseline and 48 hrs post IVC-ligation. Deletion of CD39 was 
associated with significantly increased thrombus size, with less neovascularization and 
fibrosis, despite increases in vein wall leukocyte accumulation. Prior studies have 
demonstrated that clot size is an index of thrombogenesis following ligation of the 
IVC.48,20 Moreover, the increase in thrombus cellularity in CD39-deficient mice was 
consistent with other experimental models.44,61,48 From these findings, we conclude that 
deficiency of CD39 impairs the process of thrombosis, which might be associated with 
complex interplay of factors that are likely not simply related to coagulation but also 
related to inflammatory changes.  
 
To further examine the possible contribution of CD39 to DVT pathogenesis, we 
compared vein wall leukocyte influx in CD39+/+ mice and CD39 null mice after IVC-
ligation. Our data showed in CD39-knockout mice, leukosequestration was increased and 
the vein wall appeared larger than CD39+/+ mice. Consistent with other models of 
thrombosis, we observed that neutrophils constitute the predominant leukocyte subset 
recruited to the site of DVT at 48 hrs46,45, 61. This may, through formation of neutrophil 
extracellular traps, contribute to venous thrombogenesis.62,63,64,65 Further, in contrast, 
monocyte/macrophage recruitment was not significantly increased (at 48 hrs), suggesting 
that monocyte/macrophage might play a lesser role in early thrombosis and inflammation, 
but more of a later role in thrombus resolution. Although CD39 expression is recognized 
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on certain leukocyte populations (B cells, monocytes, neutrophils; refs.60,66 the present 
investigation suggests that CD39 apyrase is an important mechanistic link between 
neutrophil-driven venous inflammation and venous thrombogenesis. 
 
To comprehensively understand how CD39 plays a role in thrombogenesis, especially 
related to leukocyte influx, the IVC was subjected to ligation in order to identify 
differentially expressed inflammatory genes, utilizing microarray technology. Microarray 
analysis is a powerful tool for identifying gene expression patterns that are reflective of 
the response to absence of CD39 during thrombogenesis, and can be informative of 
mechanisms of action.67 Using this technology, we have investigated whether CD39 
modulates inflammatory pathways during thrombus induction. Though high-throughput 
data obtained from microarray analysis may be generally of high variability, low 
reproducibility and contain non-specific noise68, this effect can be ameliorated using 
comprehensive text mining and bioinformatics approaches. Examples of such approaches 
include Gene Ontology (GO) analysis, DAVID pathway analysis, Short Time-series 
Expression Miner (STEM) cluster analysis, Dynamic Gene Network analysis, and 
Ingenuity Pathway Analysis (IPA). We chose GO and IPA as they are effective method 
to enrich the most relevant DVT-responsive genes, the biology of leukocyte recruitment 
to the vein wall of thrombosed IVCs.  
Affymetrix microarray analyses demonstrate that 132 genes were affected by IVC-
ligation, and 722 genes were affected by CD39-deficiency and IVC-ligation, with a fold 
change -2≥FC≥2. Principal component analysis revealed the microarray data were of 
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excellent quality (Fig 4B). We pooled four samples for each of the four groups for 
analysis, and examined all groups at the 48 hr time point (this was the time point with the 
highest thrombus weight in CD39 null mice (Fig 2) and highest CD39 expression (Fig 
9A). One of our initial goals was to identify the inflammatory genes that regulate CD39-
mediated leukocyte trafficking after thrombosis. We used the R statistical programing 
environment to generate hierarchical clustered heat maps of differentially expressed 
inflammatory genes identified from integrated results of GO analysis of the four 
experimental groups (CD39+/+ sham and DVT, CD39-/- sham and DVT). 179 
inflammatory and immune response genes were found to be highly upregulated during 
stasis-induced thrombosis and CD39 deficiency (Fig 5A-B). Futhermore, our analysis 
identified three groups of genes (groups I, II and III = total 76 unique probe sets) that 
show a concordant increase in expression in sham vs. DVT, and CD39+/+ IVC-ligated vs. 
CD39-/- IVC-ligated mice. The three groups were visualized as a supervised hierarchical 
clustering heatmap.  We confirmed the presence of a few of the previously reported 
inflammatory/coagulant genes (Il-6, Selp, vWF and Ccl2) 47,48,21,44 , and extend this list to 
a least 6 transcripts significantly expressed above the background during IVC-ligation 
that have known roles in coagulation and leukosequestration. In addition, Il-1β, Tnf 
(classical M1-polarized macrophage marker), Chi313, and Arg1 (M2-polarized 
macrophage marker), were upregulated during stasis-induced thrombogenesis and also 
showed a concordant increased in the absence of CD39.  
M1 macrophages are classically activated proinflammatory macrophages, whereas M2 
macrophages are alternatively activated non-inflammatory macrophages. An increase in 
the ratio of M2 to M1 macrophage would lead to a reduced inflammatory response.69 As 
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there appears to be more than one type of alternative activation state70, it is important to 
note that our data lead to the conclusion that thrombosis activates alternative macrophage 
response markers but does not exclude the possibility that there will be distinct 
differences from the M2 states induced in other models of thrombosis. Although this 
hypothesis remains to be tested, further analysis is needed to gain a better understanding 
of the biological role of these alternative activation M2 markers in other thrombogenic 
models of DVT.  
In an effort to better understand the dynamic biological interactions of differentially 
regulated inflammatory genes, 76 unique datasets representing genes with altered 
expression profiles derived from our microarray analysis were imported into the 
Ingenuity Pathway Analysis Tool. The list of differentially expressed genes analyzed by 
IPA revealed 19 significant networks affected by CD39-deficiency and IVC-ligation (Fig 
7A). Of the networks, leukocyte extravasation signaling was chosen from the pathway 
identified in IPA analysis for closer examination. Leukocyte extravasation signaling is of 
interest to our study because it encompasses genes that are regulated during thrombosis 
and inflammation.71 The classic paradigm of leukocyte extravasation has focused upon 
recruitment and activation of leukocytes. PSGL-1 (P-selectin glycoprotein ligand-1) has 
been shown to play an important role in leukocyte rolling, adhesion and transmigration at 
the site of inflammation and thrombus generation.72,45 In our study, we show in that 
PSGL-1 was significantly down-regulated in the sham-operated group (Fig 7B). 
Conversely, during thrombus induction and CD39 deficiency, PSGL-1 was profoundly 
up-regulated (Fig 7C-E) compared to IVC-ligated CD39+/+ group. The observation that 
most of the genes involved in both leukocyte adhesion and transmigration were activated 
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during IVC-ligation and CD39 deletion implies that CD39 plays a direct role in the 
regulation of leukocyte migration into the vascular wall during the propagation of 
thrombosis.  This postulation is consistent with that of our previous studies in ischemic 
tissues.34 It is also interesting to note that, MMP-9 (matrix metalloproteinases-9), located 
on leukocyte that has transmigrated through the capillary endothelial layer, was also 
significantly down-regulated under sham conditions. Simultaneously, during 
thrombogenesis and absence of CD39, MMP-9 gene expression levels were signifcanly 
up-regulated (Fig 7B-E). This finding is complementary to recent work in which deletion 
of MMP-9 impaired vein wall fibrosis and inflammation in a IVC-ligation mouse model 
deep venous thrombosis.52,73 Consistent with our qRT-PCR analysis, we show in the 
sham-operated group that the interaction between Selp, vWF and other differentially-
regulated proinflammatory genes caused an upregulation in Selp and down-regulation of 
vWF and downregulation of the proinflammatory cytokine (Fig 7A). In contrast, IVC-
ligation and CD39-deficiency caused Selp and vWF to be slightly up-regulated (1.4 fold), 
and proinflammatory cytokines to be moderately down-regulated (by 4 fold) (Fig 7F-G). 
This suggests that Selp and vWF may play an important role in leukocyte rolling and 
tethering on the endothelium during IVC-ligation, even in the absence of CD39. Taken 
together, we demonstrated gene expression profiles of acute venous-thrombosed CD39-
deficient mice by microarray assay, integrated with a multi-step bioinformatics strategy 
to understand the dynamic interactions that occured during luekosequestration and 
thrombogenseis. Our results indicate immune response genes play a critical role in 
thrombogenesis in the absence of CD39. The analysis performed in the IPA platform 
provide basic information for the association of key inflammatory mediators during 
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thrombus induction, which provided our laboratory with an initial step for better 
deciphering the molecular mechanisms involved in the protective role of CD39 during 
acute venous thrombosis.  
 
This in silico analysis has a couple of limitations. First, our 76 differentially expressed 
inflammatory genes and the follow up pathway/network analyses were conducted based 
on computational strategies. Although informative, this approach generally requires 
extensive experimental validation. Therefore, further validation of specific novel genes 
using more samples is needed. Second, the pathway crosstalk analysis was based on the 
scores measured by Jaccard Coefficient (JC) and Overlap Coefficient (OC). In this study, 
we selected the pathway pairs empirically, that is, those ranked in the top 10%. P values 
from a statistic test would be better applied to select significant crosstalk.  
 
To take our in silico experiment a step further, we validated some key findings based on 
the results obtained. Our in silico analysis identified Selp and vWF as key modulators of 
thrombogensis in our CD39 deletion model. This integrated experimental and theoretical 
approach yielded several key insights and suggested three new experiments that required 
extensive experimental validation. To discern the localization of P-selectin and vWF in 
CD39 null mice via immunohistochemical analysis, we stained tissue sections from 
CD39+/+ and CD39-/- sham operated or IVC-ligated mice 48 hrs post-tIVC-ligation. We 
showed an increase in expression of P-selectin and vWF in CD39 null mice 48 hrs post-
thrombus induction (Fig 8D-H). Concordant with our in silico findings we also show a 
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large number of inflammatory cells recruited to the thrombus that were stained with anti-
P-selectin antibody in CD39-/- IVC-ligated mice compared to CD39+/+ IVC-ligated 
thrombus induced group (Fig 8B, D). This suggests that some of the anti-inflammatory 
properties of CD39 may play a role in increasing stores of vein wall P-selectin and 
activating vWF in the endothelium during thrombosis.  
To further examine the possible contribution of CD39 to DVT pathogenesis, we analyzed 
the circulating levels P-selectin and vWF from CD39+/+ and CD39-/- sham-operated or 
IVC-ligated mice 48 hrs post-IVC-ligation. Concordant with our IVC date, we showed an 
increase in soluble P-selectin and VWF in the plasma of CD39−/− mice. It is interesting to 
speculate how CD39 efficiency resulted in increased plasma vWF. CD39-deficiency 
could produce slower clearance of vWF and other vascular modulators from the 
circulation and, thus, elevated vWF levels. Alternatively, vWF multimers activate 
platelets, which in turn may activate the endothelium. Previously, our laboratory34,74,75 as 
well as that of others, has shown that hypoxia alone is sufficient to trigger thrombosis at 
the blood wall interface, by triggered release of von Willebrand Factor (vWF) and P-
selectin from endothelium. Absent CD39, especially after IVC-ligation, increased 
inflammation of the vascular wall, could have the same effect 
 
Circulating blood leukocytes in DVT, particularly monocyte/macrophage and 
neutrophils39,20,40,41, display an activated phenotype that may predispose them to endothelial 
adhesion and amplification of vascular inflammation and vaso-occlusion. Thrombotic 
processes associated with enhanced platelet activation and the formation of platelet-
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leukocyte aggregates have been observed in several models of inflammation.76,77 CD39 has 
been shown by our group
37 and others 31 to be an important mechanism driving platelet-
mediated platelet recruitment, through release of ADP and activation of the P2Y12 
receptors. This can be terminally disrupted through enzymatic ADP dissipation by CD39. 
Our work in this area showed that an engineered soluble form of CD39 can prevent platelet 
aggregation in a cuvette following introduction of any of a number of platelet activation 
agonists, such as ADP, sodium arachidonate (which leads to thromboxane generation), or 
collagen. In our current study, we employed a 5-color flow cytometry of cell markers to 
simultaneously analyze platelet binding to neutrophils and monocytes in whole blood. The 
analysis of platelet- leukocyte aggregates revealed more platelets bound to monocytes than 
to neutrophils in the absence of CD39. Although, this finding was seen in 4 out of the 9 
mice we examined, these observations may provide some evidence that platelets play a role 
in enhancing leukocyte activation during thrombogenesis in CD39-deficient mice.  The 
physiological significance of increased formation of platelet-leukocyte aggregates in the 
peripheral blood during inflammatory disease still remains uncertain, however, our studies 
suggest that platelets at the thrombo/inflammatory interface may play an active role in 
DVT.  
In conclusion, these studies are the first to demonstrate a direct link between vascular 
ectoenzyme (CD39) and DVT.  We provide evidence that CD39 deficiency promotes 
inflammation and results in the increased extravasation of key inflammatory cells and 
activation of vascular coagulant reactions at the blood/vessel interface 48 hrs post-IVC 
ligation. Our present study also demonstrates through gene expression profiling with 
bioinformatics analysis that complicated inflammatory networks are activated following 
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creation of a DVT. Absence of CD39 further pushes the balance towards a 
proinflammatory vascular wall phenotype. Understanding the complex interplay of 
vascular injury, stasis and coagulation and how this is modulated by a naturally protective 
vascular ectoenzyme would lead to new therapies for DVT or other disorders at the nexus 


















































































































FIGURE V.1: TARGETING OF THE CD39 GENE BY HOMOLOGOUS CRE 
RECOMBINATION 
(A QRT-PCR analysis of 1.5µg of mRNA from various adult mouse tissues (specified on 
blots, with sample genotype) (n = 3) (B) No heart rate differences were observed between 
cd39+/+ and cd39-/- cohorts in average heart rate or (C) BP (n=4 per group). Comparisons 
between groups were performed via independent samples t test (D) Hematological profile 
of CD39flx/flx and CD39-/- mice. Circulating blood cell and coagulation parameter 
measurements of CD39flx/flx (n = 4) and CD39-/- (n = 5 to 7) mice. P = non-significant for 
statistical comparisons between all groups except platelets. Data are shown as means 
±SD.     *P < 0.05, **P < 0.001, ***P < 0.0001 
Genotype CD39+/+ CD39-/- p value
Total WBC (K/uL) 3.485 ± 0.51 4.317 ± 0.48 0.2669
Neutrophils (K/uL) 0.7775 ± 0.13 0.6871 ± 0.06 0.5519
Lymphocytes (K/uL) 2.588 ± 0.42 3.537 ± 0.42 0.1495
Monocytes (K/uL) 0.0925 ± 0.01 0.07857 ± 0.01 0.2613
Platelets (K/uL) 509.0 ± 109.7 132.2 ± 10.83       *0.0407
Hemoglobin (g/dL) 11.63 ± 0.76 11.87 ± 0.31 0.7782
RBC (M/uL) 8.075 ± 0.71 8.654 ± 0.25 0.4841
PT (sec) 8.133 ± 0.067 8.067 ± 0.089 0.5813
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FIGURE V.2: CHARACTERIZATION OF THROMBUS WEIGHT IN CD39+/+ 
AND CD39-/- MICE 48 HR POST STASIS-INDUCED THROMBOGENESIS. 
(A) Whole-blood aggregometry with 5 µM ADP stimulation was performed on WT and 
CD39-/- mice (n = 4 per group). Representative whole-blood platelet aggregation profiles 
of WT and CD39-/- mice (n = 4 per group). Quantification of relative platelet aggregation 
profiles (n = 4 per group). (B) Inferior vena cava (IVC) stasis-induced venous thrombosis 
in CD39+/+ mice was induced. Thrombus weight was measured in CD39+/+ mice at 1-6 
days following IVC ligation (All mice CD39 flox/flox  designated as CD39+/+): 1d, n = 6; 
2d, n = 20; 4d, n = 8; 6d, n = 10). (C) Thrombus weight in sham-operated and stasis-
induced venous thrombogenesis in CD39+/+ and CD39-/- mice at 48 hours. Sham: 
CD39+/+, n = 8; CD39-/- n = 8. IVC-ligated: CD39+/+, n = 15; CD39-/- n = 8. (D) 
Representative photographs of stasis-induced venous thrombosis of CD39+/+ and CD39-/- 
mice at 48 hours post ligation. Data are shown as means ±SD. *P < 0.05, **P < 0.001, 



























FIGURE V.3: HISTOLOGICAL ANALYSIS AND INFLAMMATORY CELL 
COUNTS OF THE THROMBUS-CONTAINING IVC 48H POST IVC LIGATION 
IN CD39+/+ AND CD39-/- MICE. 
(A-D) Hematoxylin and eosin stained inferior vena cava section of 48 hr sham operated 
(A and C) and thrombosed IVC (B and D) of CD39+/+ and CD39-/- mice. (B) Compared 



























































































matrix deposition (magnification = original x400). T = thrombus W= vein Wall. (E-G) 
Morphometric evaluation of inflammatory cell counts of five high-powered field in the 
vein wall of CD39+/+ and CD39-/- mice 48 hr post IVC ligation and sham-operated 
controls. Total inflammatory cell (E), Polymorphonuclear cells (neutrophils) (F) and 
Monocytes (G) (n = 3-5 all groups). Data are shown as means ±SD.     *P < 0.05, **P < 








































































FIGURE V.4: MICROARRAY QUALITY CONTROL ANALYSIS OF CD39+/+ 
AND CD39-/- MICE 48 HR POST-IVC-LIGATION. 
(A) Quality control plots of CD39+/+ and CD39-/- sham operated or IVC-ligated mice 48 
hr post IVC ligation depicts the distribution of the probes for each chip: with Agilent 
2001 Bioanalyzer to ensure that each samples prepared for microarray hybrization meet 
the Affymetrix guidelines. All samples came from the same distribution with only 
difference being the location and scale based the normalization procedure. Each 
expression value for each gene used a robust multi-array average (Irizarry et al. 2003). 
(B) Principle component analysis (PCA) of CD39+/+ and CD39-/- mice 48 hr post-
thrombus induction. Red, blue (CD39+/+ and CD39-/- sham-operated mice) green and 
purple (CD39+/+ and CD39-/- IVC-ligated mice) dots represent linear combinations of the 
expression data, including relative expression value and variance of the 28,939 probe sets 
in IVC from each experimental group. The PCA software examined two component of 
genes in different samples for those similar or different expression profiles. The first 
component shown in the x-axis, includes genes with a high degree of variance within the 
different strains (CD39+/+ sham and IVC-ligated vs. CD39-/- sham and IVC-ligated). The 
second component, displayed in the y-axis, encompasses genes that also had a high range 
of variance within the sham and thrombus inducted group  (Sham - CD39+/+ and CD39-/- 
vs. IVC-ligated- CD39+/+ and CD39-/-). (C, D)  Venn diagrams illustrating the number of 
probe sets identified as significantly differentially expressed (Fold change ≥2; P≤0.001) 
in each pairwise comparison. (C) CD39+/+ sham vs. CD39-/- sham; CD39+/+ IVC-ligated 
vs. CD39-/- IVC-ligated and common and unique genes between each group (D) CD39+/+ 
sham vs. CD39+/+ IVC-ligated; CD39-/- sham vs. CD39-/- IVC-ligated group and common 

















































































































































































































































































































































































































































































































































































































































































FIGURE V.5: HIERARCHICAL CLUSTERING OF DIFFERENTIALLY 
EXPRESSED INFLAMMATORY GENES RELATED TO CD39+/+ AND CD39-/- 
MICE 48 HR POST-IVC-LIGATION. 
(A-D) Genes involved in inflammation and immune response were analyzed. ANOVA 
was first performed to identify genes that are differentially expressed due to CD39 
deficiency or stasis-induced thrombogenesis. Each lane represents the expression profile 
of inflammatory genes of two mice (A) Differentially expressed genes between sham 
(CD39+/+ sham compared to CD39-/- sham) and DVT (CD39+/+ IVC-ligated compared to 
CD39-/- IVC-ligated), (B) CD39+/+ (CD39+/+ IVC-ligated compared to CD39+/+ sham) and 
CD39-/- (CD39-/- IVC-ligated compared to CD39-/- sham) groups were visualized as 
heatmaps for microarray analysis. Red and blue colors indicate up and down – regulated 
expression levels, respectively. White color indicates no change in expression levels. 
Inflammatory genes highly upregulated during stasis-induced thrombosis and CD39-/- 
deficiency were categorized as group I, II, III and supervised hierarchical clustering of 76 
unique probe sets were visualized as a heatmap using oligo package of bioconductor 
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FIGURE V.6: VALIDATION OF MICROARRAY RESULTS VIA 
QUANTITATIVE RT-PCR ANALYSIS OF CD39+/+ AND CD39-/- MICE 48 HR 
POST-IVC-LIGATION. 
 (A-J) Gene expression of proinflammatory mediators and chemokines were analyzed in 
CD39+/+ and CD39-/- 48 hr post IVC ligation, selected on the basis of the output of the 
microarray studies, and were assessed during qRT-PCR. Fold changes were normalized 
to β-actin. Results are shown as the mean ± SD of at least six independent experiments. 
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FIGURE V.7: IPA GENERATED MOLECULAR NETWORK PATHWAY 
ANALYSIS OF CD39+/+ AND CD39-/- MICE 48 HR POST-IVC-LIGATION. 
The demonstrated network/pathway diagrams are taken from IPA analysis of the 
microarray data based on upregulated genes and visualized using the network analysis 
tool. (A) Integrated gene network analysis reveals strong differences in gene expression 
of CD39+/+ and CD39-/- mice 48 hrs post-IVC-ligation. Cellular functions identified by 
IPA as being affected by IVC induced thrombosis or CD39 deficiency are illustrated with 
bar graphs based on the levels of –log (p-value), the higher the levels the more significant 
of the effect. White bars indicate functions affected by IVC-ligaton, whereas the black 
bars denote those affected by CD39-deficiency and IVC-ligation. 4 independent 
biological replicates for each arrayed group were performed. (B-E) Leukocyte 
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sham vs. CD39-/- sham pathway C, represents the subnetwork of the CD39+/+ IVC-ligated 
vs. CD39-/- IVC-ligated pathway D, CD39+/+ sham vs. CD39+/+ IVC-ligated pathway and 
E, CD39-/- sham vs. CD39-/- IVC-ligated pathway. Color nodes: genes that changed 
significantly in CD39+/+ and CD39-/- mice 48 hrs post-thrombus induction with a fold 
change >2. Red: upregulation; green: downregulation. The diagram was modified from 
Ingenuity Pathway Analysis (Ingenuity® Systems). (F-I) Key inflammatory gene co-
expression network analysis. F, represents the subnetwork of the CD39+/+ sham vs. 
CD39-/- sham pathway G, represents the subnetwork of the CD39+/+ IVC-ligated vs. 
CD39-/- IVC-ligated pathway H, CD39+/+ sham vs. CD39+/+ IVC-ligated pathway and I, 
CD39-/- sham vs. CD39-/- IVC-ligated pathway. In this visualization, genes/proteins 
(nodes) are shown as circles, and the interactions between these nodes are shown as lines 
(edges).  Nodes are colored according to the degree of dysregulation from highly up 
regulated (red), highly down regulated (green) and baseline (white). The networks were 












































FIGURE V.8: LOCALIZATION OF VEIN WALL P-SELECTIN AND VON 
WILLEBRAND (VWF) FACTOR PROTEIN BY IMMUNOHISTOCHEMISTRY 
48H POST-IVC LIGATION. 
  
(A, E) High power view of the IVC in the sham-operated CD39+/+ mouse (x 400). (B, F) 
High power view of the IVC in the CD39+/+ IVC-ligated mouse (x 400). (C, G) High 
power view of the IVC in the sham-operated CD39-/- mouse (x 400). (D, H) High power 
view of the IVC in the CD39-/- IVC-ligated mouse (x 400). Cells expressing P-selectin 




























expressed in the endothelial cells of vena cava of the CD39+/+ and CD39-/- sham-operated 
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FIGURE V.9: EXPRESSION OF SOLUBLE (SOL) CD39, P-SELECTIN AND 
VWF PLASMA PROTEIN FOLLOWING LIGATION OF THE IVC. 
(A-C) CD39+/+ mice bred on C57BL/6J background were IVC-ligated for the indicated 
time and whole blood plasma protein from retro-orbital plexus were isolated. ELISA was 
used to detect the time course of expression of soluble CD39, P-selectin and vWF (1d, n 
= 3; 2d, n = 3-4; 4d, n = 3; 6d, n = 3-6). D and E show solP-selectin and vWF 48 hrs post 
IVC-ligation. Plasma P-selectin and VWF expression obtained from CD39+/+ and CD39-/- 
sham operated or IVC-ligated mice 48 hrs post thrombus induction were determined by 
ELISA. N= 8-10 total animals in the sham-operated and IVC-ligated groups. Data are 








FIGURE V.10 : WHOLE-BLOOD ANALYSIS OF CIRCULATING LEUKOCYTE 
PLATELET AGGREGATES 48 HRS POST- IVC-LIGATION. 
(A, B) Representative fluorescence-activated cell sorter analysis of whole-blood platelet-
granulocyte (neutrophils – Gr-1+) and platelet-monocyte (CD11b+) aggregates in CD39+/+ 
and CD39-/- sham operated or IVC-ligated mice 48 hrs post-IVC-ligation. Platelets and 









































































































negative cells were subgated, and gated on forward and side-scatter CD45+ leukocytes, 
neutrophils and monocytes (data not shown). The percentage of neutrophils and 
monocytes found in heteroaggregates with P-selectin (CD62P+) and platelets (CD41+) is 
greater in CD39-/- compared to CD39+/+ IVC-ligated mice. (C, D) Quantitative cell count 
analysis of Gr-1 and CD11b-CD41+/CD62P+ cells in CD39+/+ and CD39-/- sham operated 
or IVC-ligated mice 48 hrs post IVC-ligation.  Data are shown as means ±SD.  *P < 0.05, 





TABLE V.1: GO TERMS OVERREPRESENTATION ANALYSIS  
Gene Ontology analysis revealed several over-represented biological themes due to the 




GO term (BP) p Value Odds Ratio p Value Odds Ratio
Inflammatory*response 0 3.0919848 0 4.5591088
leukocyte*ac:va:on 0.0000001 2.452202 0.0000001 2.5226555
immune*effector*process 0.0000003 2.6932053 NS NS
immune*response 0.0000012 2.3690353 0.0000316 3.5084034
localiza:on 0.0000032 1.4141233 0 1.9533259
response*to*organic*substance 0.0000041 1.6591012 0.0000027 2.1912359
response*to*external*s:mulus 0.0000044 1.8369236 0 1.5110622
leukocyte*prolifera:on 0.000006 3.1977548 0.0000626 6.5309609
receptorHmediated*endocytosis 0.0000074 3.5290737 NS NS
cell*adhesion 0.000008 1.8401734 0 2.6257471
cell*chemotaxis 0.0000106 3.3220069 0 4.4292611
regula:on*of*biological*quality 0.0000151 1.4989794 0.0000254 6.5309609
regula:on*of*homeosta:c*process 0.0000189 2.6576885 0.0000047 1.632204
lymphocyte*prolifera:on 0.0000207 3.0622135 0.0000962 2.4891514
cytokine*secre:on 0.0000223 5.2194175 0.0000016 2.9122982
posi:ve*regula:on*of*immune*system*process 0.0000226 2.1807008 0.0000018 4.5775438
neutrophil*chemotaxis 0.0000277 6.0820413 0.0000023 7.1624033
adap:ve*immune*response 0.000035 3.0982175 NS NS
leukocyte*migra:on 0.0000372 2.8543756 NS NS
B*cell*mediated*immunity 0.0000443 4.4375121 NS NS
collagen*metabolic*process 0.000054 5.4724806 NS NS
T*cell*ac:va:on 0.0000575 2.3943687 NS NS
transport 0.0000636 1.3748109 NS NS
locomo:on 0.000083 1.6107195 NS NS
myeloid*leukocyte*mediated*immunity 0.0000837 5.6421426 0.0000007 8.5973825
bone*remodeling 0.0000996 4.9737491 NS NS
CD39+/+ IVC-Ligated CD39-/- IVC-Ligated
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